Insights into the regulation of human IgE : a complete picture in vitro by Bitsaktsis, Constantine
This electronic thesis or dissertation has been 











The copyright of this thesis rests with the author and no quotation from it or information derived from it 
may be published without proper acknowledgement. 
 
Take down policy 
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing 
details, and we will remove access to the work immediately and investigate your claim. 
END USER LICENCE AGREEMENT                                                                         
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 
International licence. https://creativecommons.org/licenses/by-nc-nd/4.0/ 
You are free to: 
 Share: to copy, distribute and transmit the work  
 
Under the following conditions: 
 Attribution: You must attribute the work in the manner specified by the author (but not in any 
way that suggests that they endorse you or your use of the work).  
 Non Commercial: You may not use this work for commercial purposes. 
 No Derivative Works - You may not alter, transform, or build upon this work. 
 
Any of these conditions can be waived if you receive permission from the author. Your fair dealings and 








Insights into the regulation of human IgE : a complete picture in vitro
Bitsaktsis, Constantine
Download date: 06. Nov. 2017
To two woiiderj'Ul parents. 




A thesis submitted for the degree of Doctor of Philosophy 
in the Faculty of Medicine of the University of London. 
Department of Immunology 
Guy's, King's and St. Thomas's School of Medicine and Dentis 
The Rayne Institute 






I would like to thank Prof. D. M. Kemeny for giving me the opportunitv to carry out 
successfuliv this pr *ect and for his support throughout the past four years. Oj 
I would like to acknowledge rný second supervisor and friend, Dr. Darren Wheeler for 
all his scientific guidance and moral support. 
I \, vould also like to thank all my colleagues and friends for aiding me from the C) ZID 
beginning of my Ph. D. to this day. 
Special thanks go to Dr. Milica Vukmanovic-Stejic for the practical help that she gave Z: ) 
me and for showincy me the ropes around the laboratory. Cý 
Last, but not least, I would like to dedicate this thesis to my parents (Christos and Katia 
Bitsaktsis). I feel so grateful to have such special people next to me. A huge THANKS 
for supporting and most importantly believing in me. 
ABSTRACT. 
In this project we investigated the effects of different CD8+ T-cell secreted 
factors on IgE switching. Human tonsillar B cells were isolated by T-cell 
rosetting or positive selection (CD19 dynabeads). B cells cultured with IL-4, 
anti-CD40 and holo-transferrin provided a good system in trigerring 
secretion of IgE "in vitro". IgE secretion within the first week of culture, 
produced levels that occasionally exceeded 2ýtg/ml. The IgE levels in the 
supernatants were tested by a direct, sandwich IgE ELISA, while B-cell 
proliferation assays were also carried out using 'H-Thymidine. A wide range 
of cytokines were tested and their effects on B-cell proliferation and IgE 
secretion were confirmed using their respective neutralising antibodies. The 
effect of different CD8+ T-cell supernatants on the IL-4-dependent IgE 
synthesis was also tested. Finally the possible mode of action of these 
cytokines has been investigated. 
Cytokines found to potentiate IgE secretion included IL-6 and IL-10, while 
IL-2, IL-12, TGF-P and IFN-y downregulated the IL-4-dependent IgE 
production. The effect of these cytokines were confirmed by using their 
respective neutralising antibodies. Similarly, Tc clone supernatants were 
found to control the levels of IgE secreted in the B-cell cultures. Tcl clone 
supernatants downregulated the secretion of IgE while the Tc2 clone 
supernatants increased the levels of this immunoglobulin. 
iii 
The potentiating ability of IL-6 and IL-10 was probably due to their B-cell- 
proliferative effect while the inhibitory action of cytokines such as IFN-y and 
TGF-ý could be partially explained via the preferential switching theory; i. e. 
switching towards a different immunoglobulin isotype (e. g.: TGF-ý to IgA 
and IFN-y to IgGI) or due to the downregulation of the IL-4 receptor 
expression (seen with IL-12, IFN-y and TGF-P). 
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ABBREVIATIONS. 
ýI I rnicrolitres 
AET ')-aminoethyllsothloui-onlum bromde 
'11\ PC antigen presenting cell 
BSA bovine serum albumin 
C constant 
CD cluster of differentiation 
cDNA complementary deoxy-ribose nucleic acid 
cpM counts per minute 
CTL cytotoxic T lymphocytes 
DNA deoxy-ribose nucleic acid 
DTH delayed-type hypersensitivity 
ELISA enzyme-iinked immunosorbent assay 
FACS fluorescence-activated cell sorter 
FCS foetal calf serum 
FITC fluorescein isothiocynate 
Cr gravitational force 4: ) 
h hour 




LRP linear regression plot 
V 
mAb monoclonal antibody 
MHC major histocompatibility complex 
ml milifitre 
mRNA messenger ribose nucleic acid 
n, -, nanogram 
NK natural killer 
OVA ovalbumin 
PBMC peripheral blood nuclear cells 
PBS phosphate buffer solution 
PCR polymerase chain reaction 
PE phycoerythrin 
R receptor 
RNA ribose nucleic acid 
RPMI roswell park memorial institute 
SD standard deviation 
SEM standard error of mean 
SRBC sheep red blood cells 
STAT signal transducer and activator of transcription 
SUP supernatant 
Tc cytotoxic T cell 
TcR T-cell receptor 
TGF tumour growth factor 
Th helper T cell 
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CHAPTER 1: INTRODUCTION 
1.1 CELLS OF THE IMMUNE SYSTEM. 
Pluripotent stem cells in the bone marrow give rise to all haematopoletic cells 
in the immune system (185.200) (Figure 1.1). Co-operation between the multiple cell 
types allows the immune systern to identify the nature of antigen and mount a specific 
response, utilising the most efficient means of defence, as well as retaining specific ltý Lý 
Memory. 
1.2 CELLULAR AND HUMORAL IMMUNITY. 
Cellular immunity (cell mediated) and humoral immunity (antibody mediated) work 
together during an immune response to antigen. The immune system is able to recognise 
the antigen, recruit appropriate cells and produce the most effective immune response to 
combat the invading pathogen. Cellular immunity involves cell mediated killing and 
clearance by leukocytes such as neutrophils, macrophages, natural killer (NK) cells, 
cytotoxic T (Tc) cells, eosinophils and basophils. Humoral immunity involves B cells 
(bone marrow derived lymphocytes) which secrete immunoglobulin (1g) molecules 
(antibodies). Igs bind to antigen and can facilitate phagocytosis (opsonisation) of 
antibody targeted pathogens and complement mediated lysis via the activation of the 
classical pathway. Immunoglobulins also bind to their relevant Ig receptors on 
monocytes, neutrophils and macrophages to facilitate the removal of immune 
complexes. Pre-T cells originate in the bone marrow and travel to the thymus where they 
develop into one of the three classes of a mature T cell: cytotoxic (Tc), regulatory (Tr) or 
2 
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Figure 1-1: Cells of the immune system (Immunology. 3 rd 
edition. Kuby- 1997). 
helper (Th) T cell. Tc cells, as mentloned above. take part In the cellular Immune 
responses, while Th cells can provide help to Tc cells durino a cellular immune ltý 
response or to B cells during a humoral immune response. The role of Tr cells is later 
discussed. 
1.3 B LYMPHOCYTES. 
In adults, B lymphocytes develop in the bone marrow and are characterised by their 
ability to rearrange their immunoglobulin genes. B-cell surface bound immunoglobulin 
molecules are antigen specific. With help from antigen-specific Th cells (cognate 
interaction), B cells clonally expand and differentiate into antibody forming cells (AFC). 
1.3.1 131 and B2 Cells. 
Recently, the existence of different B-cell subpopulations (BI and B2) has been 
established. BI cells are thought to be generated from the same precursors as B2 cells. 
Precursor cell type, microenvironment and the age of the donor all play a role in the 
generation of BI or B2 cells (1). The BI/132 nomenclature replaces an earlier scheme 
based on surface phenotype alone: CD5+ B cells compared to CD5- B cells. BI cells are 
mainly present in the peritoneal cavity of mice and humans and are characterised by the 
highly autoreactive immunoglobulins on their surface which are thought to play a role in 
the positive selection of this cell subpopulatIon. B2 cells die rather than become self- 
4 
reactive (2). BI cells can be further distinguished from B2 cells as: Ig Mhi IgD10 CD233- 
('D4")'+ and CD5+ (B I a) or CD5- (B I b) cells (33). 
BI cells contribute to the production of serurn immunoglobulin and natural 
autoantibody. The main antibody isotypes secreted by BI cells in serum are IgG3 and 
1(-, M, although it has been shomi that B2 cells can contribute to the secretion of other 
serurn immunoglobulins, probably as non-specifically promoted by T cells or cytokines 
(4). Both BIa and BIbB cells reconstitute and generate IgA plasma cells in the lamina 
propria (5). Finally. the involvement of BI cells in limiting tumour development has 
been suggested. In peritoneal Bla cells, consitutive expression of STAT3 oncogene 
seems to play a role in the BI cell oncogenesis function. Expression of this gene is 
probably due to the constitutive cross-linking of the BCR by self-antigen and the unique 
cytokine exposure in the peritoneal cavity (6). Recent results emphasise the importance 
of BI cells (and marginal zone B cells), in T-cel I -independent antibody responses, 
thereby contributing to innate immunity (7), (8). 
1.4 The Immunoglobulin Molecule, Mediator of Humoral Immunity. 
The basic immunoglobulin unit is a tetrameric glycoprotein composed of two identical 
light and two identical heavy polypeptide chains which are approximatelly 220aa (25 
kDa) and 440aa (50 kDa) each respectively. Molecular weight depends on the Ig heavy 
chain class, carbohydrate content and whether the Ig molecule is the membrane bound or 
the monomeric/multimeric secreted form (table 1.1). 
5 
The immunoglobulin. light chain consists of two domains: a constant (CL) and a variable 
(VL) domain. The heavy chain consists of a variable dornain (VH) and three or four 
constant domains (CHI, CH2. C1133. CH4) depending on the Ig class and subclass. In 
some Ig molecules there is also a region called the hinge \\hich is interposed bctween 
the CHI and CH2 domains. In addition. depending on vvhether the molecule is 
membrane bound or secreted. a transmembrane region or a joining region may be 
situated next to the CH3 or CH4 domain. One light chain is bound by a disulphide bond 
(S-S) in the CL domain to the CH I domain of a heavy chain, and two heavy chain/light 
chain dimers are bound together at the hinge by between I and II disulphide bridges to 
create the tetrameric unit described before. IgM is an exception as it doe Sý not have a 
hinge and uses rigid CH2 domains in close association as a hinge-like structure. and its 
heavy and light chain dimers are disulphide bonded between the CH2 and cH, ) domains. 
Each heavy or light C and V domain contains an internal disulphide bond which 
stabilises the characteristic immunoglobulin fold tertiary-like structure. The gene 
sequence coding for the immunoglobulin fold structure is conserved and other cell 
surface molecules using it are said to be members of the immunoglobulin gene 
superfamily. In addition to covalent bonds, the Ig heavy and light chains are held 
together by non-covalent interactions between the Ig gene domains. N-linked 
carbohydrate chains are also linked to the immunoglobulin domains at various positions 
according to the Ig class, and these contribute to the structure and function of the 
molecule. Human IgG subclasses have one N-linked carbohydrate chain bound to each 
CH2 domain. This interferes with the non-covalent interactions of the CH2 domains and 
6 
Table 1.1: PHYSICO-CHEMICAL AND FUNCTIONAL 
PROPERTIES OF THE HUMAN IMMUNOGLOBULIN CLASSES 
Property 
I 
Igm IgD IgA IgE IgG 
Ig Heavy chain class tI5 
Molecular weight (kDa) 
Molecular weight of heavy chain 
(kDa) 
Number of heavy chain domains 
Ig carbohydrate content (%) 
Ability to fix complement 
Ability to cross placenta 
Staphylococcal protein A binding 
Binding to mononuclear cells 
Binding to neutrophils 
Binding to mast cells and basophils 
Binding to T and B cells 
Binding to platelets 
a pentameric form, b dimeric form 
* Only IgG4. 
ct I or u2 yL y2, 
y' ) or y4 
970' 184 33 856 188 150 
65 69.7 56 or 52 72.5 
5 4 4 5 4 
12 9 -14 7-11 12 2-3 
7 
the molecule bends outwards. This change in the 3-D structure may influence the 
effector function of the heavy chain. 
Enzyme digestion splits the immunogdobulin molecule into functional components. 
There are two identical Fab fraoments (antioen-bindino). which donate to the 1110leCLI]c a 
bi-valent antigen binding capacity. The V domains of heavy and light chains contain 
hypervariable regions: CDRI, CDR2 and CDR3. When the V domain immunoglobulin 
fold is arranged, these regions form extra polypeptide loops which associate non- 
covalently to form the antigen-binding pocket. The CHI domain of the Fab also contains 
a binding-site for complement C4b/C')b. The Fc region (fragment crystalline) contains Z__ 
binding sites for complement CIq (CF12), Fe receptors on macrophages and monocytes 
(CH2), Fc receptors on neutrophils and NK cells (CH2 and CH3) as well as 
staphylococcus protein A. 
1.4.1 Immunoglobulin Heavy Chain Classes. 
Different heavy chains confer different effector functions. In human and mouse there are 
five major classes of immunoglobulin heavy chain constant regions: M, D, G, A and E. 
The G class is further divided into: GI, G2, G3 and G4 in the human and GI, G2a, G2b 
and G3 in the mouse. Humans also has two subclasses of A: Al and A2. 
8 
1.4.2 IgD. 
In matUre B cells, the CH6 genes are transcribed witli the CHýt genes in one long rnRNA 
transcript (9). (10). Alternative splicinu, allows IgD to be co-expressed with LAI ii-i the 
membrane, but never alone. 1(-, D is present in hurnan SCrUrn at a low concentration 
(approx. 330ýtghnl), but as IgD is not secreted, this may be due to proteolytic cleavage or 
loss from the cell surface of activated B cells. The function of IgD is controversial. It is 
thought to play a role in immune tolerance. B-cell activation and memory (11). 
However, in the IgD- mouse, it is not essential for B-cell maturation (12). Instead, it may 
act as a more efficient antigen capture molecule than IgM because of its greater hinge 
flexibility (13). lgD is not secreted because the 6 heavy chain gene lacks a secretory 
protein coding region. In spite of this, some myelomas (1%) secrete IgD. This may be 
explained by unequal crossing over of sister chromatids and insertion of the Cýt 
secretory exon to the 3' of C8 (14). 
1.4.3 IgM. 
IgM is the first Ig isotype expressed on the surface of B cells. It is the first antibody 
produced during an immune response before the switch to IgG, IgA or IgE and is present 
in human serum at approximatelly: 1.5-2. Omg/ml. Secreted IgM is a pentameric 
molecule. IgM molecules are joined by disulphide bonds between CH3 and CH4 
domains, and an additional protein called the joining (J) domain. Although individual 
IgM molecules are often of low affinity, their pentameric structure compensates for this 
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by having a high antigen avidity. IgM is also the only Ig molecule apart from IgG which 
can fix complement. 
1.4.4 IgA. 
IgA is present in normal human serum at approximatelly: 1.4-4 mg/nil. The IgA 
molecule is present as a monomer in serum, but can be secreted in bodv fluids (e. i-1.: 
milk, intestinal secretions, saliva, L- tears) as 
dimers where it binds to invading pathogens 
as a first line of defence. Dimeric IgA is linked by one CH-33 domain to a joining (J) 
protein. An additional protein polypeptide called the secretory component is wound 
around the dimer and disulphide bonded to each end to one CH2 domain of each IgA 
molecule conferring resistance to GI tract enzymes. IgA-antigen complexes can bind to 
Fc(xRs on human monocytes, granulocytes, neutrophils and subpopulations of T and B 
cells (15), and mediate phagocytosis and superoxide production for bacterial cell lysis 
and killing. The human IgA subclasses: IgA I and IgA2 are found at a ratio of 9: 1 in 
normal human serum. This concentration difference could be due to the spatial distance 
between the Coc2 gene and the VDJ genes. Coc2 bearing the most 3' of the Ig heavy 
chain constant region genes. In external secretions however, IgA2 can rise up to 50% of 
serum IgA levels. This may be accounted for by the susceptibility of IgAl to proteolysis. 
IgA2, which has lost a large part of the IgA hinge region (13aa), is resistant to a number 
of bacterial proteases which attack IgA I in external secretions, especially in the gut (16). 
Interestingly, the rabbit has evolved 13 IgA subclasses which differ from each other in 
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their hinge and CH I regions. perhaps endowing them with protection against a wide 
range of bacterial proteases. The rabbit is a herbivore with a large bacterial harbouring 
caeCUm and appendix and would gain considerable selective ad\-antato: -, Ie 
from developing 
protective IgA (17). 
1.4.5 IgG Subclasses. 
The emergence of the human IgG subclasses has given a selective advantage to defence 
against invading pathogens (figure 1.2). IgG subclass heavy chain constant region genes 
are encoded by distinct gene loci. Their functional differences are a direct result of 
structural changes in the hinge regions brought about by changes in the amino acid 
sequence (18). The hinge is extremely important in the effector functions of the Ig 
molecules. Segment flexibility correlates with the ability to bind complement. If the 
hinge is deleted, the IgG molecule becomes a rigid T-shape which is unable to activate 
complement or bind to monocytes (19). IgG I has an extended hinge region with non- 
coplanar Fab arms. IgG3 has an extremely long hinge region which has arisen by 
multiple duplications of the original hinge exon. Both IgGl and IgG3 have flexible 
hinge regions and are good mediators of effector function. Both IgG2 and IgG4 have 
short hinge regions and are poor mediators of effector function. The IgG2 hinge is 
particularly rigid and inflexible due to the lack of glycine residues. The classical 
pathway of complement is activated by binding of the Clq to the CH2 of the IgG 
molecule. The flexibility of the IgG I and IgG3 Fab arms allows optimal binding for Clq 
while the rigidity of IgG2 increases steric hindrance. IgG4 does not bind CIq and does 
not activate complement. This is probably because the IgG4 Fab arms are too close to 
the Fab binding site on the Fc region. 
IgG subclasses bind to Fcy receptors with vaiiýle affinity (IgGI>IgG'i>l(-)G4>IgG-"). 
This is not due to the structure of the hinge or flexibility of the Fab arms. as all Fcs bind 
with the same affinity. There are three Fcy receptors: FcyRI (CD64). FcyRII (('D\ý '12) 
and FcyRIII (CD16) (20). CD64 is the high affinity Fcy receptor. It is found on 
macrophages. monocytes. neutrophils and is able to bind both monomeric and polymeric 
IgG. The CH2 domain of IgGI binds to CD64 and mediates antibody dependent 
cytotoxicity and clearence of immune complexes. CD332 has a low affinity for 
aggregated IgG and exists as A, B and C forms. All three are found on monocytes and 
endothelial cells. the B form occurs on B cells and A and C forms on neutrophils. IgG 
binding to this receptor mediates phagocytosis and the oxidative burst in monocytes and 
phagocytes, transport of IgG across the epithelial placenta and delivers a negative signal 
to B cells in combination with anti-Ig. CD16 also has low affinity for aggregated IgG 
and occurs in two forrns. It is a transmembrane molecule on NK cells and macrophages, 
with its glycosylphosphaticlylinositol (GPI) linked on neutrophils. GPI-linked CD16 is 
thought to work in concert with CD32 as a capture molecule for aggregated IgG (21). 
IgG-antigen complexes binding to the transmembrane mediates phagocytosis and 
cellular cytotoxicity. 
In vivo, IgG subclasses are directed against particular pathogens, to confer optimum 
protection. In the human, IgGI and IgG3 subclasses are raised against extracellular and 
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carbohydrate antigens, especially bacterial polysaccharides. Protection by IgG2 is seen 
in adults. but in young children IgGI is protecti I hvdrate ve against both protein and carbo . 
until the 1-(-YG2 response matures and takes over. IgGl is less efficient than 1(-)G2 at 
combating encapsulated bacteria (2-3). Protection against acute and early parasitic 
infection is directed maink by IgGl. (normal responses to larval antigens). followed hv 
IgE and IgG4 responses after long term exposure (24). IgG4 also increases in cases of 
chronic antigenic stimulation (allergy) (25). (26) and (27)), and confers loncy term L- 
immunity to antigen (28) and (29). 
1.4.6 IgE. 
IgE is present in normal human serum at very low concentrations (5-150 ng/ml) (30). 
Binding to the high affinity IgE receptor (FcF-RI) on basophils and mast cells causes 
degranulation and release of histamine, production of prostaglandins and leukotriene. 
Binding to the low affinity IgE receptor (FcF-Rll, CD23) on B cells, T cells and a number 
of other immune cells increases antigen processing (3 1) and induces IgE-dependent 
cellular cytotoxicity, lysis and clearance (32). IgE is also an activator of allergic 
responses. Loss of control of IgE production leads to excessive serum IgE and binding to 
FcERI on mast cells and FcF_Rll on B cells. Cross-linking with allergen on FcF_Rl leads to 
immediate type hypersensitivity reactions, release of mediators and allergic responses 
(33), (34). Binding of IgE-antigen complexes to FcF-RlI increases antigen processing by 
plasma cells and prolongs the allergic immune response (35). 
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1.4.7 Immunoglobulin Light Chains 
There are two light chain loci in the hurnan and mouse genornes, Kand /',. These have 
multiple V (variable) and J (joinin(y) genes which encode the VL domain and C regions L- - 
for the CL domain (the K locus has only one C gene). V and .1 genes are rearranged at 
random so that in a given number of B cells, many different combinations are produced. 
The hypervariable regions: C DRJ. COa and COU are encoded within the V genes, and Z-- II 
undergo sornatic hyper-mutation after antigenic stimulation of the B cell. This is 
important in the process of Ig affinity maturation in the germinal centre where antigen 
binding specificity is increased (3 ) 6), (3 7) and (3 8). 
1.4.8 Immunoglobulin Heavy Chains 
There is only one locus for the immunoglobulin heavy chain in humans and mice. The 
locus consists of multiple V, D (diversity) and J genes which make up the VH domain, 
and C genes which encode the CH domains. V, D and J genes are rearranged at random 
in a similar way to the light chains, except that the presence of D regions creates an even 
greater diversity for Ag recognition. In the heavy chain. CDRI and CDR2 regions are 
encoded by the V genes while the CDR3) region is encoded by theVPlgenes. 
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1.4.9 The Heavy Chain Constant Region Genes. 
There are eight functional heavy chain constant region genes in the mouse encoded by: 
(, ýt, C6. Cy-), Cyl, Cy2b, Cy2a. Cc and Cu. Humans have nine functional and t%\o iion- 
ftinctional pseudogenes encoded by: CýL C6, CY), C71, We, Cal, yyý C72, Cy4. CF- and 
Cu-2. Heavy chain constant region genes are not rearranged in immature B cells, but 
different heavy chain genes are expressed in B-cell maturation by a process called 1() 
class switching. 
1.5 B Cell Ontogeny and Antigen Independent Maturation. 
B-cell progenitor maturation is signalled by an antigen- independent ordered cascade of 
immunoglobulin gene rearrangements accompanied by the differentially controlled 
expression of cell surface antigens (39) (Figure 1.3 and 1.4). Pro-B cells are the first 
identifiable B-cell precursors. They express MHC class 11, CD 10 and CD34 but their 
heavy chain genes still retain genn line configuration on both chromosomes. 
Heavy chain gene rearrangements take place first on both maternal and paternal 
chromosomes. The sequence of gene rearrangement has been clarified by the use of 
murine B-cell lines, plasmacytomas, hybridomas and transformation of mouse pre- B 
cells by AMuLV (40), (41) and (42). First, D to J gene joining takes place. This is 
followed by V to DJ gene joining to give a VDJ rearranged gene which can be 
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transcribed with the heavy chain constant region gene. Cýt, to give a productive VDJCýt 
mRNA (43)). Productive mRNA, with VDJ transcribed in a viable reading frame, is able 
to produce a protein product which can be expressed, first as ýi heavy chain in the 
cytoplasm. and later on the cell SUrface with the pseudo-11(ilit chain or K and (44). 
PSCLido-liglit chain genes. \\, 'hich do not rearrange. are expressed early in the Pre-B cell 
(45). Their protein products may be associated with the newly synthesised g heavý, chain 
to form a cytoplasmic or membrane-bound complex. This occurs before the appearance 
of immunoglobulin light chain rearrangements (46), (47) and (48). The heavy chain V 
region of the pre-B cells (VpreB) has sequence homology to the light chain V regions, 
while ý, 5 and X14.1 are homologous to the light chain J and C regions. The protein 
product of ý. 5, co, is disulphide bonded to the ýt-heavy chain and the protein product of 
VpreB, t, is held in a non-covalent association to form a licavy/pseudo light chain 
heterocomplex (49). 
Appearance of the heavy chain protein product on the B cell surface., either alone, or 
possibly in association with the pseudo light chain components, prevents further heavy 
chain gene rearrangements on the other allelic chromosome (Figure 1.3a). The B cell 
may be held in stasis at this point in maturation as a self-renewing pool. When further 
maturation is required, a signal, possibly through a surface pseudo/light chain-heavy 
chain complex, may inhibit further transcription of t and o), and induce light chain 
rearrangements (50) (Figure 1.3b). K light chain genes rearrange first in a similar fashion 
to the heavy chain genes. If the K light chain product is non-functional, then ý. genes 
rearrange. Isotypic exclusion is responsible for which of the four Ig light chain alleles is 
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heavy chains in the endoplasmic reticulum (ER) and are transported to the cell-surface. 
When functional antigen receptors are expressed, further light chain rearrangements are 
inhibited (51) and (48). 
1.6 Antigen Dependent Maturation 
As soon as functional IgM (antigen receptor) is expressed at the B-cell surface. B cells Z-- 
are subject to antigen controlled development (figure 1.4). Immature B cells only 
express IgM on their surface, and it may be this stage that is important in tolerance to 
self-antigens. Mature B cells express both IgM and lgD- This change is marked by a 
change in DNA transcription. mRNA is not terminated in the ýt stop codon to the 5' of 
the C6 vene, but read-through occurs creating a primary mRNA transcript with both Cýt 
and C6 constant regions. Alternative splicing of the primary transcript deletes either Cýt 
or C6 RNA and either a ýt or 6 heavy chain protein is synthesisled and expressed with 
light chains on the surface (9), (10). At this stage B cells may take part in the primary 
immune response. 
Cross-linking of the antigen receptor with antigen, signals to the B cell and activates it. 
Site specific mutation in either the transmembrane region or the cytoplasmic tail of IgM 
indicates that these sections are critical for signal transduction. The IgM associated 
phosphoproteins, Iga or MB I (encoded by the mb I gene), and Igp or B29 (encoded by 
the b29 gene), are associated to form a linked heterodimer and are responsible for signal 
transduction of signals passed through the antigen receptor (52), (53) and (54). The 
IgeAgo heterodimer may also be involved in signaling through the pseudo/light chain 
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complex in pre-B cells (55). The MBI protein ma,.,,,, be required for transport and 
on of these complexes into the membrane (56). Although 
tý 
inserti I the IgM and IOD 
complexes on the mature B cell share the same associated proteins. other proteins rnay 
be present which confer different biological responses for tolerance. act'vatloji and 
memory mechanisms (57) 
Cross-linking of the Ig molecule with antigen and activation by T cells through cell/cell 
interaction and also by cytokines, causes B-cell activation, proliferation and loss of IgD 
(57) and (58). Under the correct conditions. B cells will differentiate into antibodv 
secreting cells (AFCs) or plasma cells. The shift from membrane IgM (mIgM) to 
secretory IgM (sIgM) is achieved at the RNA processing level and by post-translational 
regulatory control (59). 
Activated, mature B cells primarily secrete IgM. the first immunoglobulin to be secreted 
in an immune response. IgM+ B cells can also undergo heavy chain class switching to 
become IgA, IgG and IgE AFCs and to generate IgA+, IgG+ and IgE+ memory B cells. 
The function of immunoglobulin heavy chain class switching is to transfer an antigen 
binding site to a class of heavy chain which gives maximum protection against a specific 
pathogen. Immunoglobulin class switching is mainly controlled by Th cells via cell/cell 
interactions as well as by the various T-cell derived cytokines. 
20 
Pro-B 
germline heavy chain configuration, VpreB 
and X 14.1 X14.1 izene eXDression 
Pluripotent Stem Cell 
eavy chain rearrangements 
Pre-B 
Cytoplasmic ýt+ 










Activated B IgM+ 
Heavy Chain Class 
Switch 
Acl 
Activated B IgA+ 
A 
in 41; z 
Activatea ii igu-i- \1 
Memory B IgG+ 
IgG AFC IgA AFC 
Figure 1.4: B Cell Ontogeny 
Zýl 
Activated B IgE+ 
/ \4 Memory B IgE+ 
Memory B IgA 
IgE AFC 
21 
1.7 Mechanisms of Immunoglobulin Heavy Chain Class Switching 
Immunoglobulin heavy chain class switching allows an Ig molecule to chan(-Ye effector 
fI unction whilst retaining specific high affinity antigen binding sites. Ic: y, heavY chain class 
switching can take place either at the RNA or the DNA level. The most common L- 
mechanisms are outlined below . 
1.7.1 Class Switching at the RNA level. 
1) Alternative Splicing. Transcription of part or the entire heavy chain locus takes 
place producing a very long primary RNA transcript containing the VDJ and some or 
all of the heavy chain constant region genes. Alternative splicing of the large 
primary transcript, controlled by receptor/ligand binding responsive elements, 
produces a truncated mRNA with the VDJ region spliced onto the appropriate 
constant region exons, and deletion of the intervening RNA (60), (61), (9) and (10). 
This mechanism is used by the B cells for the dual expression of IgM and IgD. 
2) Trans-Splicing. Transcription of the heavy chain VDJ locus and one heavy chain C 
region (Cýt) produces a complete heavy chain pre-RNA. In addition there is 
transcription of one or more heavy chain constant region genes, possibly controlled 
by receptor signalling response elements. The pre-RNA VDJ region may be 
transpliced onto another pre-RNA C region to produce a heavy chain mRNA of 
alternative isotype (62), (63), (64) and (65). 
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1.7.2 Class Switching at the DNA Level. 
I) Unequal Sister Chromatid Exchange and 
Recombination. 
Homologous Chromosome 
Both these mechanisms involve UnCqual crossing over and recombination of DNA at 
sites of homology upstream of each heavy chain constant region gene. Sister chromatid 
exchange involves recombination of sister or duplicated chromosomes during 
metaphase. Homologous chromosome, or trans-switch, recombination involves 
recombination between the active and inactive allelic chromosomes either prior. or 
during mitosis. Both mechanisms result in the removal or transfer of C genes to the 
productive allele, changing the class of heavy chain transcribed (61) and (66). 
2) Site Specific Recombination: The Accessibility Model of Ig Heavy Chain Class 
Switching (Figure 1.5). Signalling through a cell surface receptor activates a 
responsive element which initiates the opening of, or accessibility to, the DNA at 
specific S (switch) sites. S Sites are tandernly repeating core oligonucleotide 
sequences stretching from I kb (SE) to I Okb (Sy) which are located 5' to each heavy 
chain constant region gene except for IgD (67), (68) and (69). Initial opening of the 
DNA at the S sites allows transcription of the individual constant region genes, 
producing non-productive, germline RNA (sterile transcripts). Switch site 
recombination may occur via a common switch recombinase enzyme, whose access 
to the DNA is carefully controlled, instead of site specific switch recombinases 
which are controlled individually. All heavy chain class switching may be affected 
by a common recombinase but under specific control by cytokine responsive 
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elements (61). Active cell division or mitosis. involving the unwinding of chromatin 
during chromosome replication, maY be needed to allow coming together, 
hornologous recombination of the S sites and deletion of the intervening circular 
DNA (70), (71) and (67). Cytokine responsive elements could control heavv chaiii 
class switching by increasing DNA accessibility upstream of specific heavy chain C 
region genes. In humans, a novel IL-4 responsive element has been found 5' to the v 
switch site which appears to play an important role in sterile transcript induction and 
switc recombination (72). Accessibility can be induced by creatingg: a) nucleosome Z-- 
free DNase I hypersensitive sites for recombinase or RNA polymerase access (7-3) or 
b) dernethylation of the DNA at the switch sites. The Ig and T-cell receptor (TcR) 
genes are methylated in germline and lymphold cells before activation and become 
demethylated after dernethylation of the lymphold recombinogenic sequences (e. g. 
Ig switch regions). This phenomenon is highly specific to cells of the lymphold 
lineage and such sequences are normally demethylated in other lineage cells such as 
hepatocytes and kidney cells. There is significant correlation between demethylation 
and Ig-gene transcription in the B lymphocytes (74). Finally, it is thought that sterile 
transcripts themselves may play more than a by-stander role in the Ig-heavy chain 
class switch mechanisms. Sterile transcripts occur in both mouse and human B cells 
(75), (76), (77) and (78), and may be important regulators of heavy chain class 
switching (79). Sterile transcripts may be trans-spliced into the VDJ of the current 
heavy chain RNA to allow transcription of the new Ig isotype alongside the old, 
before DNA recombination takes Place (80). This would create intermediary double 
isotype cells (633). Sterile transcripts may also a) interact with targets important in 
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chromosome structure for recombination and other DNA binding proteins involved 
in recombination (81). Each B cell will express one of the two parental I-g heavy 
chain alleles but never both -a process known as allelic exclusion. Lack of this 
process has been identified in B-cell chronic lymphocytic leukaemia patients in 
which the B cells undergo a class switch of one allcle with the incomplete expression Cý 
of the VH v-ene (82). 
1.8 IgE and Allergy. 
Over the past three decades, allergy has increased in prevalence within both 
inclustrialised and developing nations (83) and (84). Approximately 30% of the United 
Kingdom population suffers from some form of allergic disease, a statistic attributed to a 
plethora of reasons including increased diesel pollution (85) and (86), increased use of 
carpets which provide a comfortable home for house dust mites (87), and a decrease in 
early childhood infections which could be vital in preparing the immune system for later 
life and the inevitable encounter with potential allergens (88). 
Study of the involvement of the immune system in allergic disease was revolutionised in 
the 1960's by Ishizaka and colleagues with the discovery of immunoglobulin E (89) and 
(90). However, clinical investigation into the mechanisms of allergy had begun fifty 
years earlier in 192 1, when Prausnitz discovered factors in human serum which could 
transfer skin sensitivity from an allergic donor to a non-allergic recipient, later termed 
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the Prausnitz-Kustner test (Prausnitz 1921). Confirmation of the pivotal role of IgE in 
the pathology of allergic diseases was supported by clinical investigations into hayfe\-er 
(91), (92) and dust mite allergy (93)). 
1.8.1 Mechanism of IgE function. 
The function of IgE is ultimately dependent on a cell's IgE receptor expression profile. 
Two types of IgE receptor have been identified. Mast cells and basophils express the 
high affinity receptor (FcF-Rl) on their surface (94), the binding of which by IgE primes 
these cells to secrete. ) upon subsequent exposure to specific antigen. a panel of 
proinflammatory mediators. These can be immediate (histamine and heparin) or can be 
secreted at a later stage (leukotrienes, prostaglandins and cytokines). Cytokines such as 
IL-4, induces B-cell isotype class switching, IL-3 ) favours the maturation of mast cells 
and basophils, and IL-5 stimulates eosinophil infiltration (95). B cells, T cells, 
monocytes, eosinophils and some epithelial cells can express the low affinity IgE 
receptor FcF-RII, also known as CD23 ) (96). In humans there are two forms of CD23 
which differ in their intracellular amino terminal 6/7 amino acids. The A form 
corresponds to murine CD23, whereas the B form is also found on other haematopoietic 
cells including T cells. CD23 has been shown to have several different functions which 
are cell type specific. On monocytes, platelets and eosinophils CD23 mediates IgE- 
dependent cytotoxicity against parasites. CD23 expression on B lymphocytes is involved 
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in the IgE specific intemalisation of antigens for antigen processing and presentation to 
T cells. CD23 has also been shown to mediate the release of inflammatory mediators 
tI rorn macrophages and to be involved in signal transduction. The enzymatic cleavage of 
FccRII has been shown to produce a soluble form of the receptor which can regulate L- 
human 1(-11-- production and promotes T and B I. vrnphocyte prollferatlon (97). This 
indicates the role of sCD2-3) as an autocrine B-cell factor. Recent work suggests that 
sorne allergens. such as phospholipase A2 from bee venorn (98) and Der pI froni dust 
mite (99), (100) and (101). in addition to acting as immunogens, have the intrinsic 
ability to subvert the regulatory process of IgE synthesis, therby favouring an allergic 
outcome. Indeed, Der pI has been found to have a digestive function (102), cleaving 
CD2-)' from the surface of cultured B cells at two sites (103). This has been also 
confirmed "in vivo" by the use of mouse models. The upregulation of IgE via the 
digestive ability of Der pI can be also indirect as the latter cleaves CD25, the u-subunit 
of the IL-2 receptor, leading to a predominate Th2-type response with high levels of 
detectable IL-4 and IL-5 (104). 
1.8.2 Generation of IgE. 
For B cells to synthesise IgE, genetic rearrangement of immunoglobulin genes is 
required. The end product of these gene rearrangements is transcribed into mRNA 
transcripts encoding the constant and variable regions of the immunoglobulin molecule. 
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The variable regions of immunoglobulins are encoded by multiple germ line transcripts 
that are assembled into complete V(D)J regions by recombinase enzymes (105). 
Yhe isotype switching process facilitates the linka-(-)c between an antigen specific 
%ariable re()*on ofthe and different heavy chains which determine the 
fuiictionality of the final immunoglobulin produced. The recombination mechanisms 
which mediate this process delete regions between the V(D)J segments and the genes ltý 
encoding the various hea,,,, \, chain segments (CH genes). The recombination cNýcnts are 
initiated at highly repetitive regions of the genome known as switch (S) regions which 
lie 5' to the respective heavy chain region. At the level of the gene, isotype switching is 
thought to be regulated by factors which cause local alterations in chromatin structure 
thereby increasing the accessibility of the various S regions to switch recombinases 
(106). 
Isotype switching is preceded by the production of a germ line transcript immediately 
upstream of the CH gene. These transcripts contain several stop codons and are 
consequently never translated into proteins, hence they are known as "sterile 
transcripts". Whilst their role in switch recombination remains unclear. their production 
is essential for the process to occur (107), (108). 
At a cellular level, B cell immunoglobulin class switching is regulated by cytokines of 
which two have been shown to selectively promote switching to IgE, IL-4 (109) and 
(110) and IL- 133 (111). Treatment of B cells with IL-4 has been shown to initiate the 
synthesis of a 1.7-1.9 kb sterile transcript of the CF- region containing a 
2kb region 
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upstream of the F- switch region, and the four exons encoding the heavy chain domains 
of IgE (75). Ligation of the IL-4 receptor u-chain leads to STAT6 and IRS-2 activation. 
which, in combination with CD40 / CD40L interaction leads to IgE class s\vitching 
( 112). IL- 13 expression by allergen stimulated T cells is also increased in allergic 
disease and is associated with higher levels of eosl IIII :t inophil stimulatiril, ), cYtokine IE-5 
(113). Other cytokines such as IL- 10 and TGF-ý are reported to promote s--, vitchina to L- 
IoGl and IgG') (114). (115) and LYA (116) respectively. IFN-y. IL-10 and IL-2 have L- CII 
been shown to inhibit IgE transcription (117), (118). and IL-5 and IL-6 can enhance IL-4 
induced IgE production (119). IL-4 was shown to be essential for IgE synthesis in Ovo 
in mice infected with the nematode Nippostrongylus braziliensis where anti-IL-4 (120), 
and anti-IL-4 receptor (IL-4R) antibody, inhibited IgE synthesis. though these studies 
also raised the possibility of STAT6 independent pathway of type 2 response (121). 
Ongoing IgE responses in animals sensitised with the nematode Heligniosomoides 
polygyrus, which induces a chronic IgE response, were inhibited with anti IL-4 (120) 
indicating that IL-4 is required for continued IgE production. The requirement of IL-4 
for IgE synthesis was confirmed in IL-4 knockout mice (122) which were unable to 
produce IgE. It is clear from these observations that type 2 responses favour IgE 
production whilst type I responses promote the production of other immunoglobulin 
isotypes. 
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1.9 IgE Switching 
Induction of IgE in human cells involves three distinct steps: a) induction of F_ germ-line 
transcription, b) DNA recombination and c) mature RNA transcription/translation (12131). 
The study of switching to a partICUlar isotypc such as 1(-YE. is rather difficult as freshly Z, - 
isolated polyclonal B cells are required that should be homogeneous in their genetic 
make-up. Ideally. such monoclonal cells should be sIgM+, slcD+. they should undergo a t-- 
high rate of switching to all downstream Ig classes in response to physiological stimuli. 
possibly in a cytokine-directed fashion, and finally they should display the phenotypic 
changes that are putatively attributed to B cells that switch and progress through the 
germinal centres. No B-cell line witli all these properties has been reported yet. 
The importance of IL-4 and anti-CD40 in IgE B cell switching is well established 
(124). IL-4 plays multiple roles in the induction of IgE synthesis. It promotes IgE 
switching, by enhancing the accessibility of the F--switch region to the common 
recombinase (125). Furthermore, it increases the expression of MHC class 11 antigens on 
B cells, enhancing their anti gen-pre senti ng capacity (126) and (127). Thus, IL-4 would 
promote T/B cognate recognition and at the same time drive the B-cell response towards 
the IgE isotype. The possibility exists that the CD40 mAb promotes IgE synthesis in the 
presence of IL-4 because it is so effective in keeping the B cells growing in culture 
for a 
long time, thereby giving the B cells time to switch or to divide and produce IgE. 
The signals required for isotype switching are provided to the B cell by a complex 
series of interactions with an antigen specific T cell (124). Engagement of the 
T-cell 
receptor/CD3 complex by MHC class 11 molecules results in the rapid expression of 
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CD40L, which engages CD40, the counter-receptor constitutivek 7 expressed on the 
surface of B cells (128). T/B cell interactions mediated by CD40/CD40L are amplified 
by interactions of accessory molecules, particularly the CD28/137 ligand/receptor pair. 
The sequence of events taking place during the interaction between T and B cells, 
leading to 1(-, E switching, are shown in fioure 1.6. Interaction between CD40 and CD40L -I- - L- 
generates the secondary signal (signal 2) for the switching process (129). Engagement of 
CD40 results in the expression of B7 molecules on B cells. B7 engages CD28. inducing 
high rate of secretion of IL-4 by the T cells (1330), (1331) and (132). IL-4 binds to the 
heterodimeric IL-4 receptor (IL-4R), which consists of an cc chain (shared by the IL- 
1-3) R) as well as ay chain (shared with the receptors for IL-2, IL-7, IL9 and IL- 15) (13 3). 
IL-4 (as well as IL-13), target the C epsilon gene for switch recombination (129) and 
(1 '14). This is signal I of the process. At this stage the B cell receives both signals 
required for IgE switching: IL-4 triggers F_ germ-line transcription, thereby targeting the 
F_ gene region for recombination. Cross-linking of CD40 with CD40L activates DNA 
recombination to the targeted F- switch region, leading to IgE isotype switching and IgE 
secretion (124). It has become clear that in the absence of IL-4 no substantial IgE 
synthesis is possible, although some murine knockout models are somewhat leaky in this 
respect (13 5). IL-4 appears to act by selectively stimulating germ line transcription at the 
CH71 locus making the CH71 gene accessible to the action of a putative switch 
recombination enzyme (70). IL-4 also induces the appearance of germ-line CHF_ RNA 



























1.9.1 IL-4/IFN-y balance 
The importance of IL-4 in IgE switching in humans, was first demonstrated by (109) and 
(I 10). The nature of IL-4 as a "type 2" cytokine has also been confirmed (119). The 
'Fli I /-I'li2 hypothesis was taken further by proving that **tNIpe F cytokines, sucl-i as I F'N-y. 
will downregulate the process of IgE production -in vitro" (I 10). This was further 
supported by the fact that helminth infected individuals can produce some IL-4 (137), 
however they also increased IFN-y production reflected both by expanded numbers of 
IFN-y-secreting T cells and increased IFN-y in culture supernatants compared to 
individuals with high serum IgE levels. A reduced production of IFN-y in the serum of 
patients with atopic dennatitis was also observed. However, a disturbed balance in the 
production of IL-4 and IFN-y is unlikely to be the only explanation for increased IgE 
synthesis in atopic patients, and it is not known why allergen-specific T cells produce 
more IL-4 than do other T cells. Although the exact inhibitory action of IFN-y is not 
fully known, it has been suggested that it acts indirectly, by blocking the effect of IL-4 
on B cells and by suppressing the ongoing IgE production by the already switched cells 
(138). The balance of "type I"Ptype 2" cytokines might be the key for explaining the 
dysregulation of IgE in atopic patients, and a possible link with this balance has been 
suggested (13 9). 
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1.9.2 IL-13 
IL-13) can cause IgE switching in human (not mouse) B cells activated by CD4+ or 
CD8+ T cells. but not to the sarne extent as IL-4 (140). IL-4 and IL- F, ) are strucairally 
and ftinctionally related and are most likelý the product of gene duplication. IL-13 did 
not have anv additive or synergistic effects on IL-4-induced IgE sYnthesis when both 
cytokines were added at saturating concentrations. suggesting similarities of the Z-- 
signaling pathways of these two cytokines (I 11). This was further supported by the 
observation that mAbs specific for the IL-4R u-chain were shown to block the 
biological functions of both IL-4 and IL-13, indicating that the IL-4R (Y-chain is a 
common component of both IL-4R and IL-13R complexes (141). The main difference 
between the biological functions of IL-4 and IL- 133 is that the latter can not drive Th2 
cell-type differentiation (142). IL-133 was found to have an indirect mode of action 
regulating IgE secretion, as it was found that it inhibits production of IFN-y and IL-12 
by monocytes (I 11). 
1.9.3 IL-2 
When B-cell cultures were stimulated with IL-4 in the presence of autologous T cells, a 
significant and dose-related increase of IgE synthesis was found. Such an increase was 
abolished by the addition of anti-IL-2 antibody. Further experiments showed that IL-2, 
even in the presence of IL-4, was unable to switch B cells to IgE, in the absence of T 
cells (143), probably due to the absence of the important CD40L. However, its presence 
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in culture was apparently important for the IL-4-dependent "In vItro- IgE synthesis. The 
potentiating action of IL-2 was indirect as it caused T cell proliferation which in turn 
secreted cytokines (such as IL-4, secreted by Th2 cells). that w-ould cause B-cell 
sxvitchino to 1(-YE. IL-2 has been shown to have variable effects on B cells which have t--- - 
been proven to be direct as B cells possess IL-2R ( 144). Experiments with IL-2 showed 
that IL-4-iiiduced IgE synthesis -in vitro", by B celJs from BALB/c or nude mice, was 
inhibited when rIL-2 was added to the culture, in the absence of T cells (145). This 
inhibition, which is expected as IL-2 is a "type F cytokine. was more pronounced when 
the cytokine was added at day 0. Addition of anti-IL-2 antibody reduced the inhibition, 
whereas addition of anti-IFN-y had no action on the reduction produced by IL-2, proving 
that the inhibition of IgE by the rIL-2 was due to this cytokine. The suppression of IgE 
and IgG I by IL-2 is probably different from that produced by IFN-y. 
1.9.4 IL-6 
IL-6 had a synergistic effect when added with IL-4 to B-cell cultures, increasing the 
levels of IgE produced (143). Anti-IL-6 was found to have a partial inhibitory effect on 
IgE synthesis. In addition, IL-6 was able to enhance spontaneous IgE production by B 
cells from patients with severe atopy, suggesting that it may act on cells already 
producing IgE, probably amplifying the secretion of this Ig class, as it does for other Igs 
too. Punnonen and de Vries, (1994), also demonstrated a synergistic effect of IL-6 on 
IL-4 in B-cell Proliferation,, IgG4 and IgE production by foetal immature B cells and 
highly purified CD19+ tonsillar B cells (146). 
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1.9.5 IL-5 
In several experimental systerns, IL-5 has been shown to enhance secretion of IgGI and 
IgE from B cells stimulated with IL-4. For example. IL-5 induces secretion of IgE of 
human PBL stimulated with IL-4 (126). Results from another study on IL-5 concluded 
that it can provide a second signal necessary for isotype switching to IgGI and IgE 
(147). However, this effect of IL-5 is dependent on an Initial B-cell activation stimulus, 
such as cross-linking surface Ig, or contact with plasma membranes, isolated from 
activated T cells. Thus, IL-5 cannot replace completely the signals provided by the B- 
cell contact with T cells. 
1.9.6 IL-9 
IL-9 can have a direct potentiating effect on IL-4-dependent IgE switching of murine B 
cells "in vitro". An indirect effect of IL-9 was suggested, as it was found to cause an 
increase in the production of IL-6 by B lymphocytes (148). 
1.9.7 IL-7 
IL-7 enhances Ig recombinase gene activity in human progenitor B cells and , 
consequently may affect VDJ recombination (149). Jeannin et al., (1998), showed that 
IL-7 synergises with IL-4 to induce human IgE and IgG4 production in a T- 
cell-dependent fashion (150). This effect is mediated at least in part through an increase 
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of both cell surface markers (such as CD23) and other cytokines such as IL-4. IL-6. IL-9 
and IL-133. 
1.9.8 IL-10 
IL- 10 is a cytokine produced by several cell types after activation. including the THO. 
Th I and Th2 CD4+ T cells. a proportion of CD8+ cells, B cells and monocytes (151). 
IL-10 prevents Ag-specific activation and proliferation of T cells by reducing the Ag- 
presenting capacity of monocytes, which is associated with a strong down-regulation of 
class 11 MHC molecules on these cells (152). In addition, IL-10 inhibits the secretion of 
pro-inflammatory cytokines and is an important suppressor factor for 
immunoproliferative and inflammatory responses IL-10 is also reported to inhibit 
spontaneous IL-4 induced IgE production by PBMCs (20 ng/ml => 2.33 ng/ml of IgE) in 
a dose-dependent fashion (153). The inhibitory effects were specific for IL-10, because 
they were completely neutralized by anti-IL-10 mAb (153). 
1.9.9 IL-12 
IL- 12 promotes cell-mediated Th I responses followed by an increase in the secretion of 
IFN-y that downregulates IgE production by human PBMCs (154). The most potent 
effects of IL- 12 occur when it synergises with IL- 18. The latter can be synthesised by 
macrophages and DCs, and in combination with IL-12, can induce an even stronger Th I- 
type response accompanied by production of IFN-y (155). IL-18 was shown to have no 
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effect on the IL-4-dependent IgE secretion when cultured with BALB/c mouse B cells 
(156). Combination of IL- 12 and IL- 18 is known to downregulate the production of IgE 
by hurnan B cells via the induction of IFN-y secretion by atopic PBMCs and human NK 
cells (157). (158) and (159). 
1.9.10 TGF-0 
It is also well established that TGF-ý is an IgA switch factor for both murine and human 
B cells. The inhibitory effect of this cytokine on the IL-4-dependent IgE switching can 
be brought about directly (inhibition at the molecular level) and indirectly (preferential 
switching to the IgA isotype) (160). 
1.10 Other factors affecting IgE switching. 
1.10.1 Chemokines. 
Chemokines can act on various cell types, including neutrophils, eosin-cphils, basophils, 
monocytes, myeloid progenitors, T and B cells (161). A study carried out by Kimata et 
al., (1996), demonstrated that RANTES and MIP- I a, both members of the P-chemokine 
subfamily, enhanced IgE and IgG4 production induced by IL-4 plus anti-CD40 m Ab in 
a dose-dependant fashion (162). In contrast, no other chemokines of the ý-subfarnily had 
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any effect on the production of JgG4 and IgE, at any concentrations. Enhancement of 
IgE production by RANTES and MIP-I(x was specific, as there was inhibition of this 
production after the addition of anti-RANTES or anti-MIP- Ia antibodies respectively. 
The enhancement was caused by stimulation of L-1 production and not by proliferation of 
IgG4+ and Ed'i- B cells, since RANTES and MIP-lu. have no proliferatino effects on B Cý 1 11 
cells. 
The fact that IL-4 inhibits IL-8 production by monocytes lead to the study of the 
effect of IL-8 on IL-4-induced IgE production. It was demonstrated that IL-8, a member 
of the oc-subfamily of chemokines, selectively inhibited IgE production in MNC 
stimulated with IL-4 (163). Inhibition by IL-8 was specific since it could be blocked by 
anti IL-8 antibodies but not by control mouse IgGl. IL-8 also selectively inhibited IgE 
production by B cells stimulated with IL-4 and anti-CD40 antibody (163)). Kinetic 
experiments showed that IL-8 had to be added at the initiation of the culture. Delayed 
addition of IL-8 after I day of culture had no effect. These results indicate that IL-8 
inhibits the early activation step during IL-4 stimulation, and that the inhibition is not 
due to cytotoxicity. Preliminary work had also shown that IL-8 inhibits proliferation of 
human B-cell lines stimulated with IL-4 (164). 
1.10.2 CD30. 
The importance of CD40 ligation in providing the secondary signal for IgE switching, 
(as well as for B cell survival), is widely accepted. However, the signaling pathway 
through CD40 does not seem to be identical to that induced by activated CD4+ T cells 
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suggesting that additional membrane bound molecules are involved in the induction of 
B-cell proliferation, isotype switching and differentiation (165). Cerruti et al.. used a 
monoclonal model of germinal centre maturation (CL-01 B cells). to investigate the role 
of CD33O in human B-cell differentiation (166). The results suggested that CD-30 
critically regulates the CD40-mediated differentiation of non-antigen selected human B 
cells. Switching was hampered by CD'30 co-engagement, possibly through interference 
with the CD40-mediated NF -kappaB -dependent transcriptional acti-vation of down- 
stream C(H) genes (166). 
1.10.3 CD23/CD21 
I. CD2-3 is a type 11 membrane glycoprotein containing four highly conserved and two 
partially conserved cystemes with C-type lectins (167). The CD23 molecule is expressed 
on a wide variety of cells,, including B cells, T cells, a subset of thymic epithelial cells, 
follicular dendritic cells, Langerhans cells, monocytes eosinophils, platelets and EBV- 
containing nasopharyngeal carcinoma cells (168). IL-4 and IL-13 increase CD23 
expression. IFN-y, which inhibits IL-4 dependent-IgE switching of B cells, was also 
found to inhibit the IL-4-mediated expression of CD23 on B cells (169). sCD23 has been 
shown to augment ongoing spontaneous IgE production by B cells obtained from atopic 
individuals,, and to act synergistically with sub-optimal concentrations of IL-4 to induce 
IgE production by nonnal human B cells (170). The importance of CD23 or its soluble 
fragments in the synthesis of human IgE "in vitro" was highlighted by the demonstration 
that certain anti-CD2-33 mAbs blocked IL-4-induced IgE production by normal B cells as 
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well as B cells obtained from atopic patients (96). It was mentioned earlier that the 
production of IgE -in vivo- requires direct contact between B and T cells. The 
potentiated action of CD23) in IgE secretion involves this T/B cell interaction. something 
that was proven when addition of anti-CD'-? ') mAbs in culture inhibited the formation of 
T/B con*ugates ( 171). Stud I CS LISIM-1 Inhibitory anti-CD21 Abs. as wc II as the bindino of 
1) * CD2-3-liposornes to recombinant CD21-transfected cells have revealed that CD23 binds 
to a subtype of CD21, a molecule that had previously been identified as a receptor for 
EBV and as complement receptor-2. CD21 is expressed on B cells, follicular dendritic 
cells and on T cells. Anti-CD21 Abs were found to decrease T/B cell interactions Oust 
like anti-CD'--") Abs), something that was expected as CD23/CD21 pairing has a role in 
T/B cell interaction. Thus. CD21 appears to be another molecule involved in the 
formation of T/B cell conjugates. Molecular analysis revealed that triggering of CD21 
increased the IL-4-dependent germline C transcription levels and had a synergistic effect 
on the expression of c transcript induced by T cells (172). Based on the observation that 
triggering of CD21 by either anti-CD21 Abs or by sCD23 enhances IgE production both 
in T-cell independent and dependent systems and based on the reported induction of 
CD23) on T cells by IL-4 and allergen, one can speculate that in allergic individuals, T- 
cell associated CD23 may interact with B-cell associated CD21 leading to an increase in 
IgE production (173). Moreover, the interaction between CD23/CD21 controls IgE 
production more selectively than CD40/CD40L, as CD23 was shown to modulate the 
Ag-specific IgE response in an isotype-selective manner "in vivo" (174). CD23, also 
known as FcF-Rll can bind IgE enhancing most antibody immune responses. The IgE- 
mediated enhancement is completely inhibited by mAbs specific for CD23 (175). "In 
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vitro". CD23 exerts its effects both as cell bound receptor and in a soluble form. Murine 
sCD2-')' was in early reports claimed not to bind IgE, but later data, proved that it can do 
so but with I 00-fold lower affinity than the receptor form of CD23 (176). The only 
receptor reported to interact , vith hurnan sCD233 was CR2/CD21 (177). Monoclonal Abs 
a(lainst IllUrine CD21 or of soluble rCD2' III 21 almost completely Inhibit the antibody 
response to conventional antigens (178). However, treatment of mice with anti-CD21 
before immunization with IgE and antigen had no inhibitory effect. thus arguing against 
the possibility that sCD23), in complex with Ag and IgE, exerts an effect via CD21. 
Production of sCD23 is dependent on the proteolytic cleavage of membrane CD23. but 
the proteases involved in this process remain largely unknown, although recent evidence 
suggests that the main enzyme involved is a zinc-dependent metal I oproteinase (179). 
Inhibition of the enzyme responsible for cleaving mCD23 would have a negative 
regulatory effect on IgE production. The use of G1129471 (a broad spectrum zinc- 
metal loproteinase inhibitor). indeed inhibited the production of sCD23 reducing the IL- 
4-dependent IgE secretion in purified B-cell cultures, after 14 day incubation. Such a 
profile of activity may be useful in the treatment of allergic diseases', especially in light 
of evidence suggesting that sCD23 may play a further role in allergic hypersensitivity 
reactions by directly inducing histamine release by human mast cells (180). 
1.10.4 CD28 / B7.1+B7.2 
In a study carried out by Life et al., it was shown that anti-CD28 mAbs produce a 
dose- 
dependent inhibition of IgE, but not IgG synthesis, by tonsillar B cells when driven by 
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an allergen specific T-cell clone in the presence of IL-4 (181). When a T-cell clone and 
tonsillar B cells were co-cultured with IL-4 under the conditions used to induce IgE 
synthesis, there was a progressive increase in the expression of CD28 on the T cells. 
while the expression of another T-cell marker. CD45RB. was not affected. Co- 
HICUbation of T and B-cell CLIltUl-eS \Vith a dialyzed anti-CD28 mAb for 14 days I-CSUlted 
in a very strong and dose-dependent inhibition of IgE synthesis which was accompanied 
by a decrease in cell aggregate formation. The effect on IgG synthesis was considerabl%, 
less marked and may be explained by a specific reduction of IgG4 isotype. the 
production of which is both IL-4 and T-cell dependent (182). Anti-CD28 mAbs inhibited 
the conjugate formation between T and B cells, which as previously mentioned is 
required for IgE switching. This is probably the inhibiting mode of action demonstrated 
by the anti-CD28 mAbs. CD28 binds with B7.1 and B7.2 which can be found in many 
cell populations such as B cells. Its interesting to note that in the study of Life el al., 
addition of anti-B7.1 antibodies in the T/B cell co-cultures did not have any effect on the 
synthesis of IgE (181). This was contradicted by the study of Jeannin et al., (1997), 
which showed that the anti-B7.2 antibody, IT2.2, could potentiate IgE and IgG4 
production by human B cells "in vitro", in the presence of IL-4 and anti-CD40 (183). 
CD28 expression on T cells increased in the presence of IL-4, as well as the levels of 
B7.1 and B7.2 on the B cells. This fact, together with the knowledge that IL-4 would 
activate Th2 cells, provides us with further evidence about the potentiating effect of IL-4 
on IgE switching and synthesis by the B cells. 
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1.10.5 ICAM-I/LFA-1 
Recently, signaling through ICAM- I has been shown to complement the help provided 
by CD40 ligation to increase Ig synthesis by B cells and anti-LFA-1 and ICA. %, I-l rn. Ahs 
can inhibit T-cell driven lu prodUCtion -in vitro" (184). 
1.10.6 mTNF-oc 
In another study, by Aversa et a/., (199' )). it was demonstrated that the 26-kD mTNF-ot 
expressed on activated CD4+ T-cell clones provides a co-stimulatory signal required for 
IL-4-dependent Ig production, including IgG4 and IgE synthesis by B cells . mAbs 
against both mTNF-a and the p55 TNF receptor (TNFR) inhibited Ig production, 
indicating that in addition to CD40L-CD40 signaling, interactions between mTNF-cc 
and its putative ligand, p55 TNFR, are involved in the induction of B-cell activation by 
activated CD4+ Th cells (185). Anti-TNF-(x mAbs did not block Ig production induced 
by anti-CD40 mAbs and IL-4 in the absence of T cells, indicating that inhibition 
occurred at the Th cell and not at the B-cell level. In addition, the observation that anti- 
TNF-(x mAbs effectively blocked Ig production in cultures where intact CD4+ T-cell 
clones were replaced by their plasma membranes, is consistent with the idea that mTNF- 
a expressed on activated T-cell clones, rather than soluble TNF-(x produced from these 
clones, was the target of the anti-TNF-ec mAbs. This notion was further supported by the 
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finding that pre-treatment of the T-cell plasma membranes with anti-TNF-cc mAbs 
decreased their capacity to induce B cells to produce Ig (185). 
1.10.7 LFA-3 (CD58)/CD2 
LFA-_') (CD58), is a cell-adhesion molecule distributed on cells of different tissues and 
present on most blood cells. Its natural ligand is CD2 present on T cells (186). Studies 
investigating the role of CD58/CD2 interactions in human B-cell differentiation have 
shown that mAbs to both CD58 and CD2 inhibited T-dependent B-cell responses by 
interfering with cell-cell interaction (187). In a study carried out by Diaz-Sanchez ef al., 
(1994), it was shown that ligation of B-cell surface CD58 can provide IL-4 stimulated B 
cells with a second signal to induce IgE production in the absence of T cells or anti- 
CD40 (188). Murine T hybridomas transfected with CD2 could induce IgE production 
by purified B cells stimulated with IL-4, suggesting that the CD58/CD2 interaction can 
provide the stimulus for class switching and subsequent production of IgE. The role of 
CD58 in IgE switching is distinct from that of CD40 stimulation, showing that adhesion 
molecules may play a vital role in the regulation of IgE switching. In the experiments by 
Diaz-Sanchez et al., no other isotypes were produced by the purified B cells in the 
culture (188). Whether the IgE-isotype specificity was due to the CD58 surface molecule 
or to the presence of IL-4 was not determined. The fact that the signal for IgE synthesis 
provided by CD58, is independent of the CD40 binding, was confirmed by addition of a 
CD40-Fc fusion protein, which caused 65% inhibition of CD40-driven IgE production. 
but did not cause a decrease in the CD58-driven IgE production. Furthermore, human 
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CD2. the natural ligand of CD58. when expressed on murine liybridoma cells. induced 
an IgE response in the absence of CD40. The addition of both anti CD58 and anti-CD40 
Abs to B cells cultured with IL-4 did not result in synergy, no co-stimulatory effects on 
1(-, E production were observed. and CD40 always gave greater 1(-, E responses. These 
findmos sucycest that CD58 and CD40. although differing In their surface receptors. rnav - L- t- L- i t-1 i- 





A second ligand has been described for CD2, this new ligand, CD59, is involved in T- 
cell adhesion (189). Whether it too can play a role in IgE induction has yet to be 
determined. Finally, human and rnurine NK cells have been shown to play a role in IgE 
production, thought to involve CD23 (190). Because NK cells express CD2, this might 
be an additional ligand by which they can modulate IgE switching and production by B 
cells. 
1.10.9 Other biological molecules. 
Apart from the various cytokines and the cell surface molecules that can regulate IgE 
switching there are other factors that can also affect this process. For example, if B cells 
tre already primed with a certain antigen. then the nature of the antigen will dictate 
whether the B cells can switch to IgE synthesis in the presence of IL-4. In such a study, 
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Snapper et aL, (1991). showed that IL-4 containIng CD4+ T-cell supernatant stImulated 
large amounts of IgGI and IgE from LPS-activated B cells, but failed to stimulate 
detectable levels of IgE with u6-dex-activated cells. despite inducing high levels of'l(-), \l 
and IgGI (191). 
Other biolooical moICCLdeS that can mOdUlate 1(-)E s\\ itching are the retinoids. Their role 
in the process was analyzed by Tokuyarna and Tokuyarna (1996). using LPS-stimulated 
murine B cells were cultured with IL-4 and IL-5 which enhanced IgE production. This 
study found that the synergistic effect of IL-5 in IgE synthesis could be attenuated bý- the 
addition of retinolds at a concentration of I nM (192). 
Another group of molecules which contribute to B-cell differentiation and hence, IgE 
switching, are the arachidonic acid (AA) metabolites (193)). To evaluate the exact role 
of AA metabolites in the regulation of IgE production. Punnonen and co-workers added Z-- 
indomethacin, an inhibitor of the cylcooxygenase pathway, or NDGA. an inhibitor of the 
lipooxygenase pathway, to IL-4-treated cultures. Both indomethacin and NDGA 
inhibited IL-4 induced IgG4 and IgE production to the same extent (193). The inhibitory 
action of the AA metabolites is not fully elucidated but may involve a combination of 
many molecular factors. 
Prostaglandins (PG) of the E series are generally known to suppress immune responses. 
However studies involving the PGs, carried out by Roper et al., found that PGE 
synergized with IL-4 to induce IgE and IgGI production in LPS-stimulated murine B 
lymphocytes (194). PGE I and 2 significantly increased IgG I and IgE production (up to 
26-fold) at all concentrations of IL-4 tested (194). In addition to its effects on IgG I and 
IgE, PGE also causes a significant decrease in IgM and IgG3 synthesis. suggesting that 
PGE may promote IL-4-induced class switching. PGE usually mediates its effects by 
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increasing the levels of cAMP. This was confirmed from the fact that other agents that 
can increase the levels of cAMP. such as cholera toxin, can also enhance the production 
of IgGl and IgE "M vitro", while diminishing that of IgG-33 and IgM. A further studv bN- Iý 
Roper et al.. dernonstrated that PGE increases the number of splenic B cells secreting 
IoI in culture. and that PGt- svncr, -, izcs with IL-4 and LPS in th I c LE s\\ltclllll(l pl*ocess Z!:, 
of B cells (195). It was also found that PGE acts on the level of transcription as it aids 
IL-4 to induce F- germline transcripts. Thus, PGE may play a role in atopy "in vivo-, 
were PGE-secreting cells, such as macrophages, follicular dendritic cells and fibroblasts 
can promote IgE synthesis (195). 
Finally, Hasbold and co-workers, showed that recombinant CD40L and IL-4 are 
sufficient to induce switching to both the IgGI and IgE isotype but also each of the 
switching events is related to division cycle number (196). This is consistent with the 
study carried out by Lundgren et al.. who proved that B-cell switching requires DNA 
replication (197). This principle is further supported by an "in vivo" study initially done 
by Kind and Malloy, showing that Ag-specific IgG+ cells usually appear in the blood 3- 
6 days after immunization, becoming more numerous with time, while the IgE-secreting 
cells appear in the circulation after day 6 (198). The relationship between division and 
isotype expression was examined by Hasbold et al., by stimulating B cells with 
membranes of insect cells infected with CD40L recombinant baculovirus and 
recombinant IL-4. From this experiment it was found that IgM, IgD and IgG I expression 
changed in a cell-division manner, and most importantly that IgE expression was also 
independent of culture time but more related to the division cycle number (196). 
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1.11 T CELLS. 
T-lymphocytes are antigen-specific cells of the immune sYstem that recognise antigen bY 
means of cell surface antigen receptor (TCR). Based on the expression of co-receptor t-- 
molecules, T cells can be subdivided into Cf)4-, and CD8-- T cells. CD4-ý- T cells are 
mainly seen as helper T cells involved in both hurnoral and inflammatory immune 
responses while CD8+ T cells are traditionally seen as cytotoxic cells NvIuch specialise in 
killing virus infected cells. In addition. the existence of a distinct subset of T cells 
expressing y6 as opposed to ccý TCR chains, has been recently established (199) and 
(200). These y6 T cells are present in the lymphold organs but are especially abundant in 
epithelial tissues where they are thought to be involved in innate immunity (201). 
1.11.1 Functional Subsets of CD4 T cells. 
The heterogeneity of CD4 cells based on cytokine secretion patterns was first described 
more than a decade ago (202). Two distinct cytokine secretion patterns were first 
recognised among differentiated mouse CD4 T cells. Thl cells secrete interleukin-2 (IL- 
2), interferon-7 (IFN-7) and lymphotoxin (LT), whereas Th2 cells secrete IL-4, IL-5, IL- 
6, IL-9,5 IL- 10 and IL- 13 (202). Human CD4 T cells display similar cytokine secreting 
phenotypes, although the synthesis of IL- 10 is not tightly restricted to the Th2 subset 
(203). Some cytokines, such as IL-3' and GM-CSF, are secreted by both Thl and Th2 
cells (204). ThO cells expressing both type I and type 2 cytkines have been described 
(205) and (206) in human and mouse systems (207) and (208). Whether ThO cells are the 
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only precursors for Thl and Th2 cells (209), (210) or represent a separate. stably 
differentiated phenotype (211). (212) and (213) is still unclear. ThO cells could play a 
role in eliminating pathogens in situations were a balance of cell mediated and humoral 
responses would ensure both eradication of the pathogen and minimal 
i mnitinopatholoý, v. 
These subsets are not an in vilro phenomenon as Thl and Th2 cells develop during an 
immune response and are present at sites of inflammation (214) and (215). Although 
many freshly isolated populations secrete a non-restricted. ThO like panel of cytokines, 
chronic inflammatory conditions usually result in highly polarised Thl/Th2 responses. 
This is probably achieved through the cross-inhibitory effects of the cytokines theý 
produce. At the single cell level, among short-term T cell populations, IL-4 and IL-5 are 
often co-expressed whereas IL-4 and IFN-y are mutually exclusive (216). (217). (218) 
and (219). However. single cell cytokine expression also indicates that patterns other ZZ) 
than the extreme Th I and Th2 exist: for example the co-expression of IL-10 and IFN-y 
(216). In addition, in some systems, CD4 clones show a random distribution of type I 
and type 2 cytokines, raising the question of the validity of the Thl/Th2 paradigm (206) 
and (207). However, most clone data supports an inverse correlation of IL-4 and IFN-y 
and positive association between IL-4 and IL-5 (206). 
The distinct cytokine profiles of Thl and Th2 cells are closely associated with their 
functional capabilities. Thl cells are primarily involved in cell-mediated inflammatory 
reactions, whereas Th2 cells play a major role in humoral and allergic responses. 
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1.11.2 Functional Subsets of CD8 T Cells. 
Historically, CD8 cells have been regarded as a homogeneous population of CD4- 
dependent cytotoxic cells producing IFN-y, directed against viral infections and 
intracellular pathogens. The role of CD8-T- T cclls in immune suppression has been L- 
identified. These cells got known as suppressor T cells (220), (221), (222) and (223). 
Recently, CD8 T cells have been found to secrete a wide variety of cytokines indicating 
a potential role in immune regulation. 
A number of groups have shown that both human and mouse CD8 T cells are able to 
produce IL-4 when stimulated with anti-CD3 or mitogens (224) and (225). especially 
when primed in vitro in the presence of IL-2 and IL-4 (226) and (227). It was also 
observed that freshly isolated peripheral blood CD8 T cells have the potential to make 
IL-4 at similar if not greater levels than those produced by comparable CD4 T cells 
(228). 
CD8 T cells secreting type 2 cytokines have also been isolated in a variety of diseases 
indicating that such cells are more than an in vitro phenomenon. Salgame et al. reported 
that some of the M leprae-specific CD8 clones generated from the patients with 
Lepromatous leprosy made IL-4, IL-5 and IFN-y but not IL-6 or IL-10 (221). These 
clones were termed type 2 clones or suppressor clones. However, they were atypical as 
they were apparently MHC class 11 restricted while IL-6 and IL-10 are usually secreted 
by such clones (229). Th2-like CD8 T cells secreting IL-4 and/or IL-5 and no IFN-y 
have also been found in HIV infected individuals (229). CD8 T cells producing high 
levels of IL-4 and IL-5, have also been isolated from lungs of asthmatic patients (237), 
(258) and (230). 
In the mouse, CD8 T cell subsets comparable to Th I and Th2 have been generated from 
naive Precursors following stimulation by antigen presenting cells in the presence of the 
polarising cytokines (2331). Analo(-lous to the CD4 nomenclature these subsets were Z7ý 
terined Tcl (secreting IL-2 and IFN-y and Tc2 (secreting IL-4 and IL--5 and varlablv 
reduced amounts of IFN-y). These results were confirmed by Sad and colleagues using 
cytokine primed alloantigen-stimulated CD8 T cells (2-332) and by Cronin and colleagues 
using a regimen of repeated stimulation without priming with exogenous cytokines 
(233). In human and rat, synthesis of IL-2, IL-6, IL-10 and IL-13 do not fit the Thl/Th2 
paradigm as closely as in the mouse and such clear cut patterns of cytokine production 
are less readily observed (2334). In addition to the human Tc2 clones from HIV patients 
such clones have also been generated from peripheral blood and peritoneum of health), 
individuals (235) and the gingiva of patients with chronic adult periodontitis (236). 
The studies mentioned above clearly demonstrate that human, murine and rat CD8 T 
cells have the potential to produce a much wider array of cytokines than was initially 
thought. Moreover, CD8 T cells appear to differentiate in a polarised fashion and can be 
divided into subsets analogous to those described for CD4 T cells. These subsets are 
alternatively termed Tc I; and Tc2. 
Unlike CD4 T cells, which readily differentiate into either Thl or Th2 cells, naive CD8 
T cells show a strong bias for differentiation into Tcl cells (237), (238) and (239). In 
both cases cytokines play the major role in driving the differentiation process of these 
cells. Two early studies indicated that IL-4 was a strong inducing factor for IL-4 
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secretion by CD8 cells (215). The effect of different cytokines on the differentiation of 
naive CD8 precursors has subsequently been investigated further. In the mouse. results 
show that as for CD4 T cells, IL-12 and IFN-y promote Type I and that IL-4. especially 
in the presence of anti-IFN-y. prornotes type 2 cells (23 ) 1) and (232). Furthermore. in the 
rat (234) and mouse (2332). IL-4 was found to inhibit the formation of IL-2 producing 
CD8 cells and promote IL-4 and IL-5 expression. Similarly, neonatal (naive) human 
CD8 T cells produced IL-4 and IL-5 after exposure to large amounts of IL-4 and IL-2 
while IL-12 enhanced the capacity of primed cells to produce IFN-y (240). 
Very little is known about the molecular mechanisms of CD8 polarisation, and 
they may be similar or distinct from those observed in CD4 T cells. It appears that the 
transcription factor T-bet plays a similar role in Tc I as in Th I cells. The role of GATA- 
and c-maf in Tc2 is not clear, but the dependence of IL-4 production in Tc2 cells on 
STAT-6 has been demonstrated (241) and (242). One of the lineage specific differences 
that has been observed is the requirement for STAT-4 activation for IFN-y production 
(243). It appears that while both CD4 and CD8 T cells require STAT-4 in IL- 12 /IL- 18 
mediated induction of IFN-y. only CD4 T cells require STAT-4 for TCR induced IFN-y 
production. 
1.11.3 CD8T cell function 
Traditionally. CD4 T cells have been regarded as helper cells that assist B cell antibody 
production, and CD8 T cells as cytotoxic cells that kill virally 
infected cells. This view 
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of the division of labour of these two T cell subsets is, in many ways. still true today. 
There are, however, a number of exceptions and CD4 T cells are now known to be 
capable of killing (244) and (245) while CD8 T cells may provide help for antibody 
responses (246). (247) and (248). The discovery of the Th I and Th2 subsets of CD4 T 
cells had a huge impact on Our understanding of immunology because the different I t, ý 
cytokine profiles were closely associated with specific functions, i. e. Thi cells were 
inflammatory T cells, while Th2 cells were helpers for antibody production. Since some 
CD8 T cells can produce potent immunoregulatory cytokines such as IL-4 , IL-10 (249) 
and TGF-B (250). they may play distinct roles in both the induction and effector phases 
of the immune response which are considered below. However a correlation between 
cytokine profile and function has yet to be defined clearly for CD8 T cells. 
Apart from their "in vivo" cytotoxic ability, CD8 T cells are known to recruit and 
activate inflammatory cells such as: macrophages, NK cells, neutrophils, eosinophils or 
mast cells/basophils in order to eliminate infection. CD8 T cells are strong inducers of 
DTH, a cell mediated inflammatory reaction. IFN-7, produced by CD8 T cells, is present 
at the site of inflammation and is chemotactic to at least some of the cells (macrophages, 
neutrophils) that migrate to the site of inflammation, causing DTH swelling. Other 
cytokines or chemokines such as TNF-(x IL-8 and MCP-I (251) are also involved in 
recruiting neutrophils and monocytes. Interestingly, Tc2 cells, which do not produce 
IFN-y can also induce substantial DTH (252). 
CD8 T cells have been also found to regulate CD4 development. CD8 T cells can alter 
the balance of Thl/Th2 responses in vivo (253) and (254) by influencing the 
development of IL-4 or IFN-y secretIng CD4 cells (255) and (256). 
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T-cell mediated suppression is another CD8 T cell function. Suppression may be 
mediated by the production of particular cytokines such as IL-4, TGF-B or IL- 10. or bv 
killing specific effector target cells (221). (222) (257) (223)). 
1.11.4 Tr and 'Fh3 cells. 
Recently it has been suggested that Thl and Tli2 may not be the only cytokme 
phenotypes of CD4 T cells. Many studies suggest that alternative regulatory populations 
exist, which may be somehow associated with. but distinct from Th2 cells (258) (259) 
and (260). Cells producing high amounts of TGF-Jand variable levels of IL-4 and IL-10 
have been isolated from mice orally tolerised to myelin basic protein (EAE- inducing 
agent) and narned Th') (261) and (262). These cells have been shown to suppress EAE. 
The induction of anergy by Th-33 cells is thought to occur due to the downregulation of 
the antigen presenting process, possibly via the production of TGF-P (263). Similar 
regulatory T cells have been isolated from the pancreas of NOD mice and shown to 
suppress diabetes (264). Distinct CD4 T regulatory I (Trl) cells characterised by high 
IL-10 production and low proliferative capabilities have also been described (265). 
These TrI cells inhibit antigen- spec i fic responses in vitro and prevent T cell mediated 
disease (colitis) in vivo probably through the secretion of high levels of IL- 10. 
Regulatory CD4 T cell subsets can inhibit not only cell mediated immune responses that 
lead to autoimmunity (266), (267) (261) (268) and (265) but also inflammatory 
pathologies mediated by Th2 cells (258), (259) and (260). It appears that this 
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Suppression can be attributed to TGF-gand /or IL-10 (in case of TrI cells) which are 
known to inhibit both Th I and Th2 development (269), (270) and (27 1). 
Both Th') and Tr cells are thought to be involved in the development of T-cell aner-ov in 
both humaii and murine models. although the interaction between the two cell types is 
vct to be resolved (272). 
1.12 B cell help. 
The discovery that some CD8 T cells can secrete "helper" cytokines led to suggestions 
that these cells may be able to help B cells. Some cases of non-cytotoxic CD8 T cells 
that could provide help for Ig synthesis (via cell surface markers and/or secreted 
cytokines), have been reported, for example in HIV infection (27-33), and in CD8 T cell 
clones derived from skin window chamber cells from delayed type hypersensitivity 
(DTH) reactions elicited by either PPD or Candida, (274). CD8 T cells vigorously 
stimulated in vitro in the presence of high concentrations of IL-4 became CD4-CD8-, 
secreted large amounts of IL-4 and were capable of switching B cells to make IgE (275) 
and (227). This is confirmed by the finding that some CD8 clones express CD40L, a 
critical signal for antibody production (233) and can provide B cell help in vitro for 
switching to IgE (276), (273)) and (277) and for IgG synthesis (246). It is therefore 
possible that CD8 T cells can contribute to antibody responses and that, as for CD4 cells, 
this is associated with reduced cell-mediated immunity. On the other hand, it is difficult 
to reconcile this function with the strong cytolytic activity of Tc2 cells (278). This is 
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also consistent with the antigen processing pathways used for MHC class I presentation. 
Thus, it is likely that Tc2 cells will express cytokines and surface molecules that may 
provide antigen non-specific help for neighbouring B cells. while providing efficient L- 
killing of infected B cells presenting appropriate Ag via MI-IC class 1. 
1.13 CD8 T cells and suppression of IgE 
The ability of CD8 T cells to regulate the production of IgE is a well recognised 
example of T cell mediated suppression (279). (280), (281). (282) and (283). IgE 
inhibitory CD8 T cells have been generated following antigen inhalation (280) and (281) 
or parenteral immunisation (284) and (285). MHC class I restricted CD8 T cell clones 
specific for exogenous antigen have been shown to suppress IgE (286) (287). 
Furthermore, depletion of CD8 T cells in immunised animals enhances antigen-specific 
11-4, and suppresses IFN-Isynthesis (254) suggesting that CD8 T cells switch the CD4 
T cell response from Th2 to Thl. 
The most obvious explanation for the suppressive ability of CD8 T cells, is the secretion 
of IFN-y production during development of CD4 responses could inhibit the 
development of Th2 cells whilst favouring the development of Thl cells (282). 
Alternatively CD8 T cell-derived IFN-y could act directly on B cells to inhibit IgE 
synthesis and / or cytotoxic CD8 T cells could kill Ag-specific B cells or APCs. 
However the ability of ovalburnin (OVA)-specific CD8 T cell clones to inhibit IgE is 
unrelated to the levels of IFN-y they produce in vitro or to their cytolitic activity (288). 
A study carried out by Thomas et al., (2002), proved the ability of such clones to 
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stimulate IL-12 secretion by murine DCs, which in turn would favour the development 
of a Th I -type response over a Th2 one (289). This dernonstrates a novel regulator), 
network through which CD8 T cells can inhibit allergic sensitisation in an IFN-y- 
independent manner. 
1.14 Work that has led up to this project. 
Having established the importance of T cells in eliciting or suppressing IgE responses. 
the possible regulatory control of individual T-cell subsets on the levels of IgE has been 
studied both "in vitro" and "in vivo". Generation of Thl and Th2 cells "In vivo", can 
skew immune responses accordingly depending on the antigen (290), and the antigen- 
presenting cell (291). Type I and type 2 immune responses are accompanied by an 
appropriate cytokine profile that can influence immune responses in both an autocrine 
and a paracrine fashion. In the case of IgE regulation, the latter immunoglobulin has 
been elevated during a dominant type 2 response (driven by IL-4) while the reverse has 
been observed in a type I immune response (292). 
The existence of distinct CD8+ subpopulations in humans has been well established 
(22 1) and (273). These cells, classified into Tc I and Tc2, were shown to secrete specific 
cytokine patterns that remained stable and fitted the Thl / Th2 paradigm. This 
observation led to the study of IgE regulating potential of these CD8+ cell subsets. Such 
regulation can be indirect as the latter T cells play a role in the activation and 
differentiation of CD4+ T cells. This may be mediated through secreted products 
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(cytokines, chemokines) or by cell-cell interactions, giving rise to a relevant immune 
response which in turn would reflect on the levels of IgE secreted by B cells. 
Alternatively, secretion of type I or type 2 cytokines by Tc I and Tc2 cells respectivel, ' 
might influence the relevant IgE responses directly. 
Kemem, ci (d.. (1994), found that depletion of CD8+ cells in rats enhance, "- IuF 
production and favours a Th2-type immune response when the animals have been 
previously immunised with ricin (293). This is probably due to the rise of IL-4 
production by CD4+ T- cells although other immunoregulatory mechanisms might be 
also unmasked. Noble et al., (1993), showed that ricin-sensitive CD8+ T cells might 
favour the development of a Thl response which might explain the suppressive effect of 
these cells on IgE secretion (294). These observations led us to investigate the effects of 
different T-cell derived factors (including CD8+ soluble factors) on IgE synthesis "in 
Otro". The suppressive effects of human T-cells "in vitro- concerning IgE regulation 
were established (295). Erard et al., (19933) and Vukmanovic-Stejic et al., (2000), were 
able to generate human Tcl and Tc2 clones "in vitro" that secreted distinct cytokine 
profiles (227) and (296). Hence, the basis for an "in vitro" study of the effects of 
secreted T cell factors on IgE regulation was set. 
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1.15 Aims of the thesis. 
The study detailed in this manuscript investigated the ability of CD8+ and other 
secretory factors (e. (,,. cytokincs) to stimulate human B cells to IgE .. -, class secretion **in 
vitro". The airns set and achieved in this work N\ci-c the followirig: Z-- 
1. To confirm the effects of cytokines on IgE regulation and other immunoglobulin 
classes and subclasses. 
2. To inhibit these effects with the appropriate blocking antibodies. 
3. To test the effect of Tcl and Tc2 soluble factors on IgE synthesis. 
4. To identify modes of action of these factors that regulate IgE. 
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CHAPTER 2: MATERIALS AND METHODS. 
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2.1 Tonsils. 
Ethical committee approval to use human tonsils was obtained. Patients undergoing 
tonsillectomy gave informed consent for their tonsils to be used for research. Tonsils 
were collected from the operating theatres of Guy's Hospital in London ori the dav of the 
experiment. The donor had to be between the age range of ý, ---, '5 \ ears of w)c and the 
tonsils (obtained fresh) had to be processed within the next ') h. following the 
tonsillectomy. 
2.2 Preparation of Sheep Red Blood Cells (SRBCs). 
Sheep red blood cells in Alsever's solution were prepared (usuall, v a day prior use), in 
order to deplete the T cells from the tonsillar cell suspension, by positive selection. 
2.2.1 Reagents. 
Sheep Red Blood Cells in Alsever's solution. (TCS Biosciences Ltd. Claydon, 
Buckingham, UK). 2-aminoethylisothiouronium hydrobromide (AET), RPMI-1640. 
(SIGMA. Pool, Dorset, UK). Phosphate Buffered Saline (PBS). (INVITROGEN Plc. 
Inchinnan Business Park,, Paisley, UK). 
2.2.2 Protocol. 
1.2-aminoethylisothiouronium hydrobromide (AET) was dissolved in distilled water at 
0.5g/12.5 ml, the pH adjusted to 9.0 with 4M NaOH and sterile filtered. 
2.8 mls of sheep red blood cells (SRBQ in Alsever's solution were washed 5 times in 
sterile PBS, at 600g for 10 mins at 
AC. 
inal wash, 2ml of packed SRBC were with 8 ml of AET After the fi 
solution for 20 mins at 3 7'C and washed -3' times with cold PBS at 400g for 10 mins. 
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4. The SRBC were resuspended in tissue culture medium (Rl3MI-1640/ 2mNI L- 
Glutamine). AET treated SRBC could be stored at 4'C for a maximum of 7 days. 
2.3 Isolation and purification of tonsilar or PBMC B cells by T-cell rosetting. 
B cells were purified from the tonsilar cell suspensioll or from the PBMCs bY the 
addition of AET-treated Sheep Red Blood Cells that would bind T cells creating, a cell 
complex that was removed by the density gradient method using lymphoprep. The purity 
of the B-cells obtained was considered acceptable for our study. 
2.3.1 Reagents. 
Iscove's Modified Dulbecco's Medium (IMDM), L-Glutamine, human holo-transferrin, 
Ficoll Hypaque, NaCl powder, Penicillin/Streptomycin. (SIGMA. Poole, Dorset, UK). 
AET-treated Sheep Red Blood Cells (previously prepared). F etal Calf Seum (FCS). 
(Harlan SERA-LAB. Belton, Loughborough, UK). 
2.3.2 Solutions. 
Complete Medium. (IMDM, 2ýtM L-Glutamine, 100 U/ml penicillin/streptomycin, 10% 
FCS and 50 ýtg/rnl ho lo -trans fe rrin). 
Hypotonic sodium chloride (0.2%). (0.2 g. NaCI/I 00ml sterile H20)- 
Hypertonic sodium chloride (1.6%). (1.6 g. NaCl/100 ml sterile H20). 
2.3.3 Protocol 
I. Tonsils were obtained as described previously, cut into small fragments and suspended 
in complete medium. 
2. Tonsillar tissue was forced through a 70ýtM cell strainer. 
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33. The cell suspension obtained was washed with complete rnedlum for 10 min at 8OOg 
at 20'C and re-suspended in 20ml of complete medium, giving a final concentration of 
approximately IXI 07CelIS/Ml. 
4.20 nil of the AET-treated packed SRBC were added to 10 nil of the tonsillar 
suspension, centrifuged for 2 min at 150g and incubated for Ih at 40C. 
5. The rosetted cells were separated over 15mls of Ficoll Hypaque for 20 min, at 8OOg 
at 40C. 
6. B cells were collected from the interface. Remaining red blood cells in B cell 
preparation were lysed by adding equal amounts of 0.2% hypotonic sodium chloride 
solution followed by 1.6% hypertonic sodium chloride solution. 
7. B cells were finally washed twice in complete medium for 10 min and centrifuged at 
600g for 10 min. at 2 OT and counted. The average yield was 15-20 x 107 B 
cells/tonsil. 
8. Ficoll Hypaque was used to separate PBMCs from whole blood. 35ml of blood were 
added on 15ml of Ficoll Hypaque and centrifuged for 20min. at 8OOg and 4'C. 
Approximatelly, 106 PBMCs were obtained per I ml of whole blood. The PBMC pool 
would go through the rosetting method in order to obtain B cells. 20% of the total 
PBMC number was found to be B cells. 
2.4 Positive selection of tonsillar B cells by CD19+ Dynabeads. 
This was an alternative way of purifying B cells from a tonsillar cell suspension. B cells 
had a higher purity compared to the T-cell rosetting method of purification although they 
yielded lower levels of IgE, which was related to the sensitivity of the cells and of the 
IgE secretion process. 
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2.4.1 Reagents. 
CD 19+ Dynabeads (M 450). DETACHaBEADS. (Dynal Ltd. Wirral. Merseyside. UK). 
Phosphate Buffered Saline (PBS). (INVITROGEN Ple. Inchinnan Business Park. 
Paisley. UK). RPMI-1640 (SIGMA. Pool. Dorset. UK). Foetal Calf Serum (FCS). 
(Harlan SERA-LAB. Belton, LOUghborough. UK). 
2.4.2 Protocol. 
1. A tonsilýr cell suspension was prepared as described before. Dynabeads M-450 
CD19 (4x the number of target cells) were washed -33-5 times with PBS. 
2. The dynabeads were added to the cell suspension to a final concentration of at least 
1XI07 Dynabeads M-450/mI and incubated at 40C with slow tilting and rotation for at : -71 
least I h. (oo Wjreý). 
"I 
-3. 
The cell suspension was then resuspended in 3300ýtl of cell culture medium 
(eg.: RPM11640/FCS) and -330ýtl of 
DETACHaBEAD added. 
4. The cell suspension was further incubated for 45-60 min. at ambient temperature. 
5. The released beads were then removed by placing the eppendorf in the dynal MPC 
for 2 min. and the cell suspension was then pippeted out of the eppendorf. 
6. The process was repeated 2-3 times in order to obtain any residual cells. The total 
detached cells were then washed thoroughly by resuspending and centrifuging for 10 
min. at 8OOg 2-3 times, in order to remove any DETACHaBEADS present. 
7. The purified cells (>98% purity) were finally resuspended in 5 mls of culture media. 
2.5 B-cell purity assessed by Flow Cytometry. 
The purity level of B cells isolated by either T-cell rosetting or positive se ection was 
assessed by surface staining followed by flow cytometry. 
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2.5.1 Reagents. 
Phosphate Buffered Saline (PBS). (INVITROGEN Plc. Inchinnan Business Park. 
Paisley, UK). Bovine Serum Mbumin (BSA). (SIGMA. Pool, Dorset, UK). PE-anti- 
CD19. FI'FC-anti-CD'). FITC-anti-CD14 conjugated antibodies. (Becton-Dickinson- 
PHARMINGEN. Cowley. Oxford. UK). 
2.5.2 Protocol. 
I. Approximately 5xl 05 purified B cells were added per FACS tube and washed once 
with PBS + 0.5% BSA (Sigma) for 5 mins at 200g 
2 Extracellular B cell staming was carried out adding 10ýtl PE - conjugated anti- 
CD 19 antibody per FAC S tube. 
3 T-cell impurity was detected with 10ýtl FITC - conjugated anti-CD') antibody 
while monocyte impurity was determined by adding 10ýtl FITC - conjugated anti- 
CD 14 antibody. 
4 After the monoclonal flow cytometry antibodies were added (double staining: anti- 
CD 19 and anti-CD-3 3 or anti-CD 19 and anti-CD 14), the FACS tubes were placed on 
ice and incubated for 20 mins (at 4'C). 
5 After the incubation period the cells were washed twice with PBS + 0.5% BSA (5 
mins at 200g) and the purity was tested by flow cytometry. 
2.6 Positive selection of CD4+/CD8+ T cells. 
After a positive selection step in order to isolate the B cells from a tonsillar cell 
suspension, the CD4+/CD8+ T cells were isolated in the same manner 
by positive 





DETACHaBEADS. (Dynal Ltd. Wirral. Merseyside. UK). 
Phosphate Buffered Saline (PBS). (INVITROGEN Plc. Inchinnan Business Park. 
Paislev, UK). RPMI-1640 (SIGMA. Pool. Dorset, UK). Foctal Calf Seum (FCS). 
(Harlan SERA-LAB. Belton, Loughborough, UK). 
2.6.2 Protocol. 
1. CD8 cells were isolated first by positive selection using CD8 dynabeads, which The 
unbound cells were separated using a magnetic concentrator. Magnet was applied for 2 
minutes and unbound cells aspirated. 
2 The remaining dynabeads were gently resuspended in I ml of R-PMl 1640/2% FCS 
and reapplied to the magnet for 30 seconds and the supernatant aspirated. This 
washing procedure was repeated 4 times in total and the beads resuspended in 
100[tl of RPMI 1640/2% FCS. 
3 Bound CD8 cells were released by addition of the Detach-a-bead antibody. 
Following incubation (with rotation) for 60 minutes at room temperature, the 
magnet was applied for 2 minutes and the released CD8 cells collected. 
5 The dynabeads were then washed with I ml RPMI/2% FCS, the magnet reapplied 
for 30 seconds and the released CD8 cells collected as before. This procedure was 
repeated twice and all the released CD8 cells were pooled and washed twice by 
centrifugation at 200 g for 10 minutes to remove any residual Detach-a-bead 
solution. 
6 The same procedure was carried out using CD4 dynabeads instead of CD8 in order 
to positively select the CD4+ T cells from the cell suspension. 
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2.7 CD4+/CD8+ T-cell purity assessed by flow cytometry. 
Using flow cytometry, the purity of the CD4+ and CD8+ T cells was assessed in a very 
similar way compared to the assessment of B-cell purity described earlier on. 
2.7.1 Reagents. 
Phosphate Buffered Saline (PBS). (INVITROGEN Plc. Inchinnan Business Park. 
Paisley, UK). Bovine Serum Albumin (BSA). (SIGMA. Pool, Dorset, UK). PE-anti- 
CD4,, FITC-anti-CD8 conjugated antibodies. (Becton-Dickinson-PHARMINGEN. 
Cowley, Oxford, UK). 
2.7.2 Protocol. 
1. Approximately 5xl 05 purified T cells (CD4+ or CD8+) were added per FACS tube 
and washed once with PBS + 0.5% BSA (Sigma) for 5 mins at 200g. 
2 Extracellular T cell double surface staining was carried out adding 10ýd PE - 
conjugated anti-CD4 and FITC-conjugated anti-CD8 antibody per FACS tube. 
3 After the monoclonal flow cytometry antibodies were added, the FACS tubes were 
placed in an ice bucket and incubated for 20 mins (at 4'C). 
4 After the incubation period the cells were washed twice with PBS + 0.5% BSA (5 
mins at 200g) and the purity was tested by flow cytometry. 
2.8 B-cell proliferation assay. 
Tonsillar B cells purified by positive selection or T-cell rosetting were put into culture 




3 H-Thymidine. (Amersham. Essex. UK). 
2.8.2 Protocol. 
1. PLIrIfied B cells %vere CLIItUred at varIOLIS conditions in flat-bottomed 96 wcll ccll 
culture plates. 
2. After 4 days the cells Were pulsed Wit,, 
3 H-Thymidine (0.5ltCI/well) under sterile 
conditions. 
3. The cells were then harvested for 18h and counted using a Matrix 96 Direct ý- 
counter (Canberra Packard). 
4. The results were displayed as counts per minute (epm). 
2.9 Optimisation of the IgE system. 
In order to study the IgE production by tonsillar B cells, the latter were put into culture 
with IL-4 and anti-CD40 monoclonal antibody which have been proven to be essential 
for this process. These two antibodies were titrated in the cultures in order to find their 
optimum concentrations. Overall, switching human B cells to IgE secretion was proven 
to be a very sensitive process. 
2.9.1 Reagents. 
Iscove's Modified Dulbecco's Medium (IMDM), L-Glutamine, human holo-transferrin, 
Ficoll Hypaque, NaCl powder, Penicillin/Streptomycin, alkaline phsphatase conjugated 
anti-IgE (SIGMA. Pool, Dorset, UK). Foetal Calf Serum (FCS). (Harlan SERA-LAB. 
Belton, Loughborough, UK). AET-treated Sheep Red Blood Cells (previously prepared). 
Recombinant human IL-4 (Becton-Dickinson-PHARMINGEN. Cowley, Oxford, UK). 
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Anti-CD40 monoclonal antibody (Clone: G-28-5), human anti-IgE monoclonal antibod\- 
(Clone: -577C 
I) (Gift by Dr. Darren Wheeler. AVENTIS. New Jersey. USA). 
Human myeloma IgE. (Calbiochem. Beeston. Nottingham. UK). 
2.9.2 Protocol 
1. Tonsillar B cells were purified and isolated by T-cell rosetting, split into two groups 
and put into 96-well culture plates (105 cells/well) in complete media (as described 
above). 
2. One group of cells contained IL-4 at 20 ng/mI while the anti-CD40 monoclonal 
antibody was titrated in at a concentration range from 0-2 ýtg/ml- 
3. The second group of B cells was similarly cultured but at a constant concentration of 
anti-CD40 monoclonal antibody (0.5 ýtg/ml), while the IL-4 was titrated between 
concentrations: 0-80 ng/ml. 
4. Both sets of cultures were incubated for 10 days at 3 70C. 
5. Supernatants were then collected and the IgE levels were measured by an IgE ELISA 
(described later on). 
2.10 Time-Course of IgE secretion. 
In order to investigate the time course of IgE secretion by switched B cells -in vitro", the 
latter were put in culture under standard conditions of IL-4 and anti-CD40 and the 
supernatants were collected at set days so as to measure the 




Iscove's Modified Dulbecco's Medium (IMDM), L-Glutamine. human holo-transferrin. 
Ficoll Hypaque. NaCl powder. Penicillin/Streptomycin. alkaline phosphatase con upated 
aiitl-lgl--- (SIGMA. Pool. Dorset. UK). Foetal Calf Seum (FCS). (Harlan SERA-LAB. 
Belton. Loughbol*OLIgh. UK). AFT-ti-cated Sheep Red Blood Cells (prev IOLISI, V PFCpared). t-- 
Recombinant human IL-4 (Becton-Dickinson-PHARMINGEN. Cowley. Oxford. UK). 
Anti-CD40 monoclonal antibody (Clone: G28.5), human anti-IgE monoclonal antibody 
(Clone: 577C I) (Gift by Dr. Darren Wheeler. AVENTIS. New Jersey, USA). 
Human myelorna IgE. (Calbiochem. Beeston, Notingham, UK). 
2.10.2 Protocol. 
1. Tonsillar B cells were isolated by T-cell rosetting and cultured at 37'C with IL-4 (20 
ng/ml) and anti-CD40 (0.5 ýtg/rnl) in 96-well plates (105 cells/NA, ell). 
2. The supernatants were collected at days: 2,4,6,10,14 and 18, and 
3. The IgE levels were measured by an IgE ELISA (as described below). 
2.11 Cytokines and IgE production. 
The effects of human recombinant cytokines on IgE production were studied. 
The 
cytokines: IL-2, IL-5, IL-6, IL-7, IL-9, IL-10, IL-12, IFN-y and 
TGF-ý were titrated 
individually in the B-cell cultures. The levels of IgE in the supernatants were measured 
by a direct IgE sandwich ELISA after a 10 day incubation. 
7-2 
2.11.1 Reagents 
Iscove's Modified Dulbecco's Medium (IMDM), L-Glutarnine. human holo-transferrin. 
Ficoll Hypaque, NaCI powder, Penicillin/Streptomycin. alkaline phosphatase conjugated Z-- 
anti-IgE (SIGMA. Pool. Dorset, UK). Foetal Calf Seum (FCS). (Harlan SERA-L, \B. 
Belton, Loughborough, UK). AET-treated Sheep Red Blood Cells (previously prepared). 
Recombinant human cytokines (Becton-Dickinson-PHARMINGEN. Cowlev. Oxford. 
UK). Anti-CD40 monoclonal antibody (Clone: G28.5), human anti-l(-, E monoclonal 
antibody (Clone: 577C I) (Gift by Dr. Darren Wheeler. AVENTIS. Ne Jv Jersey. USA). 
Human myelorna IgE. (Calbiochem. Beeston, Notingham, UK). 
CD 19+ dynabeads (M-450), DETACHaBEADS. (Dynal Ltd. Wirral, Merseyside, UK). 
2.11.2 Protocol. 
1. Tonsillar B cells were isolated by T-cell rosetting or positively selected by CD19+ 
dynabeads and cultured at 37'C with IL-4 (20 ng/ml) and anti-CD40 (0.5 ýtg/rnl) in 
96-well plates (105 cells/well). 
2. One additional exogenous cytokine was titrated in the cultures at day 0. The 
concentration range was: 0,0.1,1,10,100,1000 Units/ml. Cytokines were 
reconstituted in sterile PBS and stord at -20T. 
3. After a 10 day incubation the supernatants were collected and the IgE levels were 
measured by a direct IgE sandwich ELISA (see below). 
2.12 Tc supernatants. 
The effect of Tc clone supernatants on IgE production was 
investigated. The Tc clones 
were stimulated a week prior to the collection of their supernatants with anti-CD3 and 
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anti-CD28 rather than PMA and ionomycin. excluding the chance of transferring the 
stimulus to the B cell cultures. 
2.12.1 Reagents. 
Iscove's Modified DLIlbecco's MedIL1111 (IMDM). L-Glutaminc. human holo-transicri-in. 
Ficoll Hypaque, NaCl powder. Penicillin/Streptomycin, alkaline phosphatase conjugated 
anti-IgE (SIGMA. Pool, Dorset, UK). Foetal Calf Seum (FCS). (Harlan SERA-LAB. 
Belton, Loughborough, UK). AET-treated Sheep Red Blood Cells (previously prepared). 
Recombinant human IL-4 (Becton-Dickinson-PHARMINGEN. Cuwley. Oxford, UK). 
Anti-CD40 monoclonal antibody (Clone: G28.5), human anti-IgE monoclonal antibody 
(Clone: 577C I) (Gift by Dr. Darren Wheeler. AVENTIS. New Jersey, USA). 
Human myelorna IgE. (Calbiochem. Beeston, Nottingham, UK). 
Tel clones: Al 11,2 and 5. Tc2 clones: B206, I and 4. (Kindly provided by Dr. Milica 
Vukmanovic-Stejlc). 
2.12.2 Protocol 
1. Tonsillar B cells isolated by T-cell rosetting were put into culture (96-well plates) 
with IL-4 (20 ng/ml) and anti-CD40 (0.5 ýtg/ml), in complete media. 
2. Tc clone supernatants: AIII and B206 were titrated in the 96-well plates with the B 
cells at standard conditions (with IL-4 and anti-CD40), producing a range of 
dilutions: 1/2,1/10 and 1/100. 
3. The cells were cultured for 10 days at 37'C. 
4. Supernatants were then collected and the IgE levels were measured by a direct IgE 
sandwich ELISA (described below). 
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5. Tc clone supernatants: 1.4 (Tc2). 2 and 5 (Tcl) were added with the purified 
tonsi ar B cells IL-4 and anti-CD40 in culture together NvI I ith their relevant 
neutralising . antibodies at their optimum concentrations (see below). 
6. With the Tc2 clone supernatants anti-ll--4, anti-IL-6 and IL-10 were added to the 
culture. 
7. With the Tc I clone supernatants anti-IFN-y was added. 
8. B cells were also cultured in the absence of any exogenous IL-4 and/or supernatant. 
9. After 10 days incubatioii at ' )7'C the B-cell supernatants were collected and the IgE 
levels were measured by a sandwich IgE ELISA (as described below). 
2.13 IgE ELISA. 
The IgE levels in cell supernatants were measured by a direct sandwich IgE ELISA. 
2.13.1 Reagents 
Alkaline phosphatase-anti-IgE polyclonal antibody, I p-nitrophenylphosphatase tablets, 
Bovine Serum Albumin (BSA), buffer chemicals. (SIGMA. Pool, Dorset, UK). 
Human myeloma IgE. (Calbiochem. Beeston, Nottingham, UK). 
Human anti-IgE monoclonal antibody (Clone: 577CI). (Gift by Dr. Darren Wheeler. 
AVENTIS. New Jersey, USA). 
Phosphate Buffered Saline (PBS). (INVITROGEN Plc. Inchinnan Business Park, 
Paisley, UK). Tween-20. (Becton-Dickinson-PHARMINGEN. Cowley, Oxford, UK). 
2.13.2 Buffers. 
Coating Buffer: carbonate -b i carbonate buffer (0.1 M, pH 9.6) 
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4.24g Na2CO3 and 5.04g NaHC03was dissolved in I litre of distilled water. PH was 
checked and adjusted to 9.6 if necessary. Store at 4'C. 
Wash Buffer: PBSITiveen 
PBS: 5.79g NaH-IP04XH,, O. 85(-) NaCl. 16.7g Na2HP04 
11= and 
lOo sodlurn azide werc 
resuspended in 101 of distilled water. 5ml of T\\, ecn20 was added. 
Substrate Buffer: Diethanolamine buffer(II) 
101mg of MgCl,. 6H20was added to 800ml distilled water and dissolved. 97rnl of 
diethanolamine was added, with stirring, and when fully dissolved pH was adjusted to 
9.8 with conc HCL The volurne is then adjusted to II with distilled water. 
2.13.3 Protocol. 
1.96 well Maxisorp ELISA plates were coated with the primary antibody (anti-IgE 
clone: 577C 1, at a concentration of 1.25 ýtg/rnl in carbonate buffer (I 00ýtl/well). 
2. The plates were then covered with seal and left in the fridge for overnight 
incubation. 
3. After overnight incubation the plates were washed four times with wash buffer. 
4. Each well was then blocked with 200ýtl of wash buffer and incubated for 30 mins at 
room temperature. Plates were then washed three times and I 00ýd of the standards 
and the B-cell supernatants were added per well. 
5. The top standard concentration was 360 ng/ml while human serum was used each 
time as a quality control at I /100 dilution. 
6. The standards and supernatants were left to incubate for 2 h. at 37'C and then 
washed three more times. 
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7. Alkaline phosphatase labelled secondary antibody: anti-IgE. was added at 1/500 
dilution, I 00ýtl/well, and the plates were incubated for a further I h. at -')7'C. 
8. The plates were finally washed five times and I p-Nitrophenyl phosphate solution 
was added at a concentration of I mg/nil at I 00ýtl/Nvcll. 
9. The plates ý\erc Incubated in the dark for at least '/-) h. in order to allo\\ for tile 
yellow C01OUr to develop. 
10. The OD values and their corresponding concentration levels were measured and 
calculated by the ELISA Macintosh programme: SOFTMAX (at 405nrn 
wavelength). 
2.14 IgA ELISA. 
The levels of IgA in the cell supernatants were measured by direct IgA sandwich 
ELISA. 
2.14.1 Reagents. 
Human IgA ELISA Quantitation Kit. (BETHYL LAB. Montgomery, Texas, USA). 
Phosphate Buffered Saline (PBS). (INVITROGEN Plc. Inchinnan Business Park, 
Paisley, UK). Tween-20. (Becton-Dickinson-PHARMINGEN. Cowley, Oxford, UK). 
Buffer Chemicals (See buffer section). (SIGMA. Pool, Dorset, UK). 
2.14.2 Protocol. 
1.96 well Maxisorb ELISA plates were coated with the primary antibody anti-IgA at a 
concentration of 1.25 ýtg/rnl in carbonate buffer (100ýtl/well). 
2. The plates were then covered with seal and left in the fridge for overnight 
incubation. 
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3. After overnight incubation the plates were washed four times with wash buffer. 
4. Each well was then blocked with 200[tl of wash buffer and incubated for 330 mins at 
room temperature. Plates were then washed three times and I 00ýtl of the standards 
and the B-cell supernatants wcre added per well. 
5. The top standard conceiitration %\,,, is 360 i-ig/ml \vhile hUniaii serum ývas used cLich 
time as a quality control at I/ 100 dilution. 
6. The standards and supernatants were left to incubate for 2 h. at 37'C and then 
washed three more times. 
7. Horseradish peroxidase labelled secondary antibody: anti-IgA, was added at 11500 
dilution,, I 00ýtl/well, and the plates were incubated for a further I h. at 3 70C. 
8. The plates were finally washed five times and 2,2-Azino-Bis-3-ethylbenzthiazoline- 
6-sulfonic acid (ABTS) was added at a concentration of I mg/ml at I 00ýdAý-ell. 
9. The plates were incubated in the dark for at least 1/2 h. In order to allow for the green 
colour to develop. 
10. The OD values and their corresponding concentration levels were measured and 
calculated by the ELISA Macintosh programme: SOFTMAX. 
2.15 IgGI ELISA. 
The IgGI levels in the cell supernatants were measured by a direct IgGI sandwich 
ELISA. 
2.15.1 Reagents. 
Alkaline pho sphatase -anti -1 gG I polyclonal antibody, I p-nitrophenylphosphatase 
tablets, Bovine Serum Albumin (BSA), buffer chemicals. (SIGMA. Pool, Dorset, 
UK). 
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Human myelorna IgGI. (Calbiochern. Beeston. Nottingham. UK). Human anti-12GI 
monoclonal antibody (Clone: MC003). (The Binding Site Ltd. Birmingham, UK). 
Phosphate Buffered Saline (PBS). (INVITROGEN Pic. Inchinnan Business Park, 
Paisley. UK). Tween-20. (Becton-Dickinson-PHARMINGEN. Cowley. Oxford, UK). 
2.15.2 Protocol. 
1.96 well Maxisorb ELISA plates were coated with the primary antibody (anti-IgGI 
clone: MC003, at a concentration of 1.25 ýtg/rnl in carbonate buffer (100ýtl/well). 
2. The plates were then covered with seal and left in the frid, (), c for overnight Z: ý Z-- 
incubation. 
After overnight incubation the plates were washed four times with wash buffer. 
4. Each well was then blocked with 200ýtl of wash buffer and incubated for 30 mins at 
room temperature. 
5. Plates were then washed three times and 100ýtl of the standards and the B-cell 
supernatants were added per well. 
6. The top standard concentration was 360 ng/ml while human serum was used each 
time as a quality control at I /100 dilution. 
7. The standards and supernatants were left to incubate for 2 h. at 37'C and then 
washed three more times. 
8. Alkaline phosphatase labelled secondary antibody: anti-IgGI, was added at 1/500 
dilution,, I 00ýtl/well, and the plates were incubated for a further I h. at 37'C. 
9. The plates were finally washed five times and I p-Nitrophenyl phosphate solution 
was added at a concentration of I mg/ml at I 00W/well. 
10. The plates were incubated in the dark for at least 
1/2 h. in order to allow for the 
yellow colour to develop. 
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11. The OD values and their corresponding concentration levels were measured and 
calculated by the ELISA Macintosh programme: SOFTMAX. 
2.16 IgG2, IgG3 and IgG4 ELISAs. 
The levels of these antibody isotypes were measLired bv the use of pre-calibrated FI-II-),, \ 
kits. The kits, stored at 40C . were exposed to room temperature approximately 60 min. 
prior to their use. The calibrator (standard), sample and control dilutions were prepared 
immediately before use. . In all three ELISAs the method followed was identical. 
2.16.1 Reagents. 
IgG2, IgG3 and IgG4 Quantitation ELISA KITS. (The Binding Site Ltd. Birmingham, 
UK). Buffer chemicals. (SIGMA. Pool, Dorset, UK). Human myeloma IgGI. 
(Calbiochem. Beeston, Nottingham, UK). Phosphate Buffered Saline (PBS). 
(INVITROGEN Ple. Inchinnan Business Park, Paisley, UK). Tween-20. (Becton- 
Di ckinson- PHARMIN GEN. Cowley, Oxford, UK). 
2.16.2 Protocol. 
1. The calibrator and control solutions were diluted 1/100 while the samples were used 
neat. 100 ýtl of each calibrator dilution, diluted control and sample were added to the 
appropriate wells. 
2. The wells were incubated for 2h. at 37'C and then washed with wash buffer three 
times in order to remove all unbound proteins. 
3.100 ýtl of each diluted conjugate, (dilution 1/100), was added to each of the 
respective ELISA wells and the plates were then incubated at 37'C for 2 hours, 
followed by three washing cycles with the wash buffer. 
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4. The bound coillugates Nvere visualised with 3,33', 5,5' tetramethy lbenzi dine (TMB) 
substrate. The latter is added at 100 ýtl/well and the plates incubated for 30 min. at 
room temperature. TMB substrate 21 Oves a blue reaction product, the of 
which is proportional to the concentration of IgG subclass antibody in the sample. 
Finally. phosphoric acid is added at 100 Vllwell in order to stop the reaction 
producing a yellow end point colour. The absorbance was measured at 450nm. 
2.17 Cytokine ELISAs 
The levels of IL-2, IL-6. IL-10, IL-12, IFN-y and TGF-O were measured by direct 
sandwich cytokine ELISAs. 
2.17.1 Reagents. 
All antibody pairs, recombinant human cytokines, Tween 20. (Becton-Dickinson. 
PHARMINGEN. Cowley, Oxford, UK). I p-nitrophenylphosphatase tablets, Bovine 
Serum Albumin (BSA), buffer chemicals. (SIGMA. Pool, Dorset, UK). Phosphate 
Buffered Saline (PBS). (INVITROGEN Plc. Inchinnan Business Park, Paisley, UK). 
2.17.2 Protocol. 
1. Maxisorp, ELISA plates were coated with 100ýtl/well of anti- IL-2, IL-6, IL-10, IL-12, 
IFN-y and TGF-ý respectively at I ýig/rnl in carbonate buffer and incubated overnight at 
4'C. 
2 The plates were then washed 3 timed with wash buffer, and were then blocked with 
100ýtl blocking buffer (0.5% BSA/PBS) for 30 min at 37'C. 
3. Plates were washed 3 times as above and 100ýtl of the respective standards and 
samples were added. 
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4. After a 2h incubation at ambient temperature. plates were washed 3' times as above 
and I 00ýtl/well of the corresponding biotinylated antibody were added at I ýiul; lrnl. 
5. After a further 2h incubation at room temperature and three more washes. plates were 
incubated with 100ýtl/well of streptavidin alkali II ine phosphatase at 1: 1000 dilution for I 
11. 
6. Plates were washed three more times and the substrate solution was added at 
I 00ýd/wel I. 
TOD values and their corresponding concentration levels were measured and calculated 
by the ELISA Macintosh programme: SOFTMAXTM (Version 2.35. . 1%4olecular Devices 
Corporation). 
2.18 Optimisation of the cytokine neutralising antibodies. 
The optimum concentration of the cytokine neutralising antibodies was found by 
titrating the latter with their relevant cytokines in B cell cultures and investigating their 
blocking potential on B-cell proliferation and IgE production. 
2.18.1 Reagents. 
Recombinant human cytokines. cytokine neutralising antibodies, Tween 20. (Becton- 
Dickinson-PHARMINGEN. Cowley, Oxford, UK). Phosphate Buffered Saline (PBS). 
(INVITROGEN Plc. Inchinnan Business Park, Paisley, UK). Alkaline phosphatase-anti- 
IgE polyclonal antibody, I p-nitrophenylphosphatase tablets, Bovine Serum Albumin 
(BSA), buffer chemicals. (SIGMA. Pool, Dorset. UK). Human myeloma IgE. 
(Calbiochem. Beeston, Nottingham, UK). Human anti-IgE monoclonal antibody (Clone: 
577CI). (Gift by Dr. Darren Wheeler. AVENTIS. New Jersey. USA). AntiCD40 
monoclonal antibody (Clone: 28.5). (Gift by Dr. Darren Wheeler. AVENTIS. New 
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Jersey, USA). AET-treated Sheep Red Blood Cells. (Described before). Fetal Calf Seum 
(FCS). (Harlan SERA-LAB. Belton, Loughborough, UK). (anti-IL-4: Isotype: Rat NYG2a. 
Clone: MQI-17HI2. Anti-TGF-0: Isotype: Mouse IgGl. Clone: 9016.2 anti-IFN-y: 
Isotype: Mouse IgGl. Clone: B27. Anti-IL-6: Isotype: Rat IgGl. Clone: MQ2-13A5. Anti- 
IL-10: Isotype: Rat IgG2a. Clone: JES3 -19F 1). 
2.18.2 Protocol 
1. Tonsilar B cells were cultured for 10 days at 370C under standard conditions for IgE 
switching: IL-4 (20 ng/ml) and anti-CD40 (0.5gg/ml) (Control). 
2. At day 0, one extra cytokine (IL-6, IL-10, IFN-y or TGF-P) was added at a 
concentration of 100 U/ml together with titrating amounts of its relevant cytokine 
neutralising specific antibody. Experiment was carried out in triplicates. The 
concentration of the cytokine neutralising antibodies was ranging from: 0- 1 0,000ng/ml. 
3. After a4 day incubation, B-cell proliferation was assessed as described before. 
4. After a 10 day incubation, supernatants were collected and their IgE levels were 
measured by an IgE sandwich ELISA. 
2.19 Surface Ig Profile of purified human B cells. 
The membrane bound Ig molecules on the tonsillar B cells were identified by surface 
two-colour staining followed by flow cytometry analysis. 
2.19.1 Reagents. 
AET-treated Sheep Red Blood Cells. Phosphate Buffered Saline (PBS). (INVITROGEN 
Plc. Inchinnan Business Park,, Paisley, UK). Bovine Serum Albumin (BSA). buffer 
chemicals. (SIGMA. Pool, Dorset, UK). FITC-IgM, FITC-IgG, FITC-IgE. FITC-IgA, 
FITC-IgD, PE CD 19+. (Becton-Dickinson - PHARMINGEN . 
Cowley, Oxford, UK). 
Fc-Block (Human IgG). (Miltenyi Biotec. Bisley, Surrey. UK). 
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2.19.2 Protocol. 
Tonsillar B cells were purified by T-cell rosetting and added in flow cytometi-N, tubes 
at 5x 1 05 cells /tube and washed once with PBS-0.5%BSA for 5 min. at 200g. 
2. Double surface staining was the carried out by adding 10 ýtl of FITC-CD19 amibody 
with 10 ýd of a PE-coiýjuoated lo antibody (either IgA or 1(-)G or IcD or 1(-)'\l or 
Together with the flow cytometry antibodies, I ýtl of Fc blocker was added per tube. 
4. The tubes were incubated at 4'C for 20min and then washed once with PBS-0.5% 
BSA for 5 min. at 200g. and the purity was tested by flow cytoiiietry. 
2.20 IL-411 expression on B cells. 
The effects of certain cytokines in the regulation of the IL-4 receptor expression on 
tonsillar B cells was studied as a control for the IgE synthesis process. B cells cultured 
with different cytokines were collected at various time points, washed and stained with 
biotinylated IL-4 (specific for the IL-4 receptor), followed by PE-conjugated 
streptavidin. The IL-4R. expression was measuerd by flow-cytometiy. 
2.20.1 Reagents. 
Iscove's Modified Dulbecco's Medium (IMDM), L-Glutamine, human holo-transferrin. 
Ficoll Hypaque, NaCl powder, Penicillin/Streptomycin, alkaline phosphatase conjugated 
anti-IgE (SIGMA. Pool, Dorset, UK). AET-treated Sheep Red Blood Cells (previously 
prepared). Recombinant human cytokines, biotinylated IL-4, PE-conjugated streptavidin, 
FITC-CD 19+ antibody (Becton-Dickinson-PHARMINGEN. Cowley, Oxford, UK). 
Anti-CD40 monoclonal antibody (Clone: G28.5. (Gift by Dr. Darren Wheeler. 




1. Tonsillar B cells were purified by T-cell rosetting and cultured at standard conditions 
(control) or with one exogenous cytokine (IL-6. IL-10, IL-2. IL-122. TGF-O or ll-N--, ) L- 11 
at I OOU/m I. 
2. Supernatants from all culture conditions werc collected at &ýs 2.4.6 and 8 and tile 
B cells were stained for the IL-4 receptor. 
-cells were added at 5xl 05 ith 10% FCS (pH: 4.1) B cells/tube and 500 ýtl of PBS xNI 
was added in the tubes. 
4. B cells were incubated at room temperature for 3) i-nin. and theii washed twicc with 
PBS-I%FCS. This would strip any excess IL-4 bound on the B-cell IL-4 receptors 
present since day 0 of the experiment. 
10 ýd of biotinylated IL-4 was then added in each tube and the cells were incubated 
for 330 min. at 4'C followed by the addition of 10 ýtl of PE-conjUgated streptavidin 
and FITC-conjugated CD19 antibody. 
6. A further incubation for 20 min. at 40C took place and finally the cells were washed 
once with PBS- I %FCS. The IL-4 receptor expression on the B cells was estimated 
by flow cytometry. 
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CHAPTER 3: PLEIOTROPIC EFFECTS OF 
CYTOKINES ON It! CLASS PRODUCTION. 
DEVELOPMENT OF THE It! E SYSTEM. 
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3.1 INTRODUCTION. 
B cells can express different 11111711tinoolobulin heavy chain isotypes. depending on their 
differentiation stage or activation state (297). B cells emeroinu, from the bone marrow tý - 
are IgM / 1, -, D double positivc and although considercd as mature cells they are still 
immunologically -naYve" as they would not have encountered any antigen. According to 
the immunological status of the individual, B cells will undergo isotype sxvitching in 
\vIiich new Ig molecules are secreted or expressed on the surface of the B cell. This is a 
T-cell dependent process and takes place in the secondary lymphoid organs such as the 
lymph nodes and the spleen. It is been suggested that Ig class switching is related to the 
number of B cell divisions, a process that is independent of division rate (196). The 
process of switching dernands replication of the B-cell DNA that would aid the latter to 
go through the recombination stages of switching. Consequently, there should be a Z-- 
number of cell divisions before the cells switch, although this process is independent of 
division rate. 
In the case of IgE switching the direct effect of IL-4 on the B cells is widely established 
(2 98). (2 99), (3300), (111 ), (3 301) and (3 02). It has been suggested that IL-4 acts by 
opening up DNA switch regions for recombination rather than by regulation of isotype- 
specific recombinases (299). Binding of IL-4 to its receptor causes the activation of the 
signal transducer and activator of transcription 6 (STAT 6) and its translocation to the 
nucleus (303), where it binds to an IL-4-responsive element in the promoter region 5' of 
the IF, exon (304). 
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The importance of CD40-CD40L interaction between B-T cells in Ig switching is also 
widely established (305), (306), ('307), (160), (308), (166) and (309). CD40, a member 
of the turnor necrosis factor receptor superfamily. has a general activating effect leading 
to the secretion of cytokiiies that will further modulate the immune response (160). 
Engagement by CD40L (on activated T cells). or h-y antI-CD40 11jolloclonal antibod"- 
(used in this system), provides the secondary signal leading to the survival and 
differentiation of B cells including isotype class switching, which is further specified by 
the prevailing cytokine milieu at each given time (3306). Mutation of the CD40L oene t- 
results in a defective CD40-CD40L interaction, characteristic of the X-linked hyper-IgM 
syndrome in which B cells are rendered unable to switch to any other Ig isotype, due to 
the lack of CD40L expression on the T cells (307). 
In this study, tonsillar B cells were isolated by either T-cell rosetting or by positive 
selection (CD 19+ dynabeads) and their membrane Ig profile determined. The efficiency 
of the two purification methods was assessed on the basis of B-cell proliferation and IgE 
secretion. Development of the IgE system involved the titration of IL-4 and anti-CD40 
in the B-cell cultures as well as the time-course of IgE secretion. Further investigation of 
other cytokines as potential switch factors to immunoglobulin molecules including: 
IgG 1 -4 and IgA was carried out. 
Anti-CD40 antibody was always present in the study of Ig isotype secretion as it's a 
prerequisite for B-cell survival and differentiation. Cytokines that were found to have an 
effect on IgG 1 -4 and IgA subclass switching were tested in the absence of IL-4 
in order 
to distinguish between clonal expansion of precommitted B cells and actual stimulation 
of Ig production. The presence of IL-4 has a proliferative effect on B cells (3 10) and 
(311), hence it can be involved in their clonal expansion (18 5). Cytokines that enhanced 
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the secretion of Ig isotypes in the absence of IL-4. were considered to have a direct 
effect on the human B cells. as their individual proliferative activity on the latter is 
minimal, if any, compared to IL-4. 
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3.2 RESULTS 
3.2.1 Purification of tonsillar B cells. 
B cells were purified from a tonsillar cell suspension by either positive selection (CD 19- 
dynabeads) or T-cell rosettiii(-, (Slicep Red Blood Cells). Following pUrification the 
levels of B-cell purity were assessed by flow cytometry. B cells were stained by anti- 
CD I 9-PE conjugated monoclonal antibody. T cell impurities were identified bv CD3- 
FITC conjugated antibody, while the monocyte impurities \vere determined with anti- 
CD14-FITC conjugated antibody. B-cell purity levels were similar between the two 
purification techniques, since by using anti-CD19 dynabeads purity was around 99%, 
while T-cell rosetting gave purity levels of around 96% (Figure 3.1 and Table 3.1). 
3.2.2 Membrane Ig (mIg) profile of tonsillar B cells. 
Tonsillar B cells isolated by T-cell rosetting were surface stained with anti-CD19-PE 
antibody and one from each FITC-conjugated Ig antibodies from: IgM. IgD, IgG, IgA 
and IgE. Flow cytometry analysis showed that 56% of the total B cell population was 
IgM+. 18% IgD+, 11% IgG+, 27% IgA+ and only 5% IgE+ (Table 3.2). The total B 
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Fig. 3.1: B-CELL PURITY. Tonsillar B cells were isolated by either T-cell rosetting or by positive 
selection using CD 19+ dynabeads. The B-cell purity levels were measured by cell surface 
monoclonal antibodies. Anti-CD 19 PE was used for B-cell staining, anti-CD3 FITC for T- 
cell staining and anti-CD 14 FITC for monocyte staining. The analysis showed similar levels 
of B-cell purity obtained by the two methods. 
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1 .11 11114 ýI III 
Cell Populations 
B cells (CD19+) 
T cells (CD3+ CD 
Monocytes (CD14- 
CD 19-) 
Positive Selection Negative Selection 
(CD19 (T-cell rosetting) 
dynabeads) 
98.8 % 97.9% 
0.8% 2.2% 
0.5 % 0.5% 
Table 3.1: Purification levels of B cells isolated by T-cell rosetting (negative 
selection) or CD19+ dynabeads (positive selection). Tonsillar B cells were 
isolated 
by the two purification techniques and the levels of B cells, T cells and monocytes 
were measured by the relevant cell surface monoclonal antibodies. 
The table presents 
the mean values of the cell populations from three different experiments. 
ml9M+ % mlgD+ % mIgG+ % mIgA+ % mIgE+ 
56 18 11 27 5 
TOTAL B CELLS STAINED = 99% 
Table 3.2: Membrane Ig (mIg) profile of freshly isolated tonsillar B cells. 
Tonsillar B cells were isolated by T-cell rosetting and surface stained with flow 
cytometry antibodies. Double staining was carried out with FITC anti-CD 19 monoclonal 
antibody and PE-conjugated isotype-specific monoclonal antibodies (i. e.: anti-IgG, anti- 
IgM, anti-IgE, anti-IgD and anti-IgA). The cells were incubated also with a human Fc- 
blocker in order to minimise any non-specific binding. The mIg levels on the tonsillar B 
cells were measured by flow cytometry. 
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3.2.3 Optimisation of the IgE system by human B cells in vitro 
Purified B cells were cultured for 10 days with different concentrations of IL-4 and anti- 
CD40. IgE Nxas measured in the culture supernatants after 10 days. From these results it 
was concluded that the optimum IL-4 concentration for significant IgE production was 
20 nu/nil ( ILE: 450 ngy/ml) while that of anti-CD40 ý\as found to be 0.5ýtg'ml 
ng/nil) (Figures 33.2.1 and 3.22.2). No IgE was detected in the absence of IL-4 and anti- 
CD40, -vvhile higher amounts of 20 ng/ml of IL-4 and 0.5 ýtg'ml of anti-CD40 had 
negligible effects on the IgE levels secreted by the B cells. 
These conditions were used in all subsequent experiments (unless stated otherwise) and 
became the core of the IgE class switching system used. 
3.2.4 Time course of IgE secretion by human B cells in vitro 
Tonsillar B cells were cultured with IL-4 (20 ng/ml) and anti-CD40 (0.5 ýtg/ml) and the 
supernatants were collected at days: 1,4,8,10,14 and 18. The levels of IgE in the 
supernatants were measured by an IgE ELISA. IgE levels increased xN, ith time most 
rapidly between days 8- 10 (600 - 1300 ng/ml) and reached a plateau bý- day 10 (Figure 


























Fig. 3.2a: Optimisation of IL-4 concentration in the IgE system. Tonsi$r B cells 
were isolated by T cell rosetting and cultured at a concentration of 105 cells/well, 
with increasing amounts of IL-4 and a constant concentration of anti-CD40 
(0.5pg/ml). After 10 days, supernatants were collected and the IgE levels measured 
by an IgE sandwich ELISA and are expressed as the mean of three donors ± SEM 
IgE. 
Fig. 3.2b: Optimisation of the anti-CD40 concentration in the IgE system. 
Tonsilk B cells were isolated by T cell rosetting and cultured at a concentration of 
105 cells/well, with increasing amounts of anti-CD40 and a constant concentration of 
IL-4 (20 ng/ml). After 10 days, supernatants were collected and the IgE levels 
measured by an IgE sandwich ELISA and are expressed as the mean of three donors 
± SEM IgE. 
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Fig. 3.3: Time course of IgE secretion by tonsillar B cells "in 
vitro". Tonsillar B cells were purified by T-cell rosetting and cultured 
at a concentration of 105 cells/well, with EL-4 (20ng/ml), anti-CD40 
(0.5ýig/ml). The supernatants were collected at days: 1,4,8,10,14 and 
18 and the levels of IgE were measured by an IgE sandwich ELISA. 
The IgE levels are expressed as the mean of three donors ± SEM. The 
IgE levels in the supernatants increased with time, reaching a plateau 
after day I ID 
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3.2.5 Effect of purification method on B-cell proliferation and IgE secretion. 
Tonsillar B cells were purified by positive selection (CD19+ dynabeads) and T-cell 
rosetting. Both sets of purified cells were cultured with Il, -4 (20 n(-, /rnl) and anti-CD40 
(0.5 ýt , (3/ml). At day 4, plates were pulsed ý, vlth 
3 H-Thymidine in order to measure B-cell 
proliferation. At day 10. supernatants , vere collected and the lc%els Scacted \\C"c 
measured by a direct ELISA. B cells purified by T-cell rosetting secreted higher levels 
of IgE compared to B cells that were positively selected with the CD 19+ dynabeads. The 
opposite was observed with the levels of B-cell proliferation. 
3.2.6 Purification of CD4+ / CD8+ tonsillar T cells. 
CD4+ and CD8+ T cells were also isolated by positive selection using CD4+ and CD8+ 
dynabeads respectively. The purity levels of the CD4+ and CD8+ T cells was assessed 
by flow cytometry. Both T-cell populations were stained with CD4-PE conjugated 
antibody as well as CD8-FITC conjugated antibody. 97.8% of the CD4+ T cells were 





















Fig. 3.4: Effect of the purification method on B-cell proliferation and IgE 
secretion "in vitro". Tonsillar B cells were purified by positive selection (CD19+ 
dynabeads) or by T-cell rosetting and cultured with IL-4 (20 ng/ml) and anti-CD40 
(0.5 ptg/ml). At day 4, culture plates were pulsed with 3 H-Thymidine and B-cell 
proliferation was assesed. At day 10, supernatants were collected and the levels of IgE 
were measured by ELISA. The results shown are the average of three experiments and 
the standard errors have been calculated. 
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Fig. 3.5: Tonsillar CD4+ / CD8+ T-cell purity. CD4+ and CD8+ T 
cells were positivelly selected from a tonsillar cell suspension using 
anti-CD4+ and anti-CD8+ dynabeads respectivelly. The purity of the 
CD4+ and CD8+ T cells was assessed by flow-cytometry using anti- 
CD4 and anti-CD8 FITC conjugated antibodies. These results are 
representative of three experiments. 
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3.2.7 Effect of autologous CD4+ and CD8+ T cells on B-cell proliferation and IgE 
class switching. 
The effect of T-cell impurities on the B cell cultures. proliferation and IgE secretion was 
determined. For this purpose. B cells were cultured with IL-4 (20 ng/mi) and anti-CD40 
(0.5 ýtg/ml) and increasing numbers ofeither CD4+ or CD8+ T cells wcre added. B-ccll 
proliferation was assessed by the incorporation of 3 H-Thymidine, while the IgE levels 
were measured by a direct sandwich IgE ELISA. Figure 3.6 shows that both CD4+ and 
CD8+ T cells, up to a contamination of 10%, did not have a significant effect on B cell 
proliferation or IgE secretion in the cultures. 
3.2.8 Effect of cytokines on IgGI class production. 
Tonsillar B cells, purified by T-cell rosetting were cultured with IL-4 (20 ng/nil) and 
anti-CD40 (0.5 ýtg/rnl) (control conditions) as well as with one exogenous cytokine at 
100 U/ml. After 10 days supernatants were collected and IgGI levels measured by 
ELISA (Figure 33.7). IL-10, IL-12 and even more IFN-y seemed to stimulate B cells to 
IgGI production. 
In order to investigate whether the effect of these cytokines was IL-4-dependent, they 
were titrated in the B cell cultures, in the absence of IL-4. Only IFN-y was able to 
stimulate B cells to IgGI secretion independent of IL-4. The effect of IFN-y on IgGI 
was dose-dependent and did not plateau by I OOOU/ml of the cytokine. IL- 10 and IL- 12 
















































Fig. 3.6: Effect of autologous CD4+ and CD8+ T cells on the 
proliferation and IgE secretion by tonsillar B cells. Tonsillar B cells, 
CD4 and CD8 T cells were purified by positive selection using CD4 and 
CID8 dynabeads respectively. Two different culture plates were set up; in 
the first one, the CD4 T cells were titrated with the B cells, while in the 
second one CD8 T cells were titrated with the B cells. IL-4 (20 ng/ml) and 
anti-CID40 (0.5 ltg/ml) were always present in the cultures. After 4 days half 
of the supernatants were collected and the proliferation was measured (a + 
c). After 10 day culture the rest of the supernatants were collected and the 
levels of IgE were measured by an IgE ELISA (b + d). In both cases the 
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Fig. 3.7: Effect of cytokines on IgG1 production by human B cells. 
Tonsillar B cells were isolated by T-cell rosetting and cultured in the 
presence of IL-4 (20 ng/ml), anti-CD40 (0.5 ýtg/ml) and one exogenous 
cytokine at I OOU/ml. After 10 days supernatants were collected and the IgG I 
levels were measured by ELISA, and expressed as the mean of three donors 
± SEM IgG I (a). 
Human B cells were cultured with increasing amounts of cytokines found to 
have an effect on IgG I production in the absence of IL-4. After 10 days 
supernatants were collected and the IgG I levels were measured by ELISA 
and expressed as the means of three donors ± SEM IgG I (b). 
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3.2.9 Effect of cytokines on IgG2 class production. 
Tonsillar B cells, purified by T-cell rosetting were cultured with IL-4 (20 n(-', mi) and I- 
anti-CD40 (0.5 ýtg/rnl) (control conditions) as well as with one exogenous cytokine at 
the physiologic concentration of 100 U/ml. After 10 days of culture. the supernatants 
were collected and the lu)G2 levcls \\-ere measured by ELISA. None of the cvtokincs 
tested were able to stimulate human B cells to secrete IgG2 (figure 3.8). 
3.2.10 Effect of cytokines on IgG3 class production. 
Tonsillar B cells, purified by T-cell rosetting were cultured with IL-4 (20 ng/ml) and 
anti-CD40 (0.5 ýtg/rnl) (control conditions) as well as with one exogenous cytokine at 
100 U/ml. After 10 days of culture, the supernatants were collected and the IgG3 levels 
were measured by ELISA. IL-10 stimulated B cells to IgG3 production only in the 
presence of IL-4 which indicates synergy between the two cytokines. 
In order to investigate whether the effect of IL- 10 was IL-4-dependent, the latter was 
titrated in the B cell cultures, in the absence of IL-4. IL- 10 alone was unable to stimulate 
B cells to secrete significant amounts of IgG3 (figure 3.9). 
3.2.11 Effect of cytokines on IgG4 class switching. 
Tonsillar B cells, purified by T-cell rosetting were cultured with IL-4 (20 ng/ml) and 
anti-CD40 (0.5 ýtg/rnl) (control conditions) as well as with one exogenous cytokine at 
100 U/ml. After 10 days of culture, the supematants were collected and the IgG4 levels 
were measured by ELISA. IL-6 and IL-10 stimulated B cells to secrete IgG4. IL-12. 
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TGF-ý and IFN-y inhibited the IL-4-mediated 1-(-)G4 secretion h-v the human B cells. 
wfille IL-2, IL-5, IL-7 and IL-9 had no effect. 
In order to investigate whether the effect of IL-6 and IL-10 on IoG4 secretion was IL-4- 
dependent- the cytokines were titrated in the B cell cultures, in the absence of IL-4. Only 
IL-10 was able to stimulate B cells to secrete IgG4. Induction of' the latter 
immunoglobulin by IL-10 was dose-dependent while independent of IL-4. The IgG4 
stimulatory activity of IL-6 was found to be IL-4-dependent (figure 3.10). 
3.2.12 Effect of cytokines on IgA class switching. 
Tonsillar B cells, purified by T-cell rosetting were cultured with IL-4 (20 ng/ml) and 
anti-CD40 (0.5 ýtg/rnl) (control conditions) as well as with one exogenous cytokine at 
100 U/nil. After 10 days of culture. the supernatants were collected and the IgA levels 
were measured by ELISA. IL- 10 and TGF-O stimulated B cells to produce IgA. 
In order to investigate whether the effect of these cytokines was IL-4-dependent. they 
were titrated in the B cell cultures, in the absence of IL-4. Only TGF-ý was able to 
stimulate B cells to secrete IgA. The effect of TGF-P was dose-dependent while 
independent of IL-4. IL- 10 had a much lesser effect on IgA secretion in the absence of 
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Fig. 3.8: Effect of cytokines on IgG2 production by human B cells. 
Tonsillar B cells were isolated by T-cell rosetting and cultured in the 
presence of IL-4 (20 ng/ml), anti-CD40 (0.5 pg/ml) and one exogenous 
cytokine at I OOU/ml. After 10 days supernatants were collected and the 
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Fig. 3.9: Effect of cytokines on IgG3 production by human B cells. 
Tonsillar B cells were isolated by T-cell rosetting and cultured in the 
presence of IL-4 (20 ng/ml), anti-CD40 (0.5 gg/ml) and one exogenous 
cytokine at IOOU/ml. After 10 days supernatants were collected and the 
levels of IgG3 were measured by ELISA and expressed as the mean of three 
donors ± SEM IgG3 (a). 
Cytokines found to have an effect on IgG3 production (IL-10, in this case), 
were titrated in the B cell cultures in the absence of IL-4. After 10 days 
supernatants were collected and the IgG3 levels were measured by ELISA 
and expressed as the mean of three donors ± SEM IgG3 (b). 
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Fig. 3.10: Effect of cYtokines on IgG4 production by human B cells. 
Tonsillar B cells were isolated by T-cell rosetting and cultured in the 
presence of EL-4 (20 ng/ml), anti-CD40 (0.5 gg/ml) and one exogenous 
cytokine at IOOU/ml. After 10 days supernatants were collected and the 
levels of IgG4 were measured by ELISA and expressed as the mean of 
three donors ± SEM IgG4 (a). 
Human B cells were cultured with increasing amounts of cytokines found 
to have an effect on IgG4 production, in the absence of IL-4- After 10 days 
supernatants were collected and the IgG4 levels were measured by ELISA 
and expressed as the mean of three donors ± SEM IgG4 (b). 
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Fig. 3.11: Effect of cytokines on IgA production by human B cells. 
Tonsillar B cells were isolated by T-cell rosetting and cultured in the 
presence of IL-4 (20 ng/ml), anti-CD40 (0.5 ýtg/ml) and one exogenous 
cytokine at I OOU/ml. After 10 days supernatants were collected and the 
levels of IgA were measured by ELISA and expressed as the mean of 
three donors ± SEM IgA (a). 
Human B cells were cultured with increasing amounts of cytokines 
found to have an effect on IgA production, in the absence of IL-4. After 
10 days supernatants were collected and the IgA levels were measured 
by ELISA and expressed as the mean of three donors ± SEM IgA (b). 
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3.3 DISCUSSION. 
In this chapter we established the IgE system that will be used in the subsequent 
experiments to study Igf- class synthesis. Two B cell pUrification methods were carried 
OLIt and compared: positive , election and T-cell rosetting. The differences in the B-cell t: ý 
purity levels obtained with these two methods, were mainly due to T-cell impurities 
present in the cultures, which in the case of T-cell rosettinu could reach a level of 4.5% 
(CD')+ cells), although the average was around 2.2%. Monocyte impurities neNýer 
exceeded the levels of 2.5% (CD14+ cells). CD3+ B cells are not known to exist, thus 
the levels of CD3+ / CD19+ double positive cells picked up during flow cytometry 
analysis was considered an artefact. CD4+ and CD8+ T cells were added to the B-cell 
cultures. (up to 10%), but had no effect on the B-cell proliferation or IgE secretion. 
Despite the similar efficiency of the two purification methods, T-cell rosetting was 
preferred as more IgE was secreted (see figure 3.4). 
Titration of IL-4 showed optimum levels according to IgE production at 20 ng/mI while 
the efficiency of anti-CD40 in IgE switching peaked at a concentration of 0.5 ýtg/ml. IL- 
4 can directly switch B cells to IgE production by activating specific transcription 
factors (e. g.: STAT 6), followed by transcription of the IF- region (312). Anti-CD40 
provides the primary signal which will aid heavy-chain DNA switch recombination 
which in turn will position the CF- gene directly downstream of the VDJ genes making it 
accessible to the transcription factors (312). T-cells, or T-cell membranes can be used 
instead of anti-CD40, as they possess CD40L, sufficient to provide the required 
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secondary signal to the B cells. Recombinant CD40L in membrane vesicles has been 
shown to be equally effective (308). 
The time-course of IgE secretion showed that at least 90% of the potential IgE secreted 
in the B cell cultures. is present by day 10. From this result it was decided that a 10 day 
culture period would give sufficient IgE levels for our study. Switching was bellcN ed to 
Occur after at least 4 days of culture and any IgE picked up prior to that time point was 
attributed to the presence of precommitted B cells. This was confirmed by the prescnce 
of' a small population of B cells (5%) that possessed membrane IgE (ml(-, E) on their 
surface. 
In the Ig isotype secretion experiments B cells were cultured with one exogenous 
cytokine in the presence of IL-4. Cytokines that had an effect on the production of a 
specific Ig isotype were titrated to the B-cell cultures in the absence of IL-4 as the latter 
caii lead to clonal expansion of precommitted cells. If the response was not altered, theii 
the effect would be attributable to the action of the specific cytokine acting directly on 
the B cells. Where the effect was IL-4-dependent it was unclear whether clonal 
expansion was involved or a switching mechanism driven by the combination of IL-4 
with the particular cytokine. This problem might be resolved by studying the effect of 
the particular cytokines on na*fve B cells (IgM+/IgD+ cells), which haven't been 
committed to any Ig isotype. Concerning IgG I production, IL- 10, IL- 12 and IFN-y could 
upregulate it although only the latter cytokine was IL-4- independent. The IgGl 
switching properties of IFN-y were demonstrated early by Nakagawa and colleagues. 
where the addition of IFN-y with Staphylococcus Aureus (SAC)-activated B cells lead to 
the production of IgG I in the cultures. On the other hand, Briere et al., (1994), showed 
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that IL-10 could switch CD40-activated human B cells to produce IgGI in the absence 
of IL-4, a finding not in agreement with our results in which IL- 10 was unable to sustain 
significant le,,, els of IgGI in an IL-4-independent fashion (3)13)). In the case of IgG". no 
cytokines %wre able to upregulate the secretion of this antibody. The low levels detected 
ý, vherc either due to background readings or due to an IL-4-dependent clonal expansion L- 
of a small precommitted B-cell subpopulation. Interestingly. Calvert et al., (1990). have 
shown that IL-2 was able to promote low levels of IgG2 secretion by LPS-stimulated 
tonsillar B cells (314). Kawano and Norna (1996), demonstrated synergy between IL-2 
and IFN-, y for IgG2 switching by purified human B cells (315). This might be true 
although in our hands, these cytokines were unable to induce IgG2 production by the 
purified B cells individually or together with IL-4. IL- 10 was capable of promoting IgG3 
secretion but in an IL-4-dependent fashion. It has been also demonstrated that IL-10 
could switch CD40-activated na*fve tonsillar B cells to IgG3. Thus, in addition to its 
growth promoting and differentiating activities on human B cells, IL-10 may represent a 
switch factor for IgGI and IgG3 (313). 
In the case of IgG4, IL-4 was thought to induce its production. This was supported by 
Spiegelberg el al., (1990) using B cells purified from peripheral blood and activated by 
anti-CD40 (316). Upregulation of IgG4 secretion due to IL- 10 was dose-dependent and 
IL -4- independent. The possible role of IL-10 as a switch 
factor for IgG4 has not been 
suggested before. Only Jeannin et al., (1998), demonstrated that addition of IL-10 in 
human B cell cultures at day 0 could induce IgG4 secretion but only in the presence of 
IL-4 (317). Hence this increase in IgG4 production was accounted to the 
immunoproliferative activity of IL- 10 on B cells that were switched to IgG4 synthesis by 
IL-4. Interestingly, IL-12, IFN-y and TGF-ý downregulated the IL-4-dependent IgG4 
secretion in the B cell cultures. 
Finally, I L- 10 and TGF-ý were able to induce secre6on of IgA. The latter cytokine had a 
greater effect compai (1 -ed to 
IL-10 and could also function in the absence of IL-4 in a 
dose-dcpendent fashion. IL-10 \%as shown to be an 1(_)A sý\Itch factor as it was able to 
induce the production of this isotype by na*fve B cells in the absence of IL-4 (318). TGF- 
has been widely shown to switch both human and murine B cells to IgA secretion in zl.: ý 
the absence or presence of IL-4 (319), (69), (320), (321). (322) and (323). This work 
was carried out using naYve, sIgA- B cells proving the direct IgA switching effect of 
TGF-ý. These results were consistent with our findings on the protein level. 
In conclusion, cytokines that were found able to induce the secretion of certain Ig 
isotypes in an individual basis included: IL-4 (IgE), IL-10 (IgG4). IFN-y (loGl) and 
TGF-0 (IgA). 
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CHAPTER 4: EFFECT OF CYTOKINES ON It! E 
PRODUCTION BY HUMAN B CELLS. 
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4.1 INTRODUCTION. 
The maturation of resting B lymphocytes into lo-secreting cells is a highly regulated 
phenomenon. thought to be coupled to considerable proliferation. which reqUires the 
participation of antigen. T cells and accessory cells acting through cell-cell interactiol's I- L_ 
via specific membrane ligands and through the release of cytokines (3'24). 
During B-cell development and differentiation. cytokines act in autocrine and paracrine 
fashion. During B-cell ontogeny, IL-7 induces proliferation of B-cell precursors (35-25)), 
and drives the development of the latter to an immature B cell (326). IL-10 has been 
shown to be involved in the development of plasma cells from immature B cells (327). 
IL-4 and IL- 13 can switch nafve B cells to IgG4 and IgE production (I 70)ý (165), (127) 
and (I 11). Abnormal expression of cytokine receptors. aberrant signal transduction and 
altered cytokine profiles "in vivo ". can cause functional abnormalities of the B cells 
(328). 
Apart from the cytokines, cell-surface markers play an essential role in the regulation of 
Ig subclass switching, especially in the case of IgE. As established in Chapter 33, anti- 
CD40 is a very important factor in the process of IgE production by the human B cells. 
This soluble monoclonal antibody can substitute for activated T cells or T-cell 
membranes by providing the survival signal for the B cells "in vitro". Hence, anti-CD40 
together with IL-4 (at their optimum concentrations), were used as control conditions in 
our IgE system. 
Previous studies. concerning the IgE regulation in both humans and mice, have followed 
the Thl/Th2 paradigm. Consequently, type I cytokines such as IL-2, IFN-y and TGF-ý I 
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have been shown to downregulate the IgE switching process by hurnaii B cells (i "' 16). 
(329). (19-3)) and (117). On the other hand. cytokines such as IL-4 ( type 2 cytokine). IL- 
5. IL-6, IL-9 and IL-133 have been shown to upregulate IgE secretion by hurnan and 
MOLIse B cells mainly "in viiro". These cytokines seem to coordinate host responses 
against lar(-, c. extracellular pathogens such as helminths (33330). Most of the characteristic 
features of atopy and asthma, especially IgE synthesis, result from the combined effects 
of type 2 cytokines and are closely associated with Th2-like cells () "3 1) and (332). 
Our results concerning the effects of the cytokines tested on the IL-4-dependent IgE 
secretion were contradictory with some of the previous findings although the general 
type 1 /type 2 cytokine theory fell into place. 
B-cell proliferation experiments were also carried out in parallel with the IgE secretion 
studies in order to assess the possible correlation between B-cell proliferation and IgE 
production by the human B cells. For this purpose, linear regression plots (LRP) have 
been constructed for each cytokine that was found to have an effect on the IgE secretion 
system "in vitro". 
In this chapter we attempted to investigate the regulation of different cytokines on the 
IL-4-dependent IgE switching of the human B cells "in vitro". 
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4.2 RESULTS. 
4.2.1 Effect of IL-13 on B-cell proliferation and IgE production in the presence or 
absence of IL-4. 
IL-I 33 was added the B cell cultures at a concentration range from 0-1000 t1ml. in the 
presence or absence of IL-4. B-cell proliferation was assessed by 3 H-Thymidine 
incorporation after 4 days, while the levels of IgE were measured by the standard IgE 
sandwich ELISA after 10 days. In figure 4.1 we compared the proliferation of B cells 
cultured with IL- 13) in the presence or absence of IL-4. Both IL-4 and IL- 13' stimulated 
B-cell proliferation (12000cpi-n and 2000cpm ± SEM respectively). IL-4 was much more 
potent than IL-13. Similarly. IL-4 induced more IgE than IL-13 alone. No synergy 
between IL-4 and IL- I-")' was observed for proliferation or IgE synthesis. 
4.2.2 Effect of IL-6 and IL-10 on the IL-4-dependent B-cell proliferation and IgE 
production. 
IL-6 and IL- 10 were individually titrated in the B-cell cultures at concentrations ranging 
from 0-1000 U/ml, together with IL-4 (20 ng/ml) and anti-CD40 (0.5 ýtg/ml). B-cell 
proliferation was assessed by 
3 H-Thymidine incorporation after 4 days of culture, while 
the levels of IgE were measured by the standard IgE sandwich ELISA after 10 days of 
culture. The proliferation and IgE switching experiments were repeated at 
least three 
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Fig. 4.1: Effect of IL-13 on B-cell proliferation and IgE secretion in the 
presence or absence of IL-4. Tonsillar B cells were purified by T-cell rosetting and 
cultured for 4 days in the presence (filled squares) or absence of IL-4 (20 ng/ml) 
(filled circles) with increasing amounts of IL-13. Anti-CD40 was added at a 
concentration of 0.5 ýg/ml. Proliferation was measured by 3H-Thymidine 
incorporation after 4 days of culture (a). 
Supernatants were collected after a 10 day incubation and the IgE levels measured 
by ELISA (b). The results are representative of three donors and the standard 
deviations have been calculated. 
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Both IL-6 and IL-10 significantly increased IL-4-dependent B cell proliferation and 1(2E 
secretion when added at a concentration of I ng/ml or more (figures 4.2 and 4. 'ý 
respectively). IL-6 increased B-cell proliferation up to I 8000cpm and IgE levels to 3,000 
m)/ml while IL-10 pushed the B-cell proliferation levels to *I I just over '6000cpm while the 
levels reached levels of 4000 nuilml. The immunoproll I III, -, and 
1-, -, E cnhanci - 
effect of IL-10 was greater than that of IL-6 (3500 ng/ml and 2500 iig/ml ± SFM 
respectively). 
4.2.3 Effect of IFN-y, TGF-0, IL-2 and IL-12 on the IL-4-dependent B-cell 
proliferation and IgE switching. 
IFN-y, TGF-P. IL-2 and IL-12 were individually titrated in the B-cell cultures at 
concentrations ranging from 0- 1000 U/ml. together , vith IL-4 (20 ng/ml') and anti-CD40 
(0.5 ýtg/rnl). B-cell proliferation was assessed by 3 H-Thymidine incorporation after 4 
days of culture, while the levels of IgE were measured by the standard IgE sandwich 
ELISA after 10 days of culture. The proliferation and IgE switching experiments were 
repeated at least three times for each cytokine (three donors shown). 
IFN-y did not affect B-cell proliferation although it inhibited IgE production more than 
50% (figure 4.4). TGF-P caused an inhibition of B-cell proliferation and IgE synthesis at 
the lowest concentration of 0.1 U/ml,, while at the highest concentrations (1000 U/ml), 
IgE production was almost reduced to background levels (figure 4.5). IL-12 had similar 
effects compared to IFN-y as it did not affect B-cell proliferation but decreased IgE 
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Fig. 4.2: Effect of IL-6 on the IL-4-dependent B-cell proliferation and IgE 
secretion. Tonsillar B cells from three donors were purified by T-cell rosetting and 
cultured for 4 days at a concentration of 105 cells/well, with IL-4 (20 ng/ml) and 
anti-CD40 (0.5ýtg/ml) with increasing amounts of IL-6. Proliferation was 
determined after 4 days of culture by 3 H-Thymidine incorporation (a). 
Supernatants were collected after 10 days of incubation and the IgE levels were 
measured by ELISA (b). Standard deviations have been calculated for each 
individual donor (triplicates). 
119 

























0.1 1 10 100 1000 
IL-10 Ulml 
Fig. 4.3: Effect of IL-10 on the IL-4-dependent B-cell proliferation and IgE 
secretion. Tonsillar B cells from three donors were purified by T-cell rosetting and 
cultured for 4 days at a concentration of 10 5 cells/well, with IL-4 (20 ng/ml) and 
anti-CD40 (0.5 ýig/ml) with increasing amounts of IL- 10. Proliferation was 
determined after 4 days of culture by 3 H-Thymidine incorporation (a). 
Supernatants were collected after 10 days of incubation and the IgE levels were 
measured by ELISA (b). Standard deviations have been calculated for each 
individual donor (triplicates). 
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hiterestingly. despite the downregulatory potential of IL-2 on the IL-4-dependent l(-yE 
synthesis. the high immunoproliferative effect on the tonsillar B cells was evident 
(figure 4.7). 
4.2.4 Linear Regression Plots (L. R. P) 
L. R. P. between B-cell proliferation and IgE secretion were plotted for IL-6 (fig. 4.8a), 
IL-10 (figure 4.8b), IFN-y (figUre 4.9a), TGF-ý (figure 4.9b). IL-12 (figure 4.10a) and 
IL-2 (figure 4.1 Ob). The correlation coefficient. r, was calculated in order to study the 
possible relation between B-cell proliferation and IgE secretion levels in response to 
each of these cytokines. The correlation coefficient of IL-6 and IL-10 was >0.9 \N,, hich 
indicated a high positive correlation between proliferation and IgE secretion by the 
hurnan B cells. A positive correlation was found in the case of TGF-P in which both 
proliferation levels and IgE production decreased in a dose-dependent fashion. A 
negative correlation was concluded in the case of IL-2 (increase of B-cell proliferation 
but drop of IgE levels), while with IL- 12 and particularly IFN-y there was no correlation 
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Fig. 4A Effect of IFN-y on the IL-4-dependent B-cell Proliferation and IgE 
secretion. Tonsillar B cells from three donors were purified by T-cell rosetting and 
cultured for 4 days at a concentration of 105 cells/well, with IL-4 (20 ng/ml) and 
anti-CD40 (0.5pg/ml) with increasing amounts of IFN-y. Proliferation was 
determined after 4 days of culture by 3 H-Thymidine incorporation (a). 
Supernatants were collected after 10 days of incubation and the IgE levels were 
measured by ELISA (b). Standard deviations have been calculated for each 
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Fig. 4.5: Effect of TGF-0 on the IL-4-dependent B-cell proliferation and IgE 
secretion. Tonsillar B cells from three donors were purified by T-cell rosetting and 
cultured for 4 days at a concentration of 10 5 cells/well, with IL-4 (20 ng/ml) and 
anti-CD40 (0.5ýtg/ml) with increasing amounts of TGF-P. Proliferation was 
determined after 4 days of culture by 3 H-Thymidine incorporation (a). 
Supernatants were collected after 10 days of incubation and the IgE levels were 
measured by ELISA (b). Standard deviations have been calculated for each 
individual donor (triplicates). 
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Fig. 4.6: Effect of IL-12 on the IL-4-dependent B-cell Proliferation and IgE 
secretion. Tonsillar B cells from three donors were purified by T-cell rosetting and 
cultured for 4 days at a concentration of 105 cells/well, with IL-4 (20 ng/ml) and 
anti-CD40 (0.5 ýtg/ml) with increasing amounts of IL- 12. Proliferation was 
determined after 4 days of culture by 3 H-Thymidine incorporation (a). 
Supernatants were collected after 10 days of incubation and the IgE levels were 
measured by ELISA (b). Standard deviations have been calculated for each 
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Fig. 4.7: Effect of IL-2 on the IL-4-dependent Bcell proliferation and IgE 
secretion. Tonsillar B cells from three donors were purified by T-cell rosetting and 
cultured for 4 days at a concentration of 10 5 cells/well, with IL-4 (20 ng/ml) and 
anti-CD40 (0.5ýig/ml) with increasing amounts of IL-2. Proliferation was 
determined after 4 days of culture by 3 H-Thymidine incorporation (a). 
Supernatants were collected after 10 days of incubation and the IgE levels were 
measured by ELISA (b). Standard deviations have been calculated for each 
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Fig. 4.8: Linear regression plots (LRP). LRPs were constructed based on the 
effects of IL-6 (a) and IL-10 (b) on B cell proliferation and IgE secretion. The 
average of three donors was taken and the best fit line was drawn. The 
possible correlation between the two processes was assessed by calculating the 



























Fig. 4.9: Linear regression plots (LRP). LRPs were constructed based on 
the effects of IFN-y (a) and TGF-P (b) on B cell proliferation and IgE 
secretion. The average of three donors was taken and the best fit line was 
drawn. The possible correlation between the two processes was assessed by 































Fig. 4.10: Linear regression plots (LRP). LRPs were constructed based on 
the effects of IL- 12 (a) and IL-2 (b) on B cell proliferation and IgE secretion. 
The average of three donors was taken and the best fit line was drawn. The 
possible correlation between the two processes was assessed by calculating 
the correlation coefficient, r. 
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4.2.5 Effect of IL-5, IL-7 and IL-9 on IL-4-dependent B-cell proliferation and IgE 
production. 
IL-5, IL-7 and IL-9 were individually titrated in the B-cell cultures at concentrations 
ranoino from 0- 1000 U/ml. together with IL-4 (20 ng/ml) and anti z -- L- -CD40 (0.5 ýig/ml). B- 
cell proliteration was assessed by 3 H-Thymidine incorporation after 4 clLivS Ot'CUIU11'e. 
while the levels of IgE were measured by the standard IgE sandwich ELISA after 10 
days of culture. The proliferation and IgE switching experiments were repeated at least 
three times for each cytokine. Three donors are shown for each cytokine and the 
standard deviations have been calculated (triplicates). Neither IL-5 nor IL-7 nor IL-9 had 
an effect on IL-4-dependent B cell proliferation and IgE secretion by the human B cells 
"in iltro" (figures 4.11.4.12 and 4.13 respectively). 
4.2.6 Possible effects of the B-cell purification methods on the IL-4-dependent 13- 
cell proliferation and IgE production. 
Having established the effects of the various exogenous cytokines on the IL-4-dependent 
B-cell proliferation and IgE production, we wanted to investigate whether the B-cell 
purification method used could add to or distort these effects. For this purpose two sets 
of B-cell cultures were prepared. In the first one, B cells were purified by T-cell 
rosetting while in the second one B cells were positively selected by CD 19+ dynabeads 
from the tonsillar cell suspension. Both sets of cells were cultured with IL-4 (20 ng/ml), 
anti-CD40 (0.5 ýtg/rnl) and titrated amounts of one exogenous cytokine (IL-6, IL-10, 
IFN-y, TGF-P, IL-2 or IL-12). The concentration of the exogenous cytokines ranged 
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from: 0-1000 U/mI. B-cell proliferation was assessed b. N" 3 H-ThYmidine incorporation 
after 4 days in culture, while the levels of IgE were measured by the standard 1(-yE 
sandwich ELISA after 10 days of culturing. The proliferation and l(, E switching t- - 
experiments were repeated at least three times for each cytokine (the avera-ue of each 
donor is shown). 
As shown on figures 4.14 and 4.15, the B-cell purification method did not have an effect 
on the general trend of each cytokine on the IL-4-dependent B-cell proliferation and IgE 
secretion. Consequently, IL-6 and IL-10, both enhanced IL-4-dependent B-cell 
proliferation and IgE secretion using either purification methods while IL- 12 and IFN-y 
did not affect the levels of B cell proliferation. Witli TGF-ý, B-cell proliferation, while 
with IL-2 there was a dose-dependent increase in proliferation. The suppressive effects 
of IFN-y. TGF-ý, IL-12 and IL-2 on IgE secretion were consistent and independent of 
the purification method used. It's worth noting that positively selected B cells had higher 
proliferation levels compared to the B cells purified by T-cell rosetting, while the 
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Fig. 4.11: Effect of IL-5 on the IL-4-dependent B cell proliferation and IgE 
secretion. Tonsilar B cells were purified by T-cell rosetting and cultured at a 
concentration of 105 cells/well, with IL-4 (20 ng/ml), anti-CD40 (0.5 ýtg/ml) and 
increasing amounts of IL-5. Proliferation was determined after 4 days by 3 H- 
Thymidine. Standard deviations (triplicates) are shown for each individual donor 
(a). Supernatants were also collected and the IgE levels measured by ELISA. 
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Fig. 4.12: Effect of IL-7 on the IL-4-dependent B cell proliferation and IgE 
secretion. Tons4r B cells were purified by T-cell rosetting and cultured at a 
concentration of 105 cells/well, with IL-4 (20 ng/ml), anti-CD40 (0.5 ýig/ml) and 
increasing amounts of IL-7. Proliferation was determined after 4 days by 3 H- 
Thymidine. Standard deviations (triplicates) are shown for each individual donor 
(a). Supernatants were also collected and the IgE levels measured by ELISA. 
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Fig. 4.13: Effect of IL-9 on the IL-4-dependent B cell proliferation and IgE 
secretion. Tonsil4r B cells were purified by T-cell rosetting and cultured at a 
concentration of 10 
5 cells/well, with IL-4 (20 ng/ml), anti-CD40 (0.5 pg/ml) and 
increasing amounts of IL-9. Proliferation was determined after 4 days by 3 H- 
Thymidine. Standard deviations (triplicates) are shown for each individual donor 
(a). Supernatants were also collected and the IgE levels measured by ELISA. 
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Fig. 4.14: Effect of purification method on B-cell proliferation. TonsiLhr 
B cells from three donors were purified by T-cell rosetting or by CID 19 
dynabeads (positive selection) and cultured for 4 days at standard 
conditions, against increasing amounts of each exogenous cytokine. B-cell 
proliferation was measured by incorporation of 31-1-Thymidine after 4 days of 
culture. The mean values of the three donors were noted. Standard errors 
are shown. 
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Fig. 4.15: Effect of purification method on IgE secretion by human B 
cells. Tonsilhr B cells from three donors were purified by T-cell rosetting or 
by CD19 dynabeads (positive selection) and cultured for 10 days at 
standard conditions, against increased amounts of each exogenous 
cytokine. The IgE levels were measured by ELISA in the supernatants and 
the means of the three donors are presented. Standard errors are shown. 
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4.2.7 Effect of IL-18 on IL-4-dependent B-cell proliferation and IgE secretion. 
Possible synergism with IL-12. 
Tonsillar B cells were purified by T-cell rosetting and cultured at standard conditions of 
11A (20 ng/ml) and anti-CD40 (0.5 ýtg/rnl) (Control). Increasing amounts of IL- 18 wei-c 
titratcd in the cultures at concentrations raneing froin 0-1000 Afici- 4 davs tlic 
cultures were pulsed with 3 H-Thyrnidme. incubated for a further 6-18 hours and 
subsequently the counts were measured with a beta-counter. B-cell proliferation was 
directly related to the incorporation of 3 H-Thymidine. After a 10 day CUItUre period, 
supernatants were obtained and the IgE levels measured by ELISA. IL-4-depeiident 13- 
cell proliferation was unaffected by IL- 18 while at the higher concentrations of the latter 
cytokine (100 and 1000 U/ml), IL-4-dependent IgE secretion was enhanced (figure 
4.16a). 
Using the same donor, B cells were also cultured at standard conditions but under the 
presence of both IL- 18 and IL- 12 at a concentration of 100 U/ml. Although IL- 18 was 
found to enhance IL-4-dependent IgE secretion at 100 U/ml, addition of IL-12 brought 
IgE production down to control levels (figure 4.16b). This experiment is a representative 



























Fig. 4.16a: Effect of IL-18 on the IL-4-dependent B-cell proliferation and IgE 
secretion. Tonsillar B cells from were purified by T-cell rosetting and cultured for 4 
days at a concentration of 105 cells/well, with IL-4 (20 ng/ml) and anti-CD40 (0.5 
ýtg/ml) with increasing amounts of IL- 18. Proliferation was determined after 4 days 
of culture by 3 H-Thymidine incorporation. Supernatants were collected after 10 
days of incubation and the IgE levels were measured by ELISA. These results are 
the mean of two donors and the standard deviations have been calculated 
(triplicates). 
Fig. 4.16b: Possible synergistic effect of IL-18 and IL-12 on IgE secretion. B 
cells from were purified by T-cell rosetting and cultured for 4 days at a 
concentration of 10 
5 cells/well, with IL-4 (20 ng/ml) and anti-CD40 (0.5 pg/ml), in 
the presence or absence of IL- 18 (100 U/ml) and IL- 12 (100 U/ml) or both. After 10 
day incubation the IgE levels in the supernatants were measured by ELISA. These 
results are the mean of two donors and the standard deviations 
have been calculated 
(triplicates). 
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4.3 DISCUSSION. 
In this study we investigated the effects of different exogenous c-vtokines on the IL-4- 
dependent 1(-)E sý, vltchinu. did not have a synergistic effect with IL-4 and on its 
own was found to rnimic the effects of ll, -4 although not the extent of the latter 
cvtokine. IL-13 was able to switch B cells to IgE secretion in the absence of IL-4. in a 
dose-dependent manner. although it was 10-fold less compared to the levels of IgE when 
IL-4 was present together with IL-13. This finding was probably related to the lower 
immunoproliferative activity of IL- I 33on B cells compared to I L-4. These results suggcst 
the similar biological nature of the two cytokines but at the same time underlines their 
different potentiating effects in IgE switching "In N71tro". The lower B cell response to 
IL-13 was also shown by Kirnata el aL (1995) and Kohler et al.. (1994) (333) and (334). 
The latter group demonstrated activation of STAT 6 by IL-13, a signalling molecule also 
activated in the IL-4 pathway. The presence of the extra ý-subunit in the IL- 1 3) receptor 
probably accounts for the I 0-fold lower proliferation and IgE secretion by the B cells "in 
vitro" (146). 
In our study, addition of IFN- y significantly reduced the IL-4-dependent IgE secretion 
in the B-cell cultures while the proliferation of the B cells was independent of the 
concentration of the cytokine. This probably indicates that the suppressive effect of IFN- 
y on IgE switching is direct, via some specific molecular pathway. This fact is supported 




Maggi el al. (1989). showed a synergistic effect of IL-6 and IL-4 on proliferation and 
IpE secretion by both human and murine B cells (143). In this studv tonsilar B-cell 
proliferation increased significantly with increasing IL-6 concentration. Similark- %\e 
tI ound that addition of IL-6 increased the IL-4-dependent IgE production hv hurnari B 
cells -In v iti-o". 
ll--5ý IL-7 and IL-9 had no direct effect on proliferation or IgE synthesis. This x\as in 
contrast with other investigations in which IL-7 and IL-9 were reported to enhanced 1(-)E 
production by hurnan B cells. In these studies PBMC were used. thus the potentiatim, 
effect of these cytokines might be indirect. via other cell types (150) and (148). 1 L-5 can 
provide the trigger for isotype switching to IgG I and IgE, by inducing the accumulation 
of productive yl and F- transcripts in PBMCs (147). The unresponsiveness of the human 
B cells to IL-5 could not be explained in our study. 
Despite the general notion that IL-10 is an immunosuppressive cytokine, in our study 
I L-10 increased B-cell proliferation and IgE secretion. It has to be noted though that IL- 
10 (together with IL-6) have been suggested to be involved in B-cell 
lymphoproliferation acting "in vivo" in a paracrine fashion via T cells (335). IL-10, (as a 
type I or type 2 cytokine), has brought about one of the biggest contradictions 
concerning its effects in IgE switching. Initially it was strongly believed that IL- 10 was 
immunosuppressive for IgE switching (153) and (317). More recent studies using 
peripheral B cells from patients with certain forms of leukaemia, such as lymphocytic 
leukaemia (CLL), hairy-cell leukaemia (HCL) and HCL variant (HCLV), have shown 
that IL- 10 can upregulate the IgE switching process "in vitro", even in the absence of 
exogenous IL-4 (336). It is quite likely that IL-10 has a dual effect on B cells regarding 
IgE production. IL- 10 expands B cells that have already switched to IgE by the action of 
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IL-4 and anti-CD40, but at the same time it might have a direct effect on these cells as 
the levels of IgE measured in the cultures were very high. 
Finally, the suppressive effect of' TGF-ý on the 11-4-dependent IgE switchill(I \\as t- ltý 
probably due to the specificity of the latter to switch B cells to lul. -N. This property of 
1'GF-(i has been widely established (33337). Indeed. the suppression of IL-4-dcpcndent 
IgE secretion by the B cells was almost 100% at the higher concentrations of TGF-0 as 
well as B-cell proliferation. From this it was concluded that the suppression of IgE tl 
synthesis by TGF-ý was due to the inhibition of B-cell proliferation and stimulation ot 
IgA production. 
The proliferative effect of IL-2 on B cells was in concordance with previous findings. 
Gearing ef al., (1985) had shown that human B cells could proliferate with IL-2 alone. 
even in the absence of anti-CD40 monoclonal antibody (3338). The existence of IL-2R on 
the surface of the human B cells, was demonstrated by Zubler et a/., (144). The decrease 
of IgE secretion by the human B cells due to the presence of IL-2 agrees with most of 
the literature. Miyajima et al.. (1991), reported that IL-2 could inhibit IL-4 induced IgE 
secretion of LPS-activated murine B cells (145). IL-2 appears to inhibit IL-2 secretion in 
a different manner compared to IFN-y. IFN-y was only inhibitory when present early 
during culture (3339). In contrast, IL-2 inhibited most when added on day 4 or 5, 
indicating that IFN-y interferes with an early step, and IL-2 with a late step in this IL-4- 
dependent B cell function. 
IL-12 decreased IgE secretion by the human B cells in a dose-dependent fashion. The 
suppressive nature of IL- 12 is widely established (156) and (157), and is believed to 
be 
indirect as it induces IFN-y production by human CD4+ 
T cells. In our experiments. 
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even in the highly purified B cell cultures (posi I itively selected vvith CD 19+ dynabeads). 
IL-12 had a downregulatory effect on the IL-4 induced IgE secretion process. This 
SLILMests the possibility that it induces IFN-y production by B cells. The IL-12 signal is 
transduced through the IL- I 2R and STAT 4 (3 340). B-cell proliferatioii was not affected 
hy thC PI-CSCIlCe Of 11-- 12 111 tllC CLIltLll'C, ) (II 100 ± SEM). 
Recently, the effects of IL-12 on IgE switching have been related to IL-18. Extensive 
studies have shown a homology between the IL-12 and the IL-18 receptors in humans 
indicating similar signalling pathways (3341). Both receptors have beeii detected on nai%, c C, 
human B cells and a synergistic effect between the two cytokines has been demonstrated 
regarding the induction of IFN-7 secretion by B cells (3 )42)ý (3 )43), (3 )44) and (157). 
IL-18 upregulated IL-4-dependent IgE synthesis while simultaneous addition of IL-12 
and IL-1 8 brought IgE production down to control levels. Z-- 
Finally, the purification method used to isolate the tonsillar B cells. did not bias the 
effect of the exogenous cytokines on the IL-4-dependent B cell proliferation and IgE 
synthesis. The overall lower levels of IgE produced by the positively selected B cells 
underlines the sensitivity of the process, while the higher proliferation levels were 
probably due to the stimulation by the CD 19+ dynabeads during the purification method. 
It is likely that the CD19 dynabeads are toxic to B cells, possibly inhibiting all types of 
immunoglobulin class switching. For this reason, T-cell resetting was extensively 
preferred over positive selection for B-cell purification. 
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CHAPTER 5: CYTOKINES AND THEIR MODES OF 
ACTION IN h! E REGULATION "IN VITRO". 
4-1 
5.1 INTRODUCTION. 
Iii this chapter. we assessed the possible mode of action b-v which c. vtokines %\cre found 
to influence IgE secretion by hurnan B cells. As described in chapter 4. such cytokines 
includc: IL-6 and 11-- 10, found to potentl I iate IL-4 secretion and IL-2. IL-1 I ll-N-y and 
TGF-ý, which inhibited this process. In the case of IL-6 and IL-10, it ývould be 
interesting to see whether the increase in IgE secretion was a direct effect of these 
cytokines on the switching of human B cells to IgE or through the expression of 
committed precursors. IL-6 is a multifunctional cytokine important I'or the 
differentiation of human B cells into Ig secreting cells (345). IL-6 has been shown to 
expand B cell precursors and caused B cell proliferation both in Ovo and in vitro (346). 
The synergistic effect of IL-6 with IL-4 in upregulating IgE switching has been shown Z: ) 
with both purified human B cells (347), and in mixed PBMC cultures (127). 
IL-10, a lymphokine produced by various cell types such as T cells, mast cells and 
macrophages, has been widely characterised as a suppressive agent in inflammatory 
responses (348). It has been also classified as aB cell growth factor (among IL-2 and IL- 
4) (327), causing proliferation and plasma cell development in germinal centres (349). 
The augmenting effect of B cell proliferation by IL-10 was also shown by Nagumo and 
Agematsu (1998), when B cells were cultured in the presence of IL-4 and CD27 ligand 
(CD70) (350). 
The way in which cytokines inhibit Ig production may involve a number of different 
mechanisms, such as the stimulation of B cells to produce a different 
Ig subclass seen in 
the case of IFN-y and TGF-P triggering the secretion of IgGI and IgA respectively. 
The 
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genetic mechanisms underlying these processes are mutually exclusive. thus switching 
one immunoglobulin isotype is irreversible and excludes the secretion of an), other Ig 
SLibclass. 
The importance of IL-4 in l, (YE production has been shown II in chapters 3 and 4. This lead 
us to study the regulation of the IL-4 receptor on the hurnan B cells. exerted by 
cytokines. There are two types of IL-4R: Class I (IL-4Roc/IL-2R7) expressed on B and T 
cells, and class 11 (IL-4Ru/L-I3)Ru) expressed on endothelial cells (351), (352). The 
shared hybrid component of the IL-4 and IL-133 receptors shares signalling pathways 
thus explaining the common biologic features between the two cytokines including IgE 
isotype switching, CD2-33 induction and eosinophilic activity (35-33), (3354). IL-4R(x is a 
critical component for the binding of IL-4 and signal transduction of the latter cytokine 
(355), (356). (357), (358) and (359). Binding of IL-4 to its receptor induces 
phosphorylation and DNA binding activation of the signal transducer and activator of 
transcription (STAT) 6 protein (3360). When STAT 6 was deleted in mice, inhibition of 
Th2 function and IgE synthesis was anticipated and confirmed (361). Subsequently, the 
IL-4Ru chain has been reported to be linked with atopy (inherited predisposition to 
make IgE to common inhaled antigens) (362) and (36-33). Consequently., regulation of the 
lL-4R expression may be a control to the study of IgE switching. It has been also shown 
that B cells activated by IL-4 increase the expression of IL-4R on their surface (352). By 
contrast, IFN-y was shown to downregulate the expression of the IL-4R on B cells both 
indirectly (activation of STAT 1) and by direct attenuation of the IL-4-induced STAT 6 
activity (352). In this study, we assessed the effect of IL-2, IL-12,, IFN-y and TGF-ý on 
the expression of the IL-4R on human tonsillar B cells. 
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Finally, another possible way by which cytokines can regulate an Ig switching is by 
inducing the secretion of other cytokines, that can in turn inhibit the production ol' the 
primary immunoglobulin. The ability of IL-12, produced by dendritic cells and 
macropliagocs, to promote a type I immune response -in vivo- has been established 
(364). It has I)cconic apparent that B cells participating in I'D responses can flienisck cs ltý 
manifest polarisation along Th I or Th2 pathway very soon after antigen challenge ýý itli 4-- 
the direction taken dependino on the nature of the antigen and the dominating cytokine 
profile at each time (365). In this study, we investigated the downregulatory effects of 
IL- 12 on IgE secretion on the basis of IFN-y production by the human B cells. 
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5.2 RESULTS. 
5.2.1 Analysing the effects of IL-6 and IL-10 on B cell proliferation and IgE 
secretion. 
Tonsillar B cells were isolated by T-cell rosetting and cultured xvith anti-CD40 (0.5 
jig/ml). and IL-6 or IL- 10 (0- 1000 U/ml) in the presence or absence of IL-4 (20 ng, "ml). I 
Following a four day culture period, the cell cultures were pulsed Nvith -"H-Thymidine 
and counted in a P-COLinter were related to assess proliferation. The effect of IL-6 and 
IL-10 on the B-cell prolif eration levels was similar. As previousIN. shown (chapter 4). 
IL-6 and IL-10 potentiated B cell proliferation in a dose-dependent fashion in the 
presence of IL-4. Similar results were observed in this case. with IL- 10 being more 
potent compared to IL-6, as the former gave maximum proliferation levels of 27000 cpm 
as opposed to 18000 cpm obtained with IL-6 (figures 5.1 + 5.2). In the absence of IL-4. 
both IL-6 and IL- 10 had a five-fold less immunoproliferative effect on the human B 
cells. 
After a ten day culture period B-cell supernatants were collected and the IgE levels were 
measured by a direct IgE sandwich ELISA. Again as previously shown in chapter 4, the 
synergistic effect of IL-6 and IL-10 with IL-4 in our IgE secretion system was proven. 
IgE levels increased with increasing amounts of IL-6 and IL-10 with the latter being 
more potent giving IgE levels that reached 2000 ng/ml. Neither of the two cytokines was 
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Fig. 5.1: Effect of IL-6 on B cell-proliferation and IgE secretion in the 
presence or absence of IL-4. Tonsillar B cells (from one donor), were 
purified by T-cell rosetting and cultured with anti-CD40 (0.5 ýtg/ml) and 
incremental amounts of exogenous EL-6, in the presence (closed circles) 
or absence (open circles) of EL-4 (20 ng/ml). B-cell proliferation was 
measured by the incorporation of 3 H-Thymidine after 4 days of culture (a) 
while the IgE levels were measured ELISA after 10 days of culture (b). 
These results are representative of three donors and the standard 
deviations have been calculated (triplicates). 
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Fig. 5.2: Effect of IL-10 on B cell-proliferation and IgE secretion in the 
presence or absence of IL-4. Tonsillar B cells (from one donor), were 
punified by T-cell rosetting and cultured with anti-CD40 (0.5 Vtg/ml) and 
incremental amounts of exogenous IIL-10, in the presence (closed circles) or 
absence (open circles) of IL-4 (20 ng/ml). B-cell proliferation was 
measured by the incorporation of 3 H-Thymidine after 4 days of culture (a), 
while the IgE levels were measured by ELISA after 10 days of culture (b). 
Results are representative of three donors and the standard deviations have 
been calculated (triplicates). 
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5.2.2 IFN-y and IgGl secretion. 
Tonsillar B cells were isolated by T-cell rosetting and cultured with anti-CD40 (0-5 
ýtg/ml), titrated arnounts ofll-N-y (0- 1000 U/ml) in the presence or absence of IL-4 (20 
ng/ml). Following a 10 day CUItUre. B-cell supernatants were collected and the 1, -, G I and 
IgEl levels measured b\ direct sand\vich 1, -)GI and ELI'ýAs respect'vely. Fl - 3a 
"I Ll I'C 5. 
shows the ability of IFN-y to upregulate the l()GI levels and downreaulate tile 1(-, E levels t: - t-- - 
secreted by the human B cells -In vitro". under the presence of IL-4. A fiNc-fold 
decrease in the levels of IgE NA, -as observed at 1000 U/ml of IFN-7 while the highest 
levels of IgGl obtained were 1150 n /ml. The IgGI switching ability of IFN-y was 9 tý L- 
confirmed by the dose-dependent increase of the antibody in the absence of IL-4 (figure 
5.3b). ILA at 20 ng/ml, did not inhibit IgGI production but IFN-y inhibited IgE at I 
ng/ml. 
5.2.3 TGF-ý and IgA secretion. 
Tonsillar B cells were isolated by T-cell rosetting and cultured with anti-CD40 (0.5 
ýtg/ml), titrating amounts of TGF-P (0- 1000 U/ml) and in the presence or absence of IL- 
4 (20 ng/ml). Following a ten day culture, B-cell supernatants were collected and the 
IgA and IgE levels measured by an IgA ELISA kit and a direct sandwich IgE ELISA 
respectively. Figure 5.4a shows the ability of TGF-P to increase the IgA levels and 
suppress IgE secreted by the human B cells "in vitro", in the presence of IL-4. A 
complete suppression of IgE secretion was observed at 1000 U/ml of TGF-O while the 



































Fig. 5.3: Effect of IFN-y on IgGI and IgE secretion. Tonsillar B cells 
isolated by T-cell rosetting were cultured with IL-4 (20 ng/ml), anti-CD40 
(0.5 ýig/ml) and incip-qsing amounts of IFN-y (a). B cells were also cultured 
with IFN-g but in the absence of IL-4 (b). After 10 days of culture the 
supernatants were collected and the IgG I and IgE levels were measured by 
ELISA. The results are the average of three donors and the standard errors 
have been calculated. 
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Fig. 5.4: Effect of TGF-P on IgA and IgE secretion. Tonsillar B cells 
isolated by T-cell rosetting were cultured with IL-4 (20 ng/ml), anti-CD40 
(0.5 pg/ml) and incraesing amounts of TGF-P (a). B cells were also cultured 
with TGF-P but in the absence of IL-4 (b). After 10 days of culture the 
supernatants were collected and the IgA and IgE levels were measured by 
ELISA. The results are the average of three donors and the standard errors 
have been calculated. 
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confinned by the dose-dependent increase of the antibody in the absence of IL-4 (figure 
5.3)b). IL-4 was unable to inhibit IgA secretion at 20 ng/ml. 
5.2.4 IL-12-dependent IFN-y secretion by human B cells. 
Tonsillar B cells were isolated by T-cell rosetting and cultured with IL-4 (20 
anti-CD40 (0.5 ýtg/rnl) and titrated amounts of IL-12 (0-1000 U/ml). The B cell 
supernatants were collected at days: 0,2,4,6 and 8. and the IgE and IFN-y levels were 
assessed by direct IgE and IFN-y ELISAs. Figure 5.5a shows a downregulation of the Zý 
IL-4-dependent IgE secretion with increasing amounts of IL-12 (also shown in chapter 
4). This inhibition became more apparent after day 6, and was greater at 1000 U/ml of 
IL- 12. 
Figure 5.5b depicts increasing IFN-y levels with increasing concentration of IL-12 on 
day 6 and onwards. The maximum levels of IFN-y secreted by the B cells, were 
observed after 8 days of culture with 1000 U/ml IL- 12, reaching the mark of 20 ng/ml. 
Any IFN-y picked up prior to day 6 or under control conditions (with IL-4 and anti- 
CD40 solely), were considered as background levels. At levels of IFN-y detected in the 

















Fig. 5.5: Effect of IL-12 on IgE secretion and IFN-y production by human 
B cells. Tonsillar B cells were isolated by T-cell rosettIng and cultured with IL. 
4 (20 ng/ml) and anti-CD40 (0.5 jig/ml), and increasing amounts of IL- 12. At 
two day intervals the supernatants were collected and the IgE levels (a) and 
the IFN-y levels (b) were measured by ELISA. These results are representative 





5.2.5 Cytokine regulation of IL-4 receptor expression on human B cells. 
Cytokines that were found to have an effect on IL-4-dependent IgE secretion -in vitro" 
(chapter 4) \\ci-c tested for their abilitY to re&'LlIate the expression of the IL-4R on B 
cells. Tonsillar B cells %\cre isolated by T-cell rosetting and CUItUred 'with IL-4 (20 
II (-' /I ml) and antl-CD40 (0.5 as %\c1l as with onc of the followinul cvtokincs: IL-6. 
IL-10, IL-2, IL-12, IFN-y and TGF-0 at 100 U/ml. At days: 0.22.4.6 and 8 the cells 
were collected and put through an acid wash sta(je (HCl - pH 4-1) in order to strip am, t7 - 
exogenous IL-4- added at day 0, that was still bound on the IL-4R. After the acid ýNash 
step. the cells were stained with CD19-FITC and biotinylated IL-4 followed by PE- 
conjugated streptavidin. The levels of the B cells expressing the IL-4R on their surface 
was assessed by flow-cytometry. As shown in figure 5.6 the levels of B cells expressing tý L- 
the IL-4R was very high under control conditions (IL-4 and anti-CD40 solely) (around 
96% on average). This expression was time- independent within 8 days of the study. 
Similar levels of expression were observed when the B cells were cultured in the 
presence of IL-6, IL-10 (figure 5.7) and IL-2 (figure 5.8). The level of IL-4R expression 
did not change with time and was unaffected by these cytokines. IL-12 downregulated 
the IL-4R expression by 30% after 8 days of culture (figure 5.8), while IFN-y and TGF- 
0 brought about a 50% inhibition of the IL-4R expression by day 4 (figure 5.9). The 
effect of cytokines on the IL-4R expression on human B cells have been summarised in 
figure 5.10. Due to the high levels of the IL-4R observed on tonsillar B cells at day 0. 
PBMC derived B cells were also stained for the receptor. The levels of the IL-4R were 
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Fig. 5.6 : Effect of IL-4 and anti-CD40 (control conditions) in the expression of IL-4R. on 
human B cells. Tonsillar B cells Nvere isolated bv T-cell rosetting and cultured Nvith IL-4 (20 
ng/ml) and anti-CD40 (0.5 ýtg/ml). At davsý 0.2.4,6 and 8 the cells were collected, washed (acid 
Nvash) and surface stained. The B-cell puntv was assessed using CD19-FITC monoclonal antibodv 
whilc the expression of the IL-4R was measured indIrectly by the binding of blot'n-vlated IL-4 
followed bv the binding of PE-conjugated streptavidin. In the pa(VQls above. the B cells expressing 
IL-4R are shown (double positive). These results are representatixe of two experiments. PBNIC 
derived B cells \\ere isolated bv T-cell rosating, -, ind stained at day 0 for control purposes. 
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Fig. 5.7 : Effect of IL-6 and IL-10 in the expression of IL-4R on hurnan B cells. 
Tonsillar B cells were isolated by T-cell rosetting and cultured with IL-4 (20 
n(Y/ml), anti-CD40 (0.5 ktg/ml) and 100 U/mI EL-6 or IL-10. At daysý 2,4,6 and 8 
the cells were collected, washed (acid wash) and surface stained. The B-cell purity 
was, assessed usin(.,, t CD19-FITC monoclonal antibody while the expression of the 
IL-4R was ineasured indirectly by the binding of biotinilated IL-4 followed by the 
binding of PE-conjugated streptavidin. In the pannels above, the B cells expressing 
IL-4R are shown (double positive). 156 
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Fig. 5.8 : Effect of IL-2 and IL-12 in the expression of IL-4R. on human B cells. 
Tonsillar B cells were isolated by T-cell rosetting and cultured with IL-4 (20 
ng/ml), anti-CD40 (0.5 pg/ml) and 100 U/mI IL-2 or IL-12. At days- 2,4,6 and 8 
the cells were collected, washed (acid wash) and surface stained. The B-cell purity 
was assessed using CD19-FITC monoclonal antibody while the expression of the 
IL-4R was measured indirectly bv the binding of biotinylated IL-4 followed by the 
binding of PE-coi jugated streptavidin. In the panels above, the B cells expressing Ij -, 
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Fig. 5.9 : Effect of IFN-7 and TGF-ý in the expression of IL-4R. 6n human B 
cells. Tonsillar B cells were isolated by T-cell rosetting and cultured with IL-4 (20 
ng/ml), anti-CD40 (0.5 ýtg/ml) and 100 U/ml IFN-y or TGF-ý . 
At days: 2,4,6 and 8 
the cells were collected, washed (acid wash) and surface stained. The B-cell purity was 
assessed using CD19-FITC monoclonal antibody while the expression of the IL-4R 
was measured indirectly by the binding of biotinylated IL-4 followed by the binding of 
PE-conjugated streptavidin. In the pan els above, the B cells expressing IL-4R are j '4' 
shown (double positive). 
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Fig. 5.10: Effect of IL-6, IL-10 and IL-2 on the IL-4 receptor expression on 
the surface of human B cells. Tonsillar B cells were isolated by T-cell rosetting 
and cultured with IL-4 (20 ng/ml), anti-CD40 (0.5 pg/ml) (control conditions) 
and one exogenous cytokine among IL-6 (a), IL- 10 (b) and IL-2 (c) at a 
concentration of 100 U/ml. At days: 0,2,4,6 and 8 the supernatants were 
collected and any bound IL-4 was stripped off by acid wash. B cells were double 
stained with CD19-PE and biotinylated IL-4 followed by streptavidin-PE. The 
% levels of the B cells expressing the IL-4R are depicted. 
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Fig. 5.11: Effect of IL-12, IFN-y and TGF-P on the IL-4 receptor 
expression on the surface of human B cells. Tonsillar B cells were isolated 
by T-cell rosetting and cultured with IL-4 (20 ng/ml), anti-CD40 (0.5 ýIg/ml) 
(control conditions) and one exogenous cytokine among IL- 12 (a), IFN-y (b) 
and TGF-P (c) at a concentration of 100 U/ml. At days: 0,2,4,6 and 8 the 
supernatants were collected and any bound IL-4 was stripped off by acid wash. 
B cells were double stained with CD19-PE and biotinylated IL-4 followed by 
streptavidin-PE. The % levels of the B cells expressing the IL-4R are depicted. 
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5.3 DISCUSSION. 
In this study we investigated the possible modes of action of cytokines that were found 
to affect IgE secretion "in vitro". The importance of 11--6 1 ý--7 in enhancing production in 
tile presence of IL-4. has been widely established (127), (347). IL-6 ý\as found to be 
unable to switch B cells to IgE production in the absence of IL-4 and the B-cell 
proliferation levels were five-fold less. This was in concordance ývvith the findings of tý 
orck et al.. (1998). that showed the 19E switching ability of IL-6. and its strong B-cell 
proliferative activity, but only in the presence of IL-4 (346). Jeppson et al., (1998), also 
demonstrated the capacity of IL-6 to enhance IgE class switching via an autocrine 
fashion. in B cells cultured with IL-4 and anti-CD40 (366). Thus, in our study, IL-6 
synergises with IL-4 to promote B-cell proliferation while the IgE secretion process is 
entirely dependent on the presence of IL-4. 
A similar case was that of IL- 10. Interestingly, IL- 10 was much more potent in inducing r: l 
B cell proliferation and IgE production compared to IL-6. Again though, proliferation 
levels dropped five-fold in the absence of IL-4 and IL-10 alone was unable to drive IgE 
secretion by the human B cells in the absence of IL-4. The low proliferative effect of IL- 
10 in the absence of IL-4 was also demonstrated by Rousset et al., (1992). although he 
sho\ved that IL-4 could be substituted with an antigen (such as SAC particles). leading to 
the activation of the B cells via their BCR (327). The ability of IL-10 to enhance IgE 
secretion in the presence of IL-4 was. as with IL-6, due to its immunoproliferative 
activity on the B cells that were in turn stimulated by IL-4 to produce IgE. Jeannin et al.. 
(1998). demonstrated a dual role of IL-10 on IgE regulation, based on the time of its 
161 
addition to PBMC cultures ('317). More specifically. IL-10 downregulated E-transcript 
expression when added with IL-4 within the first three davs of culture. Addi I I 
*t*on of IL- 10 
after day three, potentiated the IL-4-dependent secretion of IgE, possibly via clonal 
expansion of switched B cells. It is worth noting that the prior downreoulation of 1,, E t-I ýt 
class switching was reversed by CD40 ligation ,, \, hIch might explain the absence of 1(-, I" 
suppression in our system. 
The downregulatory effects on IgE secretion by IFN-y and TGF-0, were shown to be 
due to the preferential switching of these cytokines towards a different 1, (, subclass. Nloi-c 
specifically, IFN-y was found to stimulate IgGl production independently of IL-4. The 
IgG I switching ability of IFN-y has been demonstrated (367). 
A similar case was observed for TGF-P. The role of TGF-P in IgA switching is widely 
accepted (3320), (3321) and (69). "In vivo" IgA switching though has been showii to be 
more complicated as TGF-ý can cause the secretion of low levels of IgA by murine 
lymphocytes, indicating that the latter cytokine is just one of the factors driving this 
switching process (322), (319). This differed from our study with human B cells "in 
i4ti-o",, and showed that even low levels of TGF-P (I ng/ml) were able to drive B cells to 
IgA production. Hence the ability of IFN-y and TGF-P to switch human B cells to IgGl 
and IgA production explains their effect on downregulating IgE production. 
The importance of IL-4 in IgE class switching, lead us to investigate the possible 
regulatory action of cytokines on the expression of the IL-4 receptor on human B cells. 
There are two types of IL-4R: Class I (IL-4RoAL-2Ry) expressed on B and T cells, and 
class 11 (IL-4RuIL-13Roc) expressed on endothelial cells (351), (352). The high levels 
of IL-4R expression on tonsillar B cells on day 0 was quite surprising. The experiment 
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was repeated with three donors with the sarne results. Staining of PBMC derived B cells 
though showed a 31.9% expression of the IL-4R which was what would be expected 
according to the literature. Therefore the method of staining was considered reliable. 
UnfortUnately, the low yield ol. 'B cells purified by PBMCs did not allow us to repeat the 
expci-iment with these cells. Addition of IL-4 and anti-('D40 SLIstained the high levels of 
the receptor on the tonsillar B cells up to day 8 of culture. Ikizawa et aL, (1995) showed 
that IL-4 was able to upregulate the expression of its own receptor (IL-4R) on human 
lymphocytes, although the impact this might have on IgE class switchin(ul is still not clear 
(368). The ability of cytokines to regulate the expression of the IL-4R might give sorne 
indication of their effect on IgE regulation. In this study. IL-6 and IL- 10 did not affect 
the levels of IL-4R on the B cells, but the results are hardly conclusive due to the pre- 
activation state of the tonsillar B cells. IFN-y was able to downregulate the expression of 
the receptor frorn day 2 of culture, a finding that is in agreement with Young-So et al.. 
(2000), demonstrating the dual action of IFN-y which activates STAT I and inhibits 
STAT 6 (352). A novel finding was the similar suppression of IL-4R expression on the 
B cells by TGF-ý. Hence both IFN-y and TGF-ý were thought to have at least two 
modes of inhibiting IgE secretion "in vitro". 
Interestingly. IL-12 was found to clownregulate the expression of the IL-4R on the B 
cells at day 8 of culture. This was thought to be due to the ability of the latter cytokine to 
induce IFN-ýproduction by human B cells, as shown in this study. Production of IFN-y 
in the B-cell cultures was significant at higher concentrations of IL-12 by day 6 of 
culture. The indirect inhibitory action of IL-12 on the IgE class switching process 
is in 
concordance with the findings of Gagro and Gordon (1999), who established that 
IL-12 
16 3 
can direct B cell to shift towards a Thl like phenotype via the endogenous production 
and autocrine action of IFN-y in B cell cultures "in vitro" ('369). 
Cytokines that can affect IgE production "in vitro" may act via a number of different 
direct (like Icy class switching) and indirect pathway's involving B cells as well as other 
cell populations. Further studies though are required in order to establish the interactions 
of these cytokines "in vivo" concerning IgE regulation. 
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In order for the B cells to complete successfully their cell cycle they need m, o types of 
signals: The first type, called competence signal, can be provided solely by tile 
itself, especially if the lattcr is intiltivalent (T1 A(-)). This interaction caii be hi(O-ily z::, - 
important for the development of B cells during the Ag-dependant stage. as it aids tile 
formation of the germinal centres in the lymph nodes and it has also been suggested to 
be involved in the induction of Ig class switching and phenotypic differentiation ofthe B 
cells (370). The second signal for B-cell maturation, called the progression signal, is Z: ) b 
provided by the cytokines, which according to their type, they influence the hy-class Z-- 
isotype produced by the B cells. This is known as signal I in immunoglobulin class 
switching (129) and (1 -3 34). 
For example, in work done by A, Cerruti et al., (1998). using 
a homogeneous line of B cells (CL-01), they showed that IL-5 and TGF-ý induce IgA 
class switching while high amounts of IL-4 (>100 U/ml) can cause switching to IgG4 
and IgE production (166) and (371). Signal 2 is generated by the interaction between 
CD40 and CD40L, the latter being present on activated T-cells (129). 
The importance of T cells in IgE secretion can be demonstrated by the fact that activated 
T cells possess the CD40L (gp 339). important for the subsequent activation of B cells 
leading to the production of IgE (126) and (127). Addition of anti-CD40 antibody in 
these cultures. lead to the production of much higher levels of IgE compared to the 
levels of IgE produced in the absence of anti-CD40. According to Wheeler et al., (1996), 
anti-CD3 antibody "in vitro", suppresses IgE synthesis (295). 
The influence of T cells on the production of IgE depends on the predominate cytokine 
pattern secreted by these cells. Hence. addition of Thl clones in a B-cell culture leads to 
a dose-dependant inhibition of IgE production. mainly due to the presence of IFN-y 
166 
('372). On the contrary. during a predominant Th2 response. seen in alleruncs and 
immediate hypersensitivity reacti II ions, T cells %vill aid the production of I&YE. mainly via 
the secretion of IL-4. 
There is now evidence that CD8+ cells can play a role in regulating IgE secretion. t7l 
StUdics by Noble et al.. (1995). Croft ei ol.. (1994) and Sad and Mosmann. (1995) have 
revealed the existence of functionally distinct subpopulations of CD8+ T cells that can 
be broadly compartmental 1 sed along the same lines as CD4+ T cells, with IL-2 and IFN- 
secretion repres i Thl/Tcl cells. IL-4 and IL-5 secret' ent*nc Th2/Tc2 ion representing 
cells and an unrestricted cytokine profile representing ThO/TcO cells (2-334), (233 1) and 
(2-332). Mingari el al., (1984). showed that certain Tc clones could produce sufficient 
amounts of IL-4 "in vitro- when stimulated with anti-CD') or mitogens (224). These 
cells, now defined as Tc2, are not very cytolitic and are found in abundance in HIV 
infected individuals and patients with chronic B-cell leukaemia. Maggi et al., (1994), 
isolated CD8+ circulating T lymphocytes that produced "type 2" cytokines (such as: IL- 
4, IL-5 and IL-10), with poor cytolitic activity from patients infected with HIV-1 (273). 
Le Gros and colleagues showed that when CD8+ cells were incubated "in vitro" with IL- 
4, they became CD4- CD8-. they lost their cytolitic activity and started secreting "type 
2" cytokines, such as IL-4 and IL-5 (275). More specifically. Tc2 cells are less effective 
in killing tumour cells via the Fas-L pathway (3733). Stanciu et al., (1996), showed that 
the secretion of IL-4 by these Tc2 clones can be much higher than the levels of IL-4 
secreted by the Th2 cells, and Erard et al., (199' )), showed that these Tc2 clones were 
capable of switching B cells to IgE synthesis (228) and (227). 
Interestingly, some Tc2 cells can express the CD40L on their surface which can aid 13- 
cell activation by binding to the CD40 molecule on the surface of mouse B cells, causing 
167 
IgE switchinp (296). Expression of the CD40L was absent from the Tcl mouse clones. z: - 
manifesting a further inability ofthese cells to switch B cells to IgE production. 
In this chapter. we confirmed the effect of the various cytokines tested previOUSIV on 1(-lE 
production by Lisino their relevant neutralisino antibodies. The cvtokine content of the L- I-- - 
I'c clone supernatants was determined and the CffCCt Of thCSC SLIpernatants on 1(-, E 
synthesis tested in the absence or presence of the appropriate neutralisinLy antibodies. 
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6.2 RESULTS. 
6.2.1 Effect of neutralising antibodies on cytokines controlling B-cell proliferation 
and IgE production "in vitro". 
TonsIfir B cells purified by T-cell rosettino were Cultured Linder standard conditions of L- 
IL-4 (20 ng/ml) and anti-CD40 (0.5 ýtg/rnl), together with one exogenous cytokine frorn: 
IL-6, IL-10, IFN-y or TGF-O at 100 U/ml, as this concentration, (or greater). has been 
showii to affect significantly B-cell proliferation and 1(-)E switchiiig -hi Oft-o". With each 
of these cytokines, its appropriate neutralising antibody was added at titrating amounts 
ranging from: 1-10000 ng/ml, for the azide-free antibodies: anti-IL-4 and anti-TGF-ý. 
while for the azide-containing antibodies (anti-IL-6, anti-IL-10 and anti-IFN-y), the 
range was 1-1000 ng/ml. After a4 day incubation (at 37'Q, B-cell proliferation was 
determined by 3 H-Thymidine incorporation. The results showed that both the 
potentiating effects (of IL-4, IL-6 and IL- 10) as well as the suppressive effects (of TGF- 
P) on B-cell proliferation were largely eliminated at a concentration of 1000 ng/ml or 
higher of blocking antibody (Fig. 6. I a+6.1 b). Similarly with IgE regulation (after a 10 
day incubation), the potentiating effects of IL-4, IL-6 and IL-10, as well as the 
suppressive effects of IFN-y and TGF-0, were also neutrallsed at concentrations of 1000 
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Figure 6.1: Effect of cytokine neutralisisng antibodies on B-cell proliferation. 
Tonsillar B cells purified by T-cell rosetting were cultured under standard 
conditions, together with one exogenous cytokine from: IL-6, IL- 10, IFN-7 or TGF- 
0 at 100 U/ml. With each of these cytokines, the appropriate neutralising antibody 
was added at titrating amounts ranging from: 1-1000 ng/ml (anti-IL-6, anti-IL-10 
and anti-IFN-7), or from: 1-10000 ng/ml (anti-IL-4 and anti-TGF-P). After a4 day 
incubation, a B-cell proliferation assay was carried out using 3 H-Thymidine. The 
control line shows the B-cell proliferation level in the presence of IL-4 and anti- 
CD40 alone (standard conditions). These results are representative of three donors. 
The standard deviations have been calculated (triplicates). Dotted line = Control 
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Figure 6.2: Effect of cytokine neutralising antibodies on IgE production. 
Tonsillar B cells purified by T-cell rosetting were cultured under standard 
conditions, together with one exogenous cytokine from: IL-6, IL-10, IFN--y 
or TGF-O at 100 U/ml. With each of these cytokines, the appropriate 
neutralising antibody was added at titrating amounts ranging from: 1-1000 
ng/ml (anti-IL-6, anti-IL- 10 and anti-IFN--y), or from: I- 10000 ng/ml (anti- 
IL-4 and anti-TGF-0). After a 10 day incubation, the IgE levels in the 
supernatants were measured by ELISA. The control line shows the IgE level 
in the presence of IL-4 and anti-CD40 alone (standard conditions). These 
results are representative of three donors. The standard deviations have been 
calculated (triplicates). Dotted line = Control culture 2,110 ng/ml. 
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6.2.2 Cytokine levels in Te cell supernatants. 
The cytokine levels in the Tc cell supernatants: Clones Al. 11.1 and --', (Tc I type) and 
B206.21 and 4 (Tc2 tvpc) were meaSUred by ELIS. A as described in the materials and 
methods section. The reSLI1tS N\'CI'C presented as relati\ c amounts t'()i- clones AIII and 
B206 (fig. 6.3a+6.4a), and in a quantltatlvc form for clones 2 and 5 (Tc I) and I md 4 
(Tc2). (Table 6.1). It was concluded that clones: Al 11.2 and 5 are 1-c type I due to 
their high levels of IFN-y and low IL-4. while clones: B206. I and 4 are clearly Tc tYpe 
2 clones with hi0h levels of IL-4 and IL-10 (as well as IL-6) and really low levcls of' 
IFN-y. 
6.2.3 Effect of Tc clone supernatants on the IL-4-dependent IgE secretion by, 
human B cells "in vitro". 
The Tc clone supernatants used were characterised as Tcl or Tc2 according to their 
cytokine profiles detected by the cytokine ELISAs (Fig. 6.3a and 6.4a and Table 6.1). 
The supernatants, kindly provided by Dr. Milica Vukmanovic-Stejic. included: the Tc I 
clones: AI 11.2 and 5 and the Tc2 clones: B206, I and 4. 
Tonsilar B cells purified by T-cell rosetting. were cultured with IL-4 (20 nL01111) and 
antl-CD40 (0.5ýtg/ml), in the presence or absence of one supernatant at a time. In the 
case of the supernatants from clones AIII and B206, a titration protocol was carried out 
which created the following dilutions of the supernatant: 1/2.1/10 and 1/100. After a 10 
day incubation, the B-cell supernatants were collected and their IgE content was 
measured using an IgE sandwich ELISA. It was shown that the levels of I(-)E in the 
cultures increased Nvith increasing concentration of the Tc2 clone supernatant: B206 
(figure 6.4b), while the reverse occurred with the Tc I clone supernatant: AIII (figure 
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6.3b). In both cases, the IgE levels were compared to the control levels where the B cells 
were cultured with IL-4 (20ng/ml) and anti-CD40 (0.5 ýtg/rnl). 
In order to assess the effects of cytokines present in the CD8+ T-cell supernatants. 
neutrallsim-) antibodies were individually added in the cultures. Consequently. antl-IFN-y 
was added at the optinIL1111 concentration of 1000 ng/ml together with the Tc I clones. Cý Z: ý 
and 5. Similarly, anti-IL-4 (10000ng/ml), anti-IL-6 and anti-IL-10 were individually 
added at 1000 ng/ml, together with the Tc 2 clones: I and 4. In order to investigate 
whether the IL-4 content of each of the supernatant was sufficient to sýý itch B cells to 
IgE secretion, the latter were added in the cultures in the presence or absence of any 
exogenous IL-4. Further addition of anti-IL-4 (at 10000 ng/ml) with the Tc type 2 cell 
supernatants would confirm the importance of IL-4 in IgE synthesis. The experiment 
was carried out twice in triplicates and the 96-well plates were cultured for 12 days. The 
levels of IgE in the cultures were measured by ELISA. Tc type I supernatants: 2 and 5 
were able to downregulate the IL-4-dependent IgE switching observed in the control 
cultures (standard conditions of IL-4 and anti-CD40). In the absence of IL-4, the levels 
of IgE were negligible. This downregulation was blocked by the addition of anti-IFN-y 
antibodies, highlighting the suppressive effect of IFN-y on IgE production (figures 6.5 
and 6.6). 
Tc2 cell supernatants: 2 and 4. were able to enhance the IL-4-dependent IgE secretion 
and were also able to switch B cells to IgE in the absence of exogenous IL-4. Addition 
of anti-IL-4 suppressed entirely the levels of IgE in the supernatants. When anti-IL-6 
and anti-IL- 10 were added separately with Tc2 supernatants, reduced the levels of IgE 
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Figure 6.3a: Relative cytokine amounts in AIII clone supernatant. 
Figure 6.3b: Effect of A 111 supernatant on IgE production. 
Tonsillar B cells were purified by T-cell rosetting and put into culture with IL-4 (20 
ng/ml) and anti-CD40 (0.5 [tg/ml) (Control Conditions). Clone AIII supernatant, 
(relative cytokine amounts calculated by cytokine ELISAs, presented in figure 6.3a), 
was titrated in the B-cell cultures at the following dilutions: 1/2,1 /10,1 /100. After 10 
days of culture, B-cell supernatants were collected and the IgE levels were measured 
























1/2 Dil. 1/10 Dil. 1/100 Dil. Control 
Supernatant Dilution 
Figure 6.4a: Relative cytokine amounts in B206 clone supernatant. 
Figure 6.4b: Effect of B206 supernatant on IgE production. 
Tonsillar B cells were purified by T-cell rosetting and put into culture with IL-4 (20 
ng/ml) and anti-CD40 (0.5 ýtg/ml) (Control Conditions). Clone B206 supernatant, 
(relative cytokine amounts calculated by cytokine ELISAs, presented in figure 6.4a), 
was titrated in the B-cell cultures at the following dilutions: 1/2,1 /10,1 /100. After 10 
days of culture, B-cell supernatants were collected and the IgE levels were measured 
by ELISA. Results are representative of two donors. Standard deviations have been 
calculated (triplicates). 
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Figure 6.5: Effect of Tcl clone 2 supernatant on IgE secretion. 
Tonsillar B cells purified by T-cell rosetting were cultured under standard 
conditions of IL-4 and anti-CD40 (control) or in the presence of Tc I clone 
2 supernatant (I 00pl- 1/2 dilution). The supernatant was also added in the 
absence of any exogenous IL-4. The B cells were cultured for 10 days and 
their IgE content was measured by ELISA. The experiment were carried 
out twice (two donors) and the standard deviations were calculated for 
each donor (triplicates). 
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Figure 6.6: Effect of Tcl clone 5 supernatant on IgE secretion. 
Tonsillar B cells purified by T-cell rosetting were cultured under standard 
conditions of IL-4 and anti-CD40 (control) or in the presence of Tc I clone 5 
supernatant (100 ýtl-1/2 dilution). The supernatant was also added in the 
absence of any exogenous IL-4. The B cells were cultured for 10 days and 
their IgE content was measured by ELISA. The experiment were carried out 
twice (two donors) and the standard deviations were calculated for each donor 
(triplicates). 
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Figure 6.7: Effect of Tc2 clone 1 supernatant on IgE production. 
Tonsillar B cells purified by T-cell rosetting were cultured under standard 
conditions of IL-4 and anti-CD40 (control) or in the presence of Tc2 clone I 
cell supernatant at 100 W (1 /2 dilution). The supernatant was also added in 
the absence of any exogenous IL-4 ± anti-IL-4 neutralising antibody (1000 
ng/ml). Anti-IL-6 and anti-IL- 10 neutralising antibodies were also added 
individually with the Tc2 cell supernatant at standard conditions. The 
experiment was carried out twice and the standard deviations were 
calculated. 
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Figure 6.8: Effect of Tc2 clone 4 supernatant on IgE production. 
Tonsillar B cells purified by T-cell rosetting were cultured under standard 
conditions of IL-4 and anti-CD40 (control) or in the presence of Tc2 clone 
4 cell supernatant at 100 ýfl (1/2 dilution). The supernatant was also added 
in the absence of any exogenous IL-4 ± anti-IL-4 neutralising antibody 
(1000 ng/ml). Anti-IL-6 and anti-IL-10 neutralising antibodies were also 
added individually with the Tc2 cell supernatant at standard conditions. The 
experiment was carried out twice and the standard deviations were 
calculated. 
180 
CONTROL SUP. 1/2 SUP. 1/2 SUP. 1/2 SUP. 1/2 SUP. 1/2 
6.3 DISCUSSION. 
The possibility that CD8+ cells might be involved directly and autonomously in atopic 
conditions. has been StUdied by various groups. For example. Aral et al., ( 1990). 
demonstrated that IL-4 prodLICIII0 CD8+ cells could enhance the prodLiCtiOn of l()E by B 
cells (374). They also showed that CD8+ Tc2 cells could stimulate mast cell growth and 
activation. Coyle et al., (1995), showed that IL-5 producing CD8--; - cells rnLiý- cause 
eosinophilic inflammation following viral infection in allergic mouse models (375). 
Finally, CD8+ cells are capable of eliciting DTH reactions to viral antigens ('376). 
CD8+ T cells in HIV-infected individuals that were able to secrete significant amounts 
of ILA an observation which is probabaly related to the elevated IgE levels in these 
patients (hyper-IgE). These CD8+ cells also expressed high levels of the CD40L on their 
surface, essential for efficient B-cell activation and immunoglobulin class switching 
(377) and (277). 
In this chapter, we focused on the effects of various Tc cell supernatants (both Tc I and 
Tc2 type) on IgE production by human B cells "in vitro ". Classification of the Tc clones 
was confirmed by cytokine content of the cell culture supernatants. The results showed a 
clear cut classification of the clones used, as Tc I or Tc2. Consequently. clones: AI 11,2 
and 5 were confirmed as Tc 1, having a type I cytokine profile in their supernatants 
characterised by high levels of IFN-y and much lower levels of IL-4, while clones: 
B206, I and 4 were classified as Tc2, containing high levels of ILA IL-6 and IL- 10 but 
lacking in IFN-y. In both types of supernatants the levels of IL-2 and TGF-O were 
negligible, thus not considered. 
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In order to isolate the effects of the individual cytokines in the supernatants on IgE 
synthesis. their respective neutralising antibodies were used at their optimum 
concentrations. The latter ývcrc established after a series of titration experiments \\hich 
also confirmed the B-cell proliferative and I(YE secretinu, ability of the corresponding L- -- Z7 
c\ tokines. The potentiatino el'ICcts of IL-4, IL-6 and IL-1 0 on 1(, E switchim-, and B-cell Z7 t::, - 
proliferation were neutralised by the addition of their respective neutralising antibodies. L- 
In the case of IFN-y and TGF-0. their suppressive effect on IgE secretion could be 
neutra ised y the addition of anti-IFN-y and anti I *-TGF-0 respectivelY 
The effect of the supernatants used on IgE switching depended on their cytokine content, 
hence their Tc type. Thus. clone supernatant: Al II could downregulate IgE production 
by the B cells due to its high levels of IFN-y while the levels of IgE in the B-cell cultures 
increased with increasing amounts of the clone supernatant: B206. The effect of the 
latter was probably due to the hi, ()h levels of ILA IL-6 and IL-10 in this supernatant, as 
well as the low levels of IFN-y. 
In this study, the Tc2 clones supernatants used (Clones: I and 4) were able to potentiate 
IL-4-dependent IgE production. They could also stimulate B cells to IgE secretion in the 
absence of any exogenous IL-4. indicating that the content of IL-4 in these Tc cell 
supernatants was sufficient for this process. The latter effect was neutralised by the 
addition of anti-IL-4 monoclonal antibodies. The potentiating effects of IL-6 and IL-10 
present in these Tc type 2 cell supernatants could be individually blocked by their 
respective neutralising antibodies. 
The Tc type I clones used (Clones: 2 and 5), suppressed the IL-4-dependent IgE 
secretion. This suppression was completely neutralised by the addition of anti-IFN-y 
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2' 
monoclonal antibodies. indicating that the inhibitory factor produced by these cells was 
IFN-y. Tc type I cell supernatants were unable to switch B cells to IgE secretion in the 
absence of exogenous IL-4. 
183 
CHAPTER 7: DISCUSSION 
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7.1 Cytokine controlled Ig class switching. 
In thiS Study. the source of human B cells was fresh]v isolated tonsils from patients aged 
hctween 3-35 vcars of a(, )e. The B cells \\-CI'C I)Lirified using two different techniqLICS : T- 
cell rosetting (negative selection) and CD19+ dynabeads (positi-výe selection). The % of 
CD19+ B cells obtained by positive selection was similar to that obtained bv T-cell 
resetting, although in the latter method there may be some T-cell contamination (CD'I+ / 
CD19- cells). Addition of autologous T cells showed that the levels of impurities present 
in the B cell cultures would not affect B-cell proliferation or IgE secretion. Tonsillar B t-- 
cells consist of na*fve B cells, expressing surface IgM and IgD, and isotype committed B 
cells that have undergone isotype switch and express (or secrete) surface IgG. IgA or 
IgE but have lost expression of I gM and IoD13 )). Z7 
Proliferation of B cells purified by CD19+ dynabeads was slightly raised compared to 
the proliferation of T-cell rosetted B cells, probably due to activation by the CD19 
dynabeads By contrast, levels of IgE secreted by the positively selected B cells were 
lower compared to those isolated by T-cell rosetting, partly due to the lack of T-cell 
contamination but mainly due to the toxicity of the dynabeads. For this reason, T-cell 
rosetting was the method of choice. 
In order for B cells to switch they need two signals: The first is generated by the 
engagement of the IL-4R on the B cells by IL-4, while the second signal is driven by the 
engagement of the CD40 surface molecule by the CD40L on activated T-cells (129), 
(134) and ('378). The two signals have been shown to activate the C epsilon promoter in 
B-cell lines (378). 
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The importance of CD40 cross-linking was shown in this study as in the absence of 
CD40/anti-CD40 interaction, B cells did not proliferate or switch to any 
immunoglobulin subclass. 
Demonstration of the critical role of CD40/CD40L interaction "in vivo- arose from the 
discovery that the hyper-IgM syndrome. an X-linked illIMUllodeficiency. is due to a 
genetic alteration of the CD40L gene ('379). This disease is characterised by severe 
impairement of T-cell dependent antibody responses wl ient ith no B-cell memorY, defic' 
induction of somatic mutations and little or no circulating IgG, IgA or IgE (309). 
The importance of IL-4 in IgE secretion was continued in this thesis. In the absence of 
recombinant IL-4, B cells failed to proliferate excessivelly or secrete any IgE in the 
Cultures. Neutralisation of IL-4 in Tc2 type T-cell supernatants by anti-IL-4 monoclonal 
antibody blocked IgE secretion by the human B cells "in vitro" (discussed later on). IL-4 
(together with IL-1-3)), are the only known cytokines able to induce IgE synthesis "in 
vitro" when added in the recombinant form (126), (127), (111) and (380). Anti-IL-4 
antibodies preferentially inhibit IgE synthesis without affecting the levels of other 
immunoglobulin isotypes 3 81), (3 82) and (170). 
In this study, secretion of IgGI-4 and IgA was also investigated. B cells were cultured 
with various cytokines in the presence or absence of IL-4. Anti-CD40 was always 
present in the cultures as it would ensure B cell survival and provide signal 2 for the 
switching process. IL- 10, IL- 12 and IFN-y were able to increase the secretion of IgG I 
but only IFN-y though could produce the same effect in a dose-dependent fashion in the 
absence of IL-4. This indicates that IFN-y has the ability to act directly on the human B 
cells and cause them to produce IgGI confirming earlier work by (298), (383) and (384). 
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It is likely that the effect of IL-10 was due to its immunoproliferative properties in the 
presence of IL-4. The proliferative activity of IL-10 has been dernonstrated (3350). The 
ability of IL- 10 to switch anti-CD40 activated tonsillar B cells in the absence of IL-4 has 
been also reported Nonoyama et al., (1994) suggested that IL-10 was an 1(-)G'l 
s%\ I tch facto r for peripheral B cc I Is (3385), whi Ic Ehlers and Smith ( 1991 ). showed that 
IFN-yplays an important role in the IgG2 swi I itching of hurnan. nconatal B cclls (386). 
These studies provide the only evidence in the field of IgG2 class switching. In our I L- 
study, reoulation of IgG2 production remained unclear. The general switchino ability of 
IL- 10 towards most IgG subclasses was also shown by Malisan et al., (1996), by proving 
that the latter cytokine promoted switching recombination to C7 genes in CD40- 
activated human tonsillar na*fve B cells (387). In our study, no cytokines Nwre able to 
potentiate the secretion of this immunoglobulin, even in the presence of ILA suggesting r-I 
that there were probably no IgG2 committed B cells in the tonsils of the donors used in 
these experiments. IgG2 is normally directed against carbohydrate antigens which 
usually are T-cell independent, which means that they might also be cytokine 
independent. 
The enhancement of IgG I by IL-12 was surprising as the latter cytokine inhibits the IL- 
4-dependent proliferation of the B cells. It seems more likely that its action was indirect 
via the production of IFN-y by the B cells. This explanation though is not heavily 
supported because if IL-12 was acting through the induction of IFN-y. it should be able 
to switch B cells to IgGI production even in the absence of IL-4. Perhaps IFN-y was not 
around long enough or was at too low a concentration. Furthermore, once B cells have 
been stimulated for a number of days it may be hard to induce novel switching. 
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Interestingly. Kawano et al., (1995). showed that IgGI switching in human B cells can 
be upregulated by IL-6 provided that the cells have been previouslý activated by antigen 
such as pokeweed initogen (PWM) (3388). In our study. IL-6 did not seern to have an 
effect to any Of the 111111IL1110globulin subclasses tested. 
Briere et al., ( 1994). showed that I L- 10 could switch hurnan B cells to 1-, -, G-) 1011 ý producti 
(313)). In our study. IL-10 could enhance the secretion of IgG3) by the hurnan B cells but 
probably via clonal expansion of rather than direct switching, as the potentiating effect L- 
of IL-10 was lost in the absence of IL-4. even at the highest concentration tested L- 
(I OOOU/ml). The ability of IL-6 to switch antigen-activated B cells -M vitro" towards 
IgG3 production was shown by Kawano et al., (1995), but this was not confirmed by our 
results (388). 
IL-6 was able to induce IgG4 production but only in the presence of IL-4 suggesting 
clonal expansion of pre-committed B cells. It's interesting that IL-6 was able to expand 
the IgG4 committed B cells but not the IgGI B cells which were shown to be present in 
the tonsils. IL-4 and IL-10 were found to be true switch factors for IgG4 (389), (153) 
and (146). The effect of IL- 10 was novel as switching to IgG4 by IL- 10 has only been 
observed in PBMC cultures or in purified B cell cultures (313). Interestingly, IL-12, 
IFN-y and TGF-ý blocked IL-4 driven l(, G4 production in human B cells at IOOU/ml. Z-- 
As previusly described. TGF-ý was found to enhance IgA secretion by human B cells in 
an IL -4- independent manner. This has been previously demonstrated (390), (391) and 
(322). In addition, TGF-P induces the production of germline cc mRNA transcripts, a 
marker of IgA isotype switch (78). Malisa et al., (1996) and Defrance et al., (1992) 
suggested that IL- 10 can be a switch factor for IgA as the latter cytokine may promote 
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switch recombination to C(x genes (3387) and (3318). In our study. the IgA potentiati Z-7 i ing 
effect of I L- 10 was due to B cell expansion. Despite the existingy controversN concerning 
the mechanism of IgA class switching. the critical role played by TGF-ý is without a 
qUeStIOll. 
7.2 Effect of cytokines on IgE production. 
The importance of IL-4 in providing the second signal in IgE switchintg, (first signal: 
CD40 ligation) is widely accepted and also confirmed in this study. The effect of 
cytokines on IgE production were tested in the presence of IL-4. as the only other 
cytokine found to be able to switch B cells on its own was IL-133. The amount of IgE 
secreted by JL- 13) stimulated B cells was I 0-fold less compared to IL-4 driven ones and 
there was no additive or synergistic effects between the two cytokines. This observation 
was in accordance with the findings of Punnonen et al.. (1997) and de Vries (1998) 
(140) and (392). IL-13 shares many, but not all, of its biologic activities with IL-4. For 
example, T cells do not express functional IL-13) receptors. Both cytokines have growth 
promoting effects on normal B cells activated by anti-IgM or anti-CD40 mAbs and 
prevent apoptosis of these cells. Although IL-4 and IL-13 both induce IgE synthesis "in 
%, itro". the relative contribution of the two cytokines to IgE production "in vivo" remains 
to be determined. Such studies are hampered by the absence of suitable animal models 
because I L- 133. in contrast to IL-4, does not act on murine B cells (3 92). 
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IL-6 and IL-10 Nveiv both found to enhance B cell proliferation and the IL-4-dependent 
IgE secretion -In vitro". The potentiating effects of IL-6 were first shoxN, -n by Maggi et 
al.. (1989) and Vercelli et cil., (1989), followed by Bjork and Paulie (199-3), using both 
purified B cells (143) and (127) and PB'\ICs (347). IL-6 activity mi(ght have a dual 
natUl'C aS depletlOll Ol'IlIOIIOC\'tCS III the PBNIC cultures decreased the secretion of 1, -, L 
(127). Hence both an indirect and direct effect of IL-6 on the human B cells is 
suggested. 
In the case of IL-10, the augmenting effects were unexpected. IL-10 would have been 
expected to have an inhibitoi-N,, effect on IL-4-dependent IgE production. Hoýýevei- the 
PBMC inhibitory activity of IL-10 takes place mal I cultures indirectIv via T-cells 
and rnonocvtes. Downregulation of the CD40L on the former cells is the main Z: ý 
i mmuno suppressive mode of action. In addition it's been shown that depletion of 
monocytes reduces the inhibitory effects of IL- 10 on the IL-4-dependent secretion by the 
human B cells (317), (393) and (15-33). IL-10 has been found to decrease F- transcript 
expression and IgE production by IL-4 or IL- 13 stimulated PBMCs (18' )) and (15' )). 
Fluckiger et al., (1993). showed that the downregulatory effect of IL-10 was via 
increased expression of the IL-2R on B cells, hence enhancing the inhibitory role of IL-2) 
in the IL-4-dependent IgE switching process (394). In our study, both IL-10 and IL-2 
enhanced B cell proliferation while IL-2 inhibited IgE secretion. The augmenting effect 
of IL-2 on B cell proliferation paired with the blocking effect on the IL-4-dependent IgE 
switching process, was also shown by Romagnani et al., (1986) and Mivajima et al.. 
(1991) (395) and (145). The latter group demonstrated that the suppressor pathw-ay was 
different to that mediated by IFN-y. In our study. the dose-dependent decrease in IgE 
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secretion by IFN-y, was thought to be due to a direct effect on the molecular 
mechanisms of Ig class switching as B-cell proliferation was unaffected. It has been 
suggested that the effect of the latter cytokine on IL-4-dependent IgE switching iniolit 
have various modes of actions. For example IFN-y nin)ht modulate IgE switching at the ZI7. 
molecular level (3396). Alternatively it might regulate expression Of CO-StIIIILIIatoi-y 
molecules on the surface of immune cells. More specifically, in this thesis we found that 
IFN-y has a downregulatory effect on the IL-4R on the B cells thereby reducing the 
potency of IL-4 for B cells, suppressing the IgE production by the already switclied 
cells. Whatever the case might be, IFN-y has been shown to block IgE secretion by botli 
murine (170) and human purified B cells (397). Comparable effects on IgE class 
switching by IFN-y have also been observed in PBMC cultures (109), (1 10)ý (398) and 
(170). Cytokines can block switching of certain immunoglobulin subclasses by 
preferentially inducing the switching of others (also discussed later on). Thus. since 
IFN-y and TGF-P could switch B cells to IgG I and IgA respectively, it might explain 
their inhibitory action on IgE synthesis by the human B cells "in vitro". The inhibitory 
action of TGF-P was also observed by Stavnezer et al., (1995) (337). In our study, IL-5, 
IL-7 and IL-9 did not have an effect on either B cell proliferation or IL-4-dependent IgE 
production. 
The final cytokine that showed a downregulatory effect on B cell proliferation and IgE 
secretion was IL-12. The dose-dependent decrease in B cell proliferation could be one 
mode of action of IL- 12 in blocking IgE synthesis "in vitro" although it has been widely 
suggested (and also shown in this study), that the main inhibitory effects of this cytokine 
are via the induced production of IFN-y ('399), (400) and (401). This observation could 
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be confirmed by using anti- IFN-y and anti-IL-12 neutralising antibodies simultaneousk 
in the B cell cultures. 
Recently. the effects of IL-122 on I(YE switchina have been related to IL-18. Extensive L- L- 
studies have shown a homology between the IL-12 and the IL-18 receptors indicating 
similar signalling pathways (341 ). Both receptors have been detected on humall lia-i'\ c 13 
cells and a synergistic effect between the two cytokines at inhibiting IFN-y secretion has 
been established (342), ('34-33), (3344) and (157). In this study. IL-18 on its own 
upregulated IL-4-dependent IgE synthesis while addition of IL-12 blocked this 
enhancement. 
The effects of cytokines on B cell proliferation and IgE secretion, tested in this study, 
were confirmed by the use of their relevant neutrallsing antibodies. The use of such 
antibodies at their optimum concentrations re-adjusted proliferation and IgE secretion to 
control levels. 
7.3 Modes of action of cytokines in IgE production "in vitro". 
Havin(,, established the effects of different cytokines on IgE class switching their 
possible modes of action were investigated. IL- 13 was the only cytokine that was able to 
induce IgE synthesis in the absence of IL-4. The great homology of IL-4 and the IL- 13 
receptors indicates the sharing of common signalling pathways between the two 
cytokines- something that might explain the IgE switching ability of 
IL-13. The 
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difference of the IgE levels produced by B cells stimulated by IL-4 or IL- 13 were 
probably due to the higher proliferative activity of the former cytokine on B cells. 
The potentiating effects of IL-6 and IL-10 were found to be IL-4 dependent and were 
probably brou(-)Iit about via the expansion of B cells induced to make 1(, E by the 
cxogenous IL-4 added in the cultures. In the absence of IL-4. neither of the mo 
cytokines were able to stimulate B cells to produce IgE or significant proliferation. Thc 
proliferative effect of IL-6 on the hurnan B cells related to the inductIon of Ito--E sYnthes's 
was also shown by Jeppson et al.. (1998) and Bjork et al., (1998) (366) and (346). In the 
case of IL- 10, the potentiating effect towards the IgE secretion process was novel, as IL- 
10 has been mainly shown to downregulate the process in PBMC cultures. The 
proliferative effect of IL-10 (in the presence of IL-4) was shown by Nagumo and 
Agernatsu (1998) and Tangye et al.. (1998). Jeannin et al.. (1998), proved that the time 
of IL-10 addition in B cell cultures can be significant (3350), (402) and (317). The high 
correlation between B-cell proliferation and IgE secretion for both IL-6 and IL-10 was 
also shown by the construction of Linear Regression Plots (see chapter 4). 
The inhibition of IgE secretion by IL-12 was partly due to the induction of IFN-y 
secretion by the B cells in culture. The ability of IL-12 to induce IFN-y production by 
murine T cells was shown early on (401), accounting for the downregulatory effects of 
IL- 12 on IgE production. The ability of IL- 12 to induce the secretion of IFN-y by human 
T cells is established (157). Furthermore. it has been shown that IL-12 can have the 
same effect on human B cells (343) and (341), a fact which is in agreement with our 
findings. Gagro and Gordon (1999), suggested that the culture of B cells with IL-12 can 
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cause a polarisation of the latter towards a type I phenotype. which would secrete a Th I 
type cytokine profile (369). 
Of course the induction of IFN-y secretion by IL- 12 need not be the only mode of action 
ofthis cytokine in blocking 1(-YE synthesis. as our results indicated a decrease ill B cell 
proliferation which would not bc brought about by IFN-y as prcviously shoN\n. This 
indicates a direct effect of IL-12 on the human B cells resulting in the inhibition ot'l-(-, E 
secretion "in vitro". 
An alternative way in which cytokines might indirectly block the secretion of a certain 
immunoglobulin is by preferentially inducing switching towards another isotype. If the 
switch regions for two specific immunoglobulins lie close in the germline DNA and 
their promoters have similar base sequences (e. g.: due to overlap). then it is possible that 
both molecules would be transcribed, translated and eventually secreted by the cell. This 
is the case between IgE and IgGI in mice and IgE and IgG4 in humans. In our study 
preferential switching to IgGI was induced by IFN-y. Increasing the concentration of 
this cytokine increased the levels of IgGl in the B-cell cultures while the levels of IgE 
fell in a dose-dependent fashion. Preferential switching is a mode of action for TGF-P 
regarding the downregulation of IgE synthesis by the human B cells. The role of the 
latter cytokine in IgA switching in both murine and human B cells is widely accepted. 
This is in accordance with our results in which IgA secretion was TGF-P dependent. 
The 
precise protocol used might also provide a reliable "in vitro" system 
for high-rate IgA 
class production, the lack of which has been described as a major obstacle in studying 
the switching of this immunoglobulin (3 3 19). The fact that both IFN-y and 
TGF-ý can 
stimulate B cells to make 19GI and IgA respectively. in the absence of 
IL-4. defines 
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them as true immunoglobulin switch factors. In agreement with this statement. Kim and 
Kagnoff (1990) showed that the effect of TGF-ý on switching human B cells to 1, -)A 
secretion was direct and not via the clonal expansion of pre-committed ILA+ B cells 
(322). The binding of TGF-ý to its receptor IIIIIII- initiates a signalling pathwaY involvin-o the 
activation of downstream effectors tcrmed Smad proteins (4033) and (404). Thesc Smad 
complexes translocate into the nucleus \\-here they bind specific DNA sequences in 
taroet prornoters. thereby activating transcription leading to IgA class switching (405). 
Hence, the downregulatory activity of IFN-y and TGF-ý on IgE secretion. eveii in the 
presence of IL-4, was expected. It is worth highlighting the difference in the inhibitory 
potency of IFN-y and TGF-O on B cells compared to IL-4. Although the first two 
cytokines can readily inhibit IgE production, ILA a true IgE switch factor, could not 
inhibit the secretion of neither IgGI nor 1()A. The "near perfect" negative coefficient L- 
correlation between B-cell proliferation and IgE production under the effect of TGF-fi 
suggests that the suppressed IgE levels secreted by the B cells is also related to the dose- 
dependent decrease of their proliferation. 
Regulation of the IL-4R could represent a mode of action for certain cytokines that 
modulated IgE secretion "in vitro". Indeed, Keegan (1991), demonstrated increased 
expr&ion of the IL-4Ra subunit on human B cells (406) while Ikizawa et al., (1995) 
suggested that the signal transduction mediated by the up-regulated IL-4R on B cells 
from allergic individuals may be intimately associated with the induction of isotype 
switching to IgE that leads to mature C epsilon transcription and IgE production (368). 
This was further supported by Nasert et al., (1995) and Renz (1999), who administrated 
slI. -4R in PBMC cultures, and significantly 
blocked IgE production (407) and (408). 
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Binding of IL-4 to the IL-4R causes activation of STAT6 which is in tum dependent on 
the presence of - JAM within the receptor complex (409). 
In our Study. IFN-y and TGF-ý were found capable of downregulating IL-4R expression 
on the hurnan B cells after 4 days of culture. The result obtained with the former 
cvtokine was in agreement \\ ith So et al.. (2000) wlio proved both on the cellular and the 
molecular level (presence of rnRNA transcripts) (352). The effect of TGF-ý was no\, cl 
although it does not contradict the rest of our results as switching to 12A was ll--4- Z-- - 
independent. Interestingly, downregulation of IL-4R by IFN-7 did not affect B cell 
proliferation which might suggest that the signals required for the latter act early on in 
the cultures, before day 4, in which case IL-4R expression would be still unaffected. 
Downregulation of the IL-4R observed by IL-12 was probably indirect via the induction 
of IFN-7 secretion by the hurnan B cells. IL-12 induced production of IFN-y was 
observed at day 6 of culture while the decreased levels of IL-4R expression occurred at 
day 8. Our results would suggest a 2-4 day period required for the inhibitory action of 
IFN-y on the regulation of IL-4R. IL-2 did not affect IL-4R expression and thus the 
mode of IgE inhibitory action of this cytokine remains unclear. 
It has to be noted that although the downstream events of IL-4R activation consist of 
multiple signaling cascades, the biologic function of IL-4 may be regulated by the 
combination of different signaling molecules, depending on the cell types (410). 
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7.4 The effect of CD8+ Tel and Tc2 cell supernatants on IgE secretion "in vitro". 
Having established the contribution of individual cytokines to 1(-jE secretion "in vio-o". 
OUr aim was to investigate the suppressive effects of Tcl and the enliancin, -, effects of L- - 
Fc2 clone supernatants on IgF secretion. For this pUrpose, ('D8+ (TO clone supernatants 
were used containing distinct cytokine profiles. This experimental approach would help 
us understand the regulatory role of the CD8+ cells on the IgE levels "in vivo". 
Iii our study, the Tcl clones (2 and 5) Nvei-e generated with IL-12. xN,, hilc mcubatimi Nvith 
IL-4 gave rise to the Tc2 type clones (I and 4) (w-ork by Dr. Milica Vuki-nanovic-Stejic). 
This technique was established by Byun et al.. (1994) (240). T cells \vei-e stimulated 
with anti-CD33 and anti-CD28 rather than PMA and ionomycin. so that activation signals 
would not be passed on to the B cell cultures and bias our results. 
The c,, Iltokine profiles in the Tc clone supernatants confirmed the nature of the clones 
with the Tcl clones containing high levels of IFN-y and the Tc2 clones having high 
amounts of IL-4,11-6 and IL-10. IL-2 and TGF-O levels were negligible in both Tc 
supernatants. 
The effects of the Tc supernatants on IgE synthesis -In vitro" were confirmed by the use 
of neutralising antibodies. Consequently. the downregulation in IgE switching induced 
by the Tc I clones: 2 and 5 was found to be due to the high levels of IFN-y as their ability 
to inhibit IgE production was neutralised by the anti- IFN-y antibody. Unsurprisingly. 
Tc I clone supernatants were unable to switch human B cells to IgE synthesis in the 
absence of exogenous IL-4 as the latter cytokine was also absent from these 
supernatants. By contrast, the Tc2 clone supernatants: I and 4. were able to induce IgE 
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production in the absence of any exogenous IL-4 as they contained sufficient amounts of 
this cytokine. Similar results were observed with the Tc I clone supernatant: AIII and 
the Tc2 clone supernatant: B206. The enhancement of IgE secretion observed by the 
addition of' the Tc2 ClOlle SLIpernatants was confirmed by addition of anti-IL-4 
neutralisino antibody which completely blocked the secretion of this L- Ii immunou, lobLI1 111. 
Igi'l synthesis by the hurnan B cells cultUred kvitli the Tc-2 clone supernatants werc also 
due to the presence of IL-6 and IL- 10 secreted by these clones. 
7.5 FURTHER WORK. 
The advantage of the experimental approach in this study was that by \\orking at the t--- 
protein level we were measuring the amounts of IgE actually being produced by the 
human B cells, which has a higher physiological significance compared to the DNA / 
RNA level. The drawback though was that we were assessing IgE production rather than 
IgE switching. It would be interesting to assess the effects of cytokines and CD8+ T cell 
supernatants on actual IgE switching. This could be done by two ways: Either via the 
use of naYve B cells (IgM+/IgD+/IgE-), hence any IgE measured would be due to actual 
switching, or by detecting E mRNA transcripts by RT-PCR. A combination of the two 
methods would provide further accuracy and specificity in the study of IgE switching. 
Search for the true switch factors of IgG2 and IgG3 in a similar way would be 
interesting. 
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Investigate the existence of BI/ B2 cell populations and account for their cytokine 
profiles both on the molecular (RT-PCR) and the protein level (ELISA). How could 
these cells affect IgE switchii-ig) via soluble molecules or even specific surface markers. 
It would also be interestino to study the ability of Tc2 cells 1(-, I- switchino 
Setting up co-cultures of Tc I and Tc2 clones with autologous B cells could be also Z-- 
another interesting approach. Assessment of CD8+ killing vs. stimulation (i. e. 1(-, E 
switching) could be carried out giving possible answers on the role of Tc (CD8+) cells 
"in N; ivo" 
Similarly. co-cultures could be set up between B cells and other autologous professional 
antigen presenting cells (APC). such as dendritic cells and macrophages, and study their 
effect on IgE class switching. The effect of various cell surface markers on the APCs 
could be assessed. 
It would be also interesting for our study to use trimeric anti-CD40 (now commercially 
available). A possible stronger induction of IgE switching is expected which may offset, 
partly or totally, the inhibitory effects of factors such as IL- 12 and IFN-y. 
Study of the IL-4R regulation at the molecular level is also compelling. Detection of IL- 
4R(x and y chain mRNAs, by RT-PCR would be one approach. This method could be 
used to confirm the effect of cytokines on IL-4R expression "in vitro". Similarly, test the 
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effects of Tc clone supernatants on the expression of the IL-4R. A decrease in the le-vels 
of expression of the receptor would be expected by Tc I type supernatants. 
To take it further, a relationship should be established between STAT 6 and IL-4R 
cxpression. It would be of interest to study whether the two molccules are 111LItualIN 
dependent and whether factors regulating IL-4R expression affect the ST. AT 6 sionalling, Z: l - 
molecule. 
Finally, studying the effects of various factors on the regulation of IFN-y and TGF-ý 
receptors may provide us with a greater insight on the regulation of IgE switching. 
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